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3ABSTRACT
F ib re o p tic  o u t-p a t ie n t cystoscopy has become estab lish ed  in th e  
fo llo w -u p  o f b ladder cancer, and increased the  need fo r  o u t­
p a tie n t trea tm ent and p rophy lax is . D espite  a v a r ie ty  o f  
in d ica tio n s  and a c o n s te lla tio n  o f schedules, in tra v e s ic a l 
chemotherapy has been found to  prevent progression and 
recurrence. Optimum methods remain undefined. Because o f th e  
anatomical separa tion  o f the th e ra p eu tic  and to x ic  e ffe c ts  o f  
thioTEPA, not found w ith  more recent agents, i t  was thought th a t  
th e re  might be a g re a te r c l in ic a l  opportu n ity  to  e x p lo it  p o s it iv e  
lab orato ry  fin d in g s .
A model course o f ten  in s t i l la t io n s  o f in tra v e s ic a l chemotherapy 
was developed in  v i t r o .  C e lls  were less s e n s it iv e  a f te r  
trea tm en t. P o te n tia l markers or p re d ic to rs  o f drug re s is tan ce  
were s tud ied , but no d iffe re n ce s  were id e n t if ie d . The a d d itio n  o f 
a so lven t, dim ethyl sulphoxide, d id  not increase the  c y to to x ic  
e ffe c t  o f four drugs th a t have ccrrmonly been used to  t r e a t  
bladder cancer. A djusting  pH during drug exposure to  acid  lev e ls  
increased the  e f fe c t  o f thioTEPA on a range o f human u ro th e lia l  
c e ll  lin e s  a hundredfold. P i lo t  s tud ies o f a m ilo rid e  gave no 
evidence o f fu r th e r  e f fe c t ,  when used w ith  thioTEPA.
A f i r s t  p rospective  comparison o f UK methods found f le x ib le  
cystoscopy no more l ik e ly  to  miss tumours or induce b a c te r iu r ia  
than ro d -len s  cystoscopy.
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CHAPTER 1 
INTRODUCTION
EPIDEMIOLOGY
In 1986, bladder cancer a ffected  9,591 new p atien ts  in  England 
and Wales (O ffic e  o f Population Censuses and Surveys, 1991). The 
peak incidence in  absolute mrrbers is  between 60 and 79 years, 
but increases progressively in age-standardized data ( Ib id . ) .  In 
1984, an estimated 1227 patien ts  w ith  the diagnosis o f bladder 
cancer occupied hospital beds d a ily , and 86,330 cystoscopies w ith  
resection  o f bladder lesion were carried  out (Hospital Inpatien t 
S ta t is t ic s , OPCS, 1984). In Scotland, the la te s t figures are fo r  
1990, when 1208 new patien ts  were reg is tered , and in -p a tie n t  
discharges or deaths surveyed included 3,364 men w ith bladder 
tunours, who had stayed a mean o f 7 .4  days, and 1398 women, who 
had stayed 7 .6  days on average, w ith  a s im ila r  trend in the age- 
standardized data (Ocrmunity Services Agency fo r  the Scottish  
Health Service, 1991). O vera ll, the incidence is  e ith e r  steady or 
increasing (Dorn & C u tle r , 1959; C u tle r & Young, 1975; Ohno & 
Aoki, 1977). The per cap ita  incidence, adjusted fo r  va ria tio n s  in  
the age-structure in  d iffe re n t countries, is  greater in  the  
in d u s tria lised  nations, (Muir e t  a l . ,  1989), but as the emergent 
nations become more influenced by tobacco use and industry, 
incidence there  might be expected to  catch up. Although smoking 
(L il ie n fe ld ,  Levi & Moore, 1956) and in d u s tria l carcinogens 
(Rehn, 1895) have long been recognised as predisposing to  the
17
development of bladder cancer, screening programnes in  the d /e  
and rubber industries produce only a small m inority  o f re fe r ra ls ,  
the bulk coming from the in vestig a tio n  of c l in ic a l ly  apparent 
haematuria.
SYMPTOMATOLOGY
Over 90$ o f pa tien ts  w ith  s u p e rfic ia l bladder cancer complain o f 
symptoms a t presentation (W allace, 1985), and in 60-96$ o f 
p a tie n ts , haematuria is  the main complaint (Thompson, 1960; 
M ills ,  1962; Massey, 1965; Wallace & H a rris , 1965; Greene, Hanash 
& Farrow, 1973; Varkarakis, Gaeta, Moore, e t a l . ,  1974; Hendry, 
Manning, Perry e t a l . ,  1981). Cystoscopic diagnosis and resection  
both diagnoses and tre a ts  th is  symptom, but, as an ind icato r o f 
the need fo r  review , haematuria occurs too la te . One author 
reported th a t 13 of 24 p a tien ts  w ith  recurrences a t recurrences 
a t review cystoscopy did not have haematuria (M i l le r ,  M itch e ll & 
Brown 1969), and i t  is  a c l in ic a l  canronplace th a t recurren t 
haematuria ra re ly  causes p a tien ts  to  present e a rly  fo r  review.
I r r i t a t iv e  symptoms, which ere present in  20-25$ o f patien ts  
presenting w ith p a p illa ry  tumours, are more commonly 
associated w ith  f l a t  carcinoma in  s itu  (Farrow, U tz, R ife  e t a l , ,  
1977), Although there is  l i t t l e  formal inform ation on the r e l ie f  
of symptoms from endoscopic management, patien ts  w ith  p a p illa ry  
recurrences seldom report discom fort, and the procedure i t s e l f  
produces symptoms (Monsour e t a l . ,  1985; Denholm, Conn, Newsam,
Key: Stage 0-D  by J e w e tt-S tro n g -M a rs h a l1 c la s s i f ic a t io n  (1 9 4 6 -  
1 956 ), S tages T « 'T 4 by UICC c la s s i f ic a t io n  (1 987 )
FIGURE 1
COMPARISON OF AMERICAN AND TNM STAGING
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e t a l . ,  1990).
PATHOLOGY
In the United Kingdom, a t least 90$ o f timours o f the urinary  
bladder derive from urothelium . The macroscopic appearance may be 
of a s o lid , sess ile  lesion , or even o f f l a t  erythematous patches, 
but by fa r  the carmonest appearance is  o f a fronded, p a p illa ry  
lesion or lesions. The tumour is thought to  o rig in a te  in the  
urothelium, and to  spread w ith in  the urinary t ra c t  by implanta­
tio n  o f shed c e lls  (A lbarran & Imbert, 1903; Boyd & Burnand, 
1974), or as a re s u lt o f the unmasking, a t various s ite s , o f a 
widespread malignant tendency or f ie ld  change (Melicow, 1952). 
Spread outwith the urothelium  is in i t i a l l y  by d ire c t invasion, 
through the lamina propria , to  the detrusor muscle, then the  
perivesica l fa t  and p e lv ic  structures, w ith invasion o f lympha­
t ic s ,  and occasionally blood vessels leading to  wider m etastasis. 
Progression through these stages has long been associated w ith  a 
poorer chance of cure (Jewett & Strong, 1946). There have been 
two main co d ifica tio n s  o f the h is to lo g ica l extent o f disease, the  
Jewett-Strong-Marshal 1 and the Tumour-Nodes-Metastasis Systems 
(f ig u re  1, fp 18). Since the la t te r  is  a s p e c ific  ap p lica tio n  of 
a general approach to  s o lid  tim ours, i t  is  coming to  be the more 
usual, even in American studies. At presentation, more than 60$ 
o f patients  have timours lim ited  to  the surface layers (T« or Ti 
or Tis in the TNM C la s s if ic a tio n ), w ith no evidence of tumour in
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Recurrence
Author + _ Total
Loening (1980) 46 38 84
Greene (1973 )* 36 64 100
Smith (1983) 51 43 94
C u tle r (1982) 64 124 188
NBCOGAf1977)291 44 89 133
Total 241 358 599
% 40 60 100
*  Grade I tumours only. 
+ = recurrence present 
-  = recurrence absent
TABLE 1
NUMBERS OF PATIENTS WITH T«-i BLADDER TUMOURS WHICH
RECURRED WITHIN 1 YEAR
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b la d d e r m uscle on endoscopic b io p s ie s  (C u t le r  e t  a l . ,  1982).
Because o f  th e  n a tu re  o f p ra c t ic e  in  th e  U n ite d  S ta te s  o f  Am erica  
d iscourages h o s p ita l r e f e r r a l  o f  p a t ie n ts  w ith  lo w -r is k  tum ours, 
t h is  f ig u r e  is  probab ly  an u n d eres tim ate  o f  th e  in c id en ce  and 
p a r t ic u la r ly  o f th e  p o s it io n  in  th e  U n ite d  Kingdom.
F la t  carcinom a in  s i tu  may encompass a number o f  d isease  e n t i t i e s  
w ith  d i f f e r in g  prognosis , as in vas io n  ra te s  as low as 0% o f  10 
cases (B a rle b o , Sorensen & Soeborg-O lsen , 1 9 7 2 ), and 11% (Farrow  
e t  a l . ,  1977) and as h igh as 61% (D a ly , 1976 ), 73% (U tz , Hanash
& Farrow , 1970) and 50 to  80% (W hitm ore, 1979) have been 
re p o rte d . F la t  carcinom a in  s itu  is  d i f f e r e n t  in  in c id e n c e , 
appearance, symptomatology and imp 1ic a t  ions from p a p i l la r y  t r a n ­
s i t io n a l  c e l l  carcinom a, and w i l l  no t be fu r th e r  considered  h e re .
The p resen t s tu d ie s  c h ie f ly  concern th e  commoner, exo p h y tic  
s u p e r f ic ia l  le s io n s . These a re  u s u a lly  e le c tro c o a g u la te d  o r  
e n d o s c o p ic a lly  removed a t  th e  tim e  o f  d ia g n o s is , a lthough  b i ­
o ps ies  o f  mucosa a d ja c e n t to  th e  tumour, o r a t  s e le c te d  d is ta n t  
s i te s  may s t i l l  show a ty p ia  o r ,  o c c a s io n a lly , fra n k  carcinom a in  
s i t u  (M elicow , 1952; A lth au sen , P rou t & D a ly , 1976; C u t le r  e t  
a l . ,  1982; Sm ith , E lto n , Beynon, e t  a l . ,  1983 ). W ith in  two years
o f  tre a tm e n t, 34-55% o f p a t ie n ts  w i l l  have a fu r th e r  tumour 
id e n t i f ie d  (Chapman, 1950; G reene, e t  a l , 1973; Loening,
Narayana, L o d er, e t  a l . ,  1980; C u t le r  e t  a l . ,  1982; Smith e t  a l . ,
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Recurrence I
I
Author + _
1
T o ta l !
Greene (1 9 7 3 )* 45 55
1
100 ! 
1
C u t1er (1982) 89 99 188 ! 
1
Chapman (1950) 23 20 43 :
T o ta l 157 174
1
331 !
i
% 47 53 100 !
*  Grade I tumours only
TABLE 2
NUMBERS OF PATIENTS WITH T « -i BLADDER TUMOURS WITH RECURRENCE
IN TWO YEARS
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1983, ta b le s  1 -2 , fp  1 9 -2 0 ) . (F u r th e r  tumours w i l l  no t h ere  be 
sep ara ted  in to  " t ru e  re cu rren ce s" a t  th e  o r ig in a l  s i t e ,  and "new 
occurrences" e lsew h ere , as th e  management is  e s s e n t ia l ly  id e n t i ­
c a l . )  W hether th e  evidence o f  d is ta n t  a ty p ia  is  accepted  as 
in d ic a t in g  th a t  p a p i l la r y  tumours a re  o n ly  th e  lo c a l m a n ife s ta ­
t io n  o f  u r o th e l ia l  f i e l d  change, o r whether im p la n ta tio n  a t  th e  
tim e  o f  re s e c tio n  is  th e  cause o f  h e te ro to p ic  tumours l a t e r ,  
lo c a l su rgery  a lo n e  does not p reven t re c u rre n c e . The f iv e -y e a r  
s tu d ie s  found 71% re c u rre d , range 58-84% ( ta b le  3 , fp  21) A t 15 
y e a rs , a f ig u r e  o f  73% has been re p o rte d  (Greene e t  a l . , 1 9 7 3 ) .
The f iv e -y e a r  s u rv iv a l o f  p a t ie n ts  w ith  s u p e r f ic ia l  b lad d er  
cancer (S tage  A o r O o f th e  Jew ett and S trong c la s s i f ic a t io n )  has 
been re p o rte d  to  be 61-83% , w ith  an o v e ra ll  f ig u r e  o f  around 67% 
(N ic h o lls  & M a rs h a ll,  1956 a&b; Barnes, Bergman, Hadley e t  a l . ,  
1967; Cox, Cass & Boyce, 1969; U tz , Schm itz, Fugelso e t  a l . ,  
1973; O 'F ly n n , Sm ith & Hanson, 1975). S eparate  f ig u re s  fo r  each 
s tag e  a t  f i v e  yea rs  a re  u n a v a ila b le  in  p a t ie n ts  t r e a te d  by TUR 
a lo n e . S u rv iv a l is  a d i f f i c u l t  en d -p o in t fo r  e v a lu a tin g  t r e a t ­
m ent, both because th e  tim e  taken  to  reach i t ,  even in  th e  age- 
group a f fe c te d  by b lad d er can cer, would pro long s tu d ie s , and 
because o th e r i l ln e s s e s  cou ld  in te rv e n e  cause d ea th . T h is  p ro ­
b ab ly  c o n tr ib u te s  to  th e  shortage  o f sep ara te  s u rv iv a l d a ta  fo r  
Ta and Ti tumours.
H is to lo g ic a l fe a tu re s  o f  in d iv id u a l c e l l s  (G rad in g ) have long
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Author
P a t-
Reci
+
ients
jrrenc
w ith  I
ii
:e 1
ii
T o ta l !
Chapman (1950) 
Greene (1 9 7 3 )*  
Althausen (1976) 
Enq1 and (1981)
12
58
109
232
20
42
20
100
i
32 1
i
100 j
i
129 I 
1
332 1
T o ta l
%
411
71
169
29
1
580 1 
1
100 I
*  Grade I tumours o n ly . 
+ = recurrence present 
-  = recurrence absent
TABLE 3
NUMBERS OF PATIENTS WITH T * - i  BLADDER TUMOURS WITH RECURRENCE
AT FIVE YEARS
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been as s o c ia te d  w ith  p rognosis  ( B roders , 1922) .  Grade changes 
may be in te rp re te d  as a p ro g re s s iv e  d e te r io r a t io n  in  th e  progno­
s i s ,  bu t th e  in t e r -  and in tra -o b s e rv e r  v a r ia t io n s  in  c a te g o r iz in g  
g iven  s l id e s  a re  c o n s id e ra b le  (Ooms, Anderson, Alons e t  a l . ,  
1 9 8 3 ), making a s in g le  o b s e rv a tio n  an u n r e l ia b le  m arker o f  
prognosis in  th e  in d iv id u a l .  Where p ro g ress io n  is  d e fin e d  as 
in c rease  in  Grade o r  S tage , ( e . g .  England, P a r is  & B landy, 1981; 
L u tz e y e r, Rubben & Dahm, 1982) s e v e ra l outcome v a r ia b le s  a re  
combined and presumed to  be o f  equal w e ig h t. E q u a lly , s tu d ie s  
showing Grade as a p ro g n o s tic  in flu e n c e  u s u a lly  f a i l  to  c o n s id e r  
th e  p o s s ib le  in flu e n c e  o f  s tage  ( e . g .  G i lb e r t ,  Logan, Kagan e t  
a l . ,  1978) .
F u rth e r  tumours a re  l i t l e  more than  an inconvenience, however, 
unless th ey  lead to  d isease  p ro g re s s io n , to  worse symptoms or 
poorer s u r v iv a l .  D isease p ro g ress io n  to  in v o lv e  b lad d er m uscle o r  
beyond is  b e lie v e d  to  have s im ila r  im p lic a tio n s  as n ew ly - 
diagnosed d isease  in v o lv in g  th e  same la y e rs , in  th e  J ew ett and 
Strong (1 9 4 6 ) and th e  TNM c la s s i f ic a t io n s  (U ICC, 1987) ,  and is  
th e re fo re  a s ig n i f ic a n t  y a rd s tic k  o f  tre a tm e n t e f fe c t iv e n e s s ,  
p a r t ic u la r ly  from  th e  p a t ie n t ’ s p o in t  o f  v iew . T h is  assum ption  
may be an o v e r s im p l i f ic a t io n ,  bu t t h is  does not appear to  have 
in v a lid a te d  Stage as a p ro g n o s tic  in d ic a to r .
C l in ic a l  exp e rie n c e  suggests th a t  s u p e r f ic ia l  tum ours, i f  th ey  
re c u r , m ostly  rem ain s u p e r f ic ia l  (J e w e tt ,  1977; M a rs h a ll,  1956;
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Number P rogressed/N im her S tu d ied
Authors Ta Ti
11
Tota l !
C u tle r , 1982 $ 4 /120 19/78
1
23/198!
i
Lu tzeyer, 1982* 19/194 27/80 46/274!i
Henev. 1983 6/144 19/63 25/201!
To ta l 29/458 65/221
i
94/673!
i
% ( 95%CI) 6 (4 .9 ) 2 9 (2 3 .3 5 ) 14(11.17')!
$ tw o-years ' fo llow -up  
*  Progression in  Grade and Stage
TABLE 4
STAGE AND NUMBERS OF PATIENTS WITH PROGRESSION AT 2 -3  YEARS
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Greene e t  a l . ,  1973; V a rk a ra k is , e t  a l . ,  1974; C u t le r  e t  a l . ,  
1 9 8 2 ). Fourteen  per c e n t o f  a t o t a l  o f  673 p a t ie n ts  w ith  
s u p e r f ic ia l  b la d d e r cancer managed by lo c a l su rgery  and fo llo w ed  
fo r  th re e  ye a rs  progressed ( t a b le  4 , f p 2 2 ) .  The f iv e -y e a r
e s tim a te  was 28% o f  345 p a t ie n ts  ( t a b le  5 , fp 2 3 ) .  One group has
re p o rte d  t h a t ,  a t  each ep isode o f re c u rre n c e , th e  in c id en ce  o f  
p ro g res io n  is  c o n s ta n t, between 5 and 10% (M ackenzie e t  a l . ,  
1981) .
On th e  o th e r hand, e ig h t y - f iv e  p e rc e n t o f  p a t ie n ts  w ith  m uscle- 
in v a s iv e  d isease  p re s e n t de novo, w ith o u t p rev io u s  evidence o f  
s u p e r f ic ia l  d is e a s e  (Kaye and Lange, 1982; P ro u t, 1982; C u t le r  e t  
a l . ,  1982) .  N in e ty -e ig h t  p e rc e n t p resen t w ith in  one year o f  
d ia g n o s is , suggesting  th a t  some a p p a re n tly  s u p e r f ic ia l  tumours 
were understaged a t  th e  i n i t i a l  assessment (C u t le r ,  e t  a l . 1982) .  
Thus, th e  presum ption th a t  c u rre n t management p reven ts  muscle 
in vas io n  is  open to  q u e s tio n .
In  re c e n t s tu d ie s  o f  p a t ie n ts  managed w ith  b lad d er c o n s e rv a tio n , 
Ta tunours (th o s e  co n ta in ed  w ith in  th e  e p ith e liu m , and not 
in vad ing  th e  lam ina p ro p r ia )  show p ro g ress io n  to  muscle in vas io n  
a t  th re e  years  in  6% o f cases , range 2-10% ( ta b le  4 , f p 2 2 ) .  A t 5 
y e a rs , 26%, range 17-32%, have been re p o rte d  to  have progressed  
( t a b le  5 , f p 2 3 ) .
Ti tumours (th o s e  invad ing  th e  lam ina p ro p r ia , bu t n o t b lad d er
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Number Progressed/Number Studied
Authors Ta T i T o ta l
V a rk a ra k is ,1974 6 /36 34/130 40/166
A lthausen, 1976 31/110 8 /19 39/129
Stephenson.1985 7/22 9 /28 16/50
T o ta l 44/168 51/177 95/345
%(95%CI) 26 (13 .39 ) 2 9 (1 7 .4 1 ) 2 8 (1 9 .3 7 )
TABLE 5
STAGE AND NUMBERS OF PATIENTS WITH PROGRESSION AT 5 YEARS
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muscle) show 29% progression a t 2-3  years, range 24-34% (ta b le  
4 , fp22) and 29% a t  5 years, range 26-42% (ta b le  5 , fp 23 ). The
three-year fig u re  fo r  a l l  s u p e rfic ia l tumours in  these studies  
was 17%, range 12-23% (ta b le  3, fp 21 ); and the 5-year, 28%,
range 24-32% (ta b le  4 , fp 22 ). The fiv e -y e a r figu res are somewhat
surpris ing , a t  f i r s t  glance, suggesting th a t the e ffe c t  o f stage 
on progression o f s u p e rfic ia l bladder tumours is  tra n s ie n t, but 
may be influenced by the predominance o f American hospital 
series , from which low -risk  p a tien ts , p a r t ic u la r ly  those w ith  T« 
disease, may have been excluded by re fe r ra l b ias. The series  
reported from the London Hospital (England e t a l . ,  1981) and of
comparable s ize  to  the to ta ls  in ta b le  5 , but trea ted  w ith  a 
combination o f local surgery, in traves ica l thioTEPA, and rad ica l 
radiotherapy, d istinguished the 6% ra te  in T« from 28% in  Ti .
Although the presence o f lamina propria  invasion did not appear 
to  a ffe c t  progression w ith in  f iv e  years o f diagnosis in  the  
studies reviewed above tre a te d  w ith local resection alone, other 
ch a ra c te ris tics  o f the tunour may ind icate  low need of 
surve illance against progression. One group found tunour s ize  
re la te d  to  progression w ith in  one year (C u tle r e t  a l . ,  1982), but 
not a t  two, as the incidence o f progression was low. Other 
studies have fa ile d  to  id e n tify  an association between 
progression and s ize  greater than 5 cm, although there was a lin k  
between recurrence and s ize .
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Tunour m u lt ip lic ity  was found to  be re la te d  to  progression in  
several studies o f apparently unselected patien ts  managed by 
local surgery. Percentages w ithout denominators, ranges, or 
confidence in te rva ls  were reported a t  th ree  years a f te r  diagnosis 
(Lutzeyer e t a l . ,  1982). In T« tumours, 18* o f s in g le  lesions 
progressed, compared w ith  43* o f p a tien ts  w ith  m u ltip le  tumours; 
in Ti , 33* compared w ith  46*. Lerman and colleagues reported a
v ariab le  length of fo llow -up o f 103 p a tien ts . Of pa tien ts  w ith
s ing le  tunours, 5 * o f s ing le  "papillom ata", and 14* o f patien ts  
w ith  m u ltip le  papillom ata, became "carcinomata" (Lerman, H utter & 
Whitmore, 1970). The fa lse-n egative  ra te  was 5 * , 95* confidence 
in te rv a l (0 ,2 6 * ) ,  q u ite  aceptable fo r  se lection  o f a low -risk
group. Heney's 58 patien ts  re fle c te d  an association between 
m u lt ip lic ity  and progression in an average follow -up o f three  
years, w ith a fa lse -n egative  ra te  o f 14 (0 ,4 5 )*  (Heney, Ahmed, 
Flanagan e t a l . ,  1983). Patients w ith low-grade low-stage tunours 
followed fo r f iv e  years (Althausen e t a l . ,  1976) showed progres­
sion in 4 *  o f 23 patien ts  w ith s ing le  tunours, and 43* o f 
patien ts  w ith m u ltip le  tumours. The population studied was sm all, 
but i t  is  tempting to  surmise th a t th is  may be representative  of 
a genuinely more s ig n ific a n t ro le  o f m u lt ip lic ity  in  low-stage 
low-grade disease, which is  swamped by the e f fe c t  o f grade. The
apparent s ign ificance o f m u lt ip lic ity  has been obscured by poor
presentaton o f data, selected study populations, and by a fa i lu r e  
to  use a precise end-point fo r fo llow -up . Two groups have 
reported th a t tunours th a t are m u ltip le  a t  presentation are more
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lik e ly  to  show invasion o f the lamina propria (Varkarakis e t 
a l . ,  1974; W illiam s e t a l . ,  1977). The poorer prognosis in 
patients  w ith m u ltip le  tunours than those w ith s o lita ry  tunours 
(England e t a l . ,  1981b; Heney e t  a l . ,  1983) might in p art
represent the d i f f ic u l t y  o f examining a l l  areas o f the tunour fo r  
invasion. England's group (1981b) found th a t patients  w ith f iv e  
or more tunours a t  each recurrence a l l  progressed w ith in  15 
months, and 11/28 (39$) pTi G3 tunours and 29/59 (49$) o f pTi G2
tunours progressed w ith in  5 years, but only 8/140 (6$) o f pT«. 
This strongly suggests th a t i t  should be possible to  se lect 
patien ts  whose s u p e rfic ia l tunours are u n lik e ly  to  progress, fo r  
less intensive fo llow -up , or poor-prognosis patien ts  who might 
b en efit from more rad ica l treatm ent.
S u p erfic ia l bladder tunours are l ik e ly  to  remain s u p e rfic ia l, but 
w ith recurrences, and are u n lik e ly  to  decrease survival 
appreciably. The e ffe c t  o f s ize  is  unclear, and m u lt ip lic ity  a t  
diagnosis, or on successive recurrences, grade and stage 
progressively more s ig n ific a n t in prognosis.
CURRENT MANAGEMENT
Conventional management o f s u p e rfic ia l lesions (those th a t , on 
biopsy, do not invade detrusor muscle) involves cystoscopic 
diagnosis and resection , followed by surve illance , usually under 
general anaesthesia, one to  four times per year. Usually cl in i -
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cians in the United Kingdom advise follow -up fo r a t  least f iv e
years a fte r  the la te s t recurrence, as asymptomatic recurrences
are ccnrmon. The survival o f patien ts  w ith s in g le , s u p e rfic ia l,  
w el1-d if fe re n t ia te d  tunours approaches normal 1 ife-expectancy fo r  
age (N icho lls  & Marshal 1, 1956b). There is  l i t t l e  proportionate
b en efit in surv ival possible as a re s u lt  o f treatm ent. In the  
absence o f symptoms, the primary aim of su rve illance is  to  
prevent progression.
Management by review cystoscopy has a physical and psychological 
m orbidity (Monsour e t a l . ,  1985, Denholm e t a l . ,  1990). The
number o f cystoscopies required to  detect one episode o f recur­
rence was seventeen in one series (Meuleman & Delaere, 1988), 
although the exact nunber w il l  depend on p a tien t se lec tio n , and 
on the frequency o f examination chosen. As patien ts  in the age- 
group most a ffec ted  by bladder cancer are o ften  subject to  other 
chronic complaints which make o u t-p a tien t anaesthesia too haz­
ardous, the surve illance  o f bladder cancer makes major demands on 
urological in -p a tie n t resources, fo r a re la t iv e ly  low tunour
pick-up ra te . In the main age-range fo r  th is  disease, l i f e -  
expectancy is  already lim ite d , and p a tien ts ' p r io r it ie s  are  
l ik e ly  to  be d if fe re n t  from those o f younger age-groups. Demands 
on q u a lity  o f l i f e  may be as important to  the ind iv idual as 
poten tia l changes in  su rv iva l, p a r t ic u la r ly  to  those already  
suffering  from chronic illn esses . In the United Kingdom, cysto- 
scopic review is  carried  out in most cases under general
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anaesthesia. Patients are predominantly male, and the S-shaped 
male urethra has to  be d is to rted  to  acconmodate the s tra ig h t rod- 
lens cystoscope, or the bigger resectoscope. Under the same 
general anaesthetic, i t  is possible to  diagnose and t re a t  
recurrent tunours by resection. In Europe and the United States  
of America, where the fin a n c ia l resources fo r such management are  
less re a d ily  a v a ila b le , o f f ic e  cystoscopy, and treatm ent o f small 
tumours by cystodiathermy, are s t i l l  cannon, as indeed they used 
to  be in the UK. This tends to  reduce the recruitm ent o f good- 
prognosis tunours to  hospital se ries , and should be remembered in  
in te rp re tin g  series from these sources. This author finds th a t UK 
patients  who have experienced r ig id  instrumentation under top ica l 
and under general anaesthesia fin d  general anaesthesia h ighly  
desirab le .
In the peak age-group fo r bladder cancer, the s ix th  to  eighth  
decades, chronic conditions th a t complicate general anaesthesia  
are prevalen t, such as diabetes, chronic b ro n ch itis , and 
cardiovascular disease. Patients w ithout the necessary fam ily , 
transport, and telephone f a c i l i t ie s  fo r safe o u t-p a tien t pro­
cedures are more lik e ly  to  depend on adnission to  public  
hosp ita ls , where th e ir  adnission competes unfavourably w ith  those 
of emergency p a tien ts , fo r reducing numbers o f beds. In th is  
s itu a tio n , i t  would be helpfu l i f  o u t-p a tie n t methods o f manage­
ment could be found.
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Authors No (90 Missed I Total (95 * C l)  I
Abu-Yousef 1984 1 (6 ) 17
i
( -5 ,1 7 * ) !
Boccon-Gibod 6 (20) 30 ( 6 ,3 4 * )!  
1
1985
111
Brun 1984 14 (29) 49 ( 1 ,4 6 *)!  
1
Dershaw 1987 0 (0 ) 25 ________11
Juul 1986 20 (25 ) 79 (1 6 ,3 5 * ) j
Malone 1986 22 (50) 50 (3 5 ,6 5 *)!
Rosenki1de- 6 (9 ) 67 (2 ,1 6 * )!
i
Olsen 1985
iiii
Vallancien 1986 15 (26) 58 (1 5 ,3 7 *)!
Total 84 (221 375 (1 8 .2 6 *)!
TABLE 6
NUMBER ( * )  OF PATIENTS MISDIAGNOSED AS TUMOUR-FREE BY 
TRANSABDOMINAL ULTRASOUND
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The present studies o f in traves ica l chemotherapy developed from 
the introduction o f f le x ib le  f ib re o p tic  cystoscopy, which the  
present author had studied in both a d is t r ic t  and a teaching  
ho sp ita l, and found to  be acceptable to  p a tien ts , less tim e- 
consuming than rod-lens examination, accurate and safe  
(Appendices 1 -3 ). With the p ro b a b ility  th a t diagnosis would no 
longer need general anaesthesia or hospital adnission in the  
considerable m ajo rity  o f p a tien ts , an o u t-p a tien t approach to  
treatment and, more irrmediately, to  prophylaxis against recur­
rence and progression was needed.
LESS INVASIVE DIAGNOSIS OF RECURRENCE : ULTRASOUND
Minim ally invasive follow -up by transabdcminal ultrasound has a 
s ig n ific a n t fa lse -n egative  ra te . Comparison w ith the find ings a t  
cystoscopy gives 0/25 (Dershaw & Scher, 1987) to  22/44 (Malone, 
Weston-Underwood, Aron e t a l , 1986) fa ls e  negative ultrasounds. A 
sunmary o f the data ava ilab le  is given in  ta b le  6 (fp 2 8 ). In most 
o f these studies, i t  appears th a t the cystoscopist was aware of 
the re s u lt o f the ultrasound, so no assessment o f the fa ls e -  
negative ra te  o f cystoscopy was derived. O vera ll, 22(0-50)95 o f 
patients w ith a tumour had negative ultrasounds in these studies. 
Ultrasonographers providing a general ultrasonograpy service  
might be expected to  miss more. As Boccon-Gibod and co-authors 
point out (Boccon-Gibod, Le Portz , Godefroy e t a l . ,  1985), there  
may be a greater number o f f l a t  mucosal abnorm alities missed by
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ultrasound, th a t could be detected by the add ition  o f cyto log ical 
re s u lts . Ju u l's  group (Ju u l, Torp-Pedersen, Larsen e t a l . ,  1986) 
with combined cytology and abdominal ultrasound, s t i l l  had a 
fa ls e ly  negative te s t  in 19% of 79 patien ts  w ith tunours, 14% of 
a l l  105 negative te s ts . In theory, transurethra l ultrasound may 
overcome some o f the problems o f the transabdominal rou te , but 
requires r ig id  or sem i-rig id  instrum entation, s im ila r  to  rod-lens  
cystoscopy (Nakamura & N ijim a, 1980; Abu-Yousef, Narayana, Fran- 
ken e t a l . ,  1984; Devonec, Chapelon, Codas, e t a l . ,  1987). 
Ultrasound has never been able to  detect carcinoma in s itu ,  as 
cytology can, and cystoscopy may. The contribution  o f ultrasound  
to  follow -up needs fu rth e r development.
LESS INVASIVE DIAGNOSIS OF RECURRENCE: URINE CYTOLOGY
I t  has been argued th a t cytology of bladder washings can id e n tify  
88% of patien ts  who have cystoscopically v is ib le  tumour (Flanagan 
& M il le r ,  1978), and is  a v a lid  sub stitu te  fo r  cystoscopic 
fo llow -up. Seme authors report 4% o f a l l  patien ts  tested as 
having fa ls e  negative cytology in th e ir  hands (Legramandi G ian- 
noni, Ricci Barbini e t  a l . ,  1989) but do not report i t  as a
proportion o f those w ith cystoscopic tumour, so the ra te  could 
re s u lt from studying a population w ith few recurrences. C yto log i­
cal examination is  p a r t ic u la r ly  sen s itive  in high-grade disease 
(Kern, Bales & Webster, 1968), where i t  is probable th a t more 
rad ical treatm ent is  ca lled  fo r  (B irch & Harland, 1989; Jenkins,
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e t a l . ,  1989) and in  CIS th a t is  recurrent a f te r  inrmunotherapy
(Harland e t  a l . ,  1991), where a s im ila r  rad icalism  could be 
ju s t if ie d .  Thus, i t  could be argued, cytology is  most e ffe c tiv e  
as the  horse is  b o ltin g , i f  not a f te r  i t  has bolted; but not a t  a 
tim e when treatm ent could close the s tab le  door. In the United  
Kingdom, the present cyto log ical establishment has d i f f ic u l t y  
coping w ith  the workload generated by cerv ica l cytology on a 
th re e -y e a rly  screening o f women over 35, so i t  would be hard to  
s ta f f  a three-monthly cyto log ical fo llow -up fo r a l l  p a tien ts  w ith  
s u p e rfic ia l bladder cancer. Attempts a t automation have ye t to  
gain widespread acceptance.
FIBREOPTIC CYSTOSCOPY
The ap p lica tio n  o f modern fib re o p tic  technology to  urology o ffe rs  
the p o s s ib ility  o f bladder tumour diagnosis under top ica l 
analgesia in  o u t-p a tien ts  (Fowler, 1984; Powell, e t  a l . ,  1984; 
Fawcett, e t  a l . ,  1991). I t  now seems l ik e ly  th a t f le x ib le  cystos­
copy w il l  g re a tly  reduce the need fo r  more invasive methods of 
diagnosis, and improve the q u a lity  o f l i f e  fo r p a tien ts  under­
going fo llow -up .
F ib reop tic  cystoscopes can negotiate the signoid male urethra  
without d is to rtin g  i t .  As a re s u lt ,  the r is k  o f in ju rin g  or 
abrading the u re th ra , and the need fo r  anaesthesia are reduced. 
The proportion o f cystoscopies under general anaesthesia a t  which
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there  was no recurrence was reduced in one series  from 61& to  2396 
(Fowler e t  a l . ,  1984). P atien ts  in a London Teaching Hospital
found the procedure under to p ica l analgesia comfortable compared 
w ith  previous rod-lens examinations under general anaesthesia 
(Flannigan e t a l . ,1 9 8 8 ) ,  and in the USA, w ith rod-lens examina­
tio n s  carried  out under to p ica l analgesia on the same day 
(Figueroa, e t  a l . ,  1984). A more recent report from Edinburgh, 
comparing synchronous, but non-randomised groups, found th a t  
patien ts  having f le x ib le  examinations experienced fewer symptoms 
than those undergoing r ig id  instrumentation (Denholm e t a l . ,  
1990). The present author, introducing f le x ib le  cystoscopy in a 
d is t r ic t  general h o s p ita l, and then in a London teaching hospi­
t a l ,  tested the b ac te rio lo g ica l and diagnostic safety of the  
procedure, and i ts  a c c e p ta b ility  to  patients  (Appendices 1 -3 ).
Early investigators studied induced b a c te riu ria  in d ire c tly . Fow­
le r  (1984) reported th a t b a c te r iu r ia  hadbeen id e n tif ie d  fo llow ing  
f le x ib le  cystoscopy, but the patien ts  had undergone other pro­
cedures also , including M arshal1-M archetti-Krantz operations. 
When the less elaborate aseptic  precautions taken fo r  f le x ib le  
cystoscopy were used used fo r  rod-lens cystoscopy in out­
p a tien ts , the incidence o f b a c te r iu r ia  was &6 (Fozard, Green, 
Harrison, e t  a l . ,  1983). The questionnaire study o f Denholm and 
colleagues (1990) reported a higher incidence o f symptoms in tth e  
f i r s t  week a f te r  rod-lens cystoscopy than f ib re o p tic  cystoscopy, 
but did not report b ac te rio lo g ica l data. The present author, with
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a group a t Frimley Park H ospita l, Surrey, found a lower incidence 
o f b a c te riu ria  in patien ts  undergoing f le x ib le  cystoscopy than in  
a simultaneous, non-randomised group undergoing rod-lens cystos­
copy, although the d ifference was not s ta t is t ic a l ly  s ig n ific a n t.  
There was no evidence o f a greater tendency to  induce b a c te riu ria  
by the f le x ib le  method (Appendices 1 -3 ).
I f  f le x ib le  cystosoopy is to  replace rod-lens examinations in 
fo llow -up , the s e n s it iv ity  o f diagnosis o f recurrence is c ru c ia l. 
As Pope and Wickham (1991) have pointed out, the view v ia  a 
stationary  f ib re o p tic  instrument remains fragmented because o f 
the f ib re  bundle diam eter, and in fe r io r  to  rod-lens o p tics , but 
as the instrument is  moved in use, i t  is  possible fo r  the  
observer to  in tegrate  and in trap o la te  data to  compensate. 
Because anaesthesia fo r rod-lens cystoscopy in the United Kingdom 
d iffe rs  from th a t in Europe and in the United States o f America, 
the present author carried  out the f i r s t  prospective, double­
b lind  con tro lled  comparison of the like lihood  o f missing the  
diagnosis of a recurrence (the fa lse -n egative  ra te )  (Walker & 
Liston, 1987; Appendix 3 ). P ractice in  the USA leads to  rod-lens  
cystoscopy being carried  out under to p ica l analgesia, so American 
studies do not compare the options appropriate to  the United 
Kingdom (dayman, Reddy & Lange, 1984; Figueroa e t a l . ,1 9 8 7 ) .  The 
two comparisons carried  out in the United Kingdom were p i lo t  
studies o f the adequacy o f the procedure before i ts  su b stitu tio n  
fo r rod-lens examination, and both examinations were carried  out
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under general anaesthesia (Fowler 1984; Powell e t  a l . ,  1984). The 
study o f Meyhoff's group (Meyhoff, Andersen, Klarskov e t  
a 1.,1988) used the same general or spinal anaesthetic fo r  both 
procedures. The only authors to  study two re levan t anaesthetic  
techniques were Webb and colleagues (Webb, B u tler & F itzg e ra ld , 
1984) who reported an open comparison in 23 p a tie n ts , who had 
f iv e  episodes o f recurrence, two o f which (40%) were not 
diagnosed w ith  the f le x ib le  choledochoscope used. The t in y  number 
o f tumour episodes av a ila b le  to  be diagnosed defies  s ta t is t ic a l  
analys is , and as the re s u lt o f the f le x ib le  cystoscopy was 
apparently known to  the rod-lens cystoscopist, there  was no 
mechanism to  assess the accuracy o f the conventional examination, 
dayman reported missing tumour episodes in one p a tie n t w ith each 
instrument, and one o f two synchronous tumours in another 
p a tie n t, but does not report the to ta l number of tumours or 
tumour episodes (dayman e t a l . ,  1984). Meyhoff reported missing
3/15 (20%) tumour episodes on f le x ib le  cystoscopy, but none on
rod-lens examination (Meyhoff e t  a l . ,  1988), when both were
carried  out under spinal or general anaesthetic. F igueroa's group 
missed one tumour w ith each instrument, used under to p ica l 
analgesia but give no denominator (Figueroa e t a l . ,  1987). Fowler 
(1984) reported th a t there were no fa ls e -p o s itiv e  examinations, 
when f le x ib le  cystoscopy was compared w ith rod-lens examination 
under general anaesthesia, but gave no data on missed tumours. 
The proportion o f tumours missed is  the re levan t measurement i f  
f le x ib le  cystoscopy is  safe to  be used to  avoid anaesthetic ris ks
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in  p a t ie n ts  who do n o t have tumour re c u rre n c e s .
O u t -p a t ie n t  d iag n o s is  by f ib r e o p t ic  cystoscopy has developed and 
spread s in c e  i t  became a p o s s ib l i ty  in  th e  mid 1980s, and th e  
need fo r  methods o f  a n t ic ip a t in g  and p re v e n tin g  p ro g ress io n  has 
been u n d e rlin e d .
PREDICTIVE TESTING
The t e s t  used to  choose p a t ie n ts  s u ita b le  fo r  lo w - in te n s ity  
s u rv e il la n c e  re q u ire s  to  be a s e n s it iv e  p re d ic to r  o f  th e  
p o s s ib i l i t y  o f p ro g ress io n  (o r  re c u rre n c e  i f  symptoms r a th e r  
than  p ro g ress io n  a re  to  be a n t ic ip a te d  and p re v e n te d ), whereas 
th e  emphasis o f  a t e s t  used to  dec ide  which p a t ie n ts  need more 
ra d ic a l  tre a tm e n t needs to  be s p e c if ic  fo r  h igh r i s k ,  to  avo id  
o v e r - t re a tm e n t . Most p ro g n o s tic  te s ts ,  such as loss o f  b lood
group a n tig e n s , and even Grade and Stage have been developed
r e t r o s p e c t iv e ly , by te s t in g  p a t ie n ts  w ith  known p ro g re s s io n , 
using  a rc h iv a l m a te r ia l ,  and tend  to  be more s p e c if ic  than  
s e n s it iv e .  On th e  w hole , th e  problems outw eigh th e  p o te n t ia l  
b e n e f i t  (A b e l, 1988 ).
A b n o rm a lit ie s  o f  th e  mucosa in te rv e n in g  between e x o p h y tic  tumours 
have been g e n e ra lly  recogn ised  to  r e la t e  to  prognosis  s in c e
M e lic o w 's  (1 9 5 2 ) study o f  cystectom y specimens. D e f in i t io n s  o f  
th e  a b n o rm a lit ie s  vary  c o n s id e ra b ly , in  a d d it io n  to  th e  incon -
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s is te n c ie s  o f  c a te g o r iz a t io n  m entioned above (Ooms e t  a l . ,  1983 ), 
and th e  v a r ia b le  d ec is io n s  w hether to  in c lu d e  carcinom a in  s i t u  
a s s o c ia te d  w ith  a p a p i l la r y  tum our. F u r th e r , th e  a b n o rm a lity  may 
be assayed on th e  m argins o f  th e  o r ig in a l  re s e c tio n  o r a t  
a r b i t r a r y  p o in ts  in  th e  quadrants o f  th e  b la d d e r. As a r e s u l t ,  
s tu d ie s  a re  r a r e ly  com parable.
Two re c e n t s tu d ie s  using th e  N a tio n a l B ladder Cancer C o -o p e ra tiv e  
Group c r i t e r i a ,  o ver much th e  same d u ra t io n , have te s te d  b io p s ie s  
a t  d is ta n t  s i t e s .  C u t le r 's  (1 9 8 2 ) group found in v a s iv e  tumours 
developed in  15% o f p a t ie n ts  o v e r a l l ,  w ith  40% in  th e  more 
d y s p la s t ic  subgroup (95% con fid en ce  in te r v a l 10,70%) and a f a ls e -  
n e g a tiv e  r a t e  o f  9%, which m igh t be thought low enough to  use to  
s e le c t  p a t ie n ts  fo r  m inim al s u r v e il la n c e . Heney's (1983 ) group, 
over a longer p e r io d , found a 10% (0 ,25% ) inc id en ce  o f  in vas io n  
o v e r a l l ,  33% in  those w ith  m oderate to  severe d y s p la s ia , and a 
f a ls e -n e g a t iv e  r a te  o f  8 (3 ,1 2 )% .
The S p e c if ic  Red C e ll Adherence t e s t  was th e  f i r s t  method o f  
d e te c tin g  changes in  c e l lu la r  s u rfa c e  a n tig e n s , which were found  
to  be d e le te d  in  more in v a s iv e  tumours s tu d ie d  in  re tro s p e c t . A 
number o f  s tu d ie s  o f  a rc h iv a l b io p s ie s  (summarised in  ta b le  7 , 
fp 3 5 ) found th a t  5% o f  301 p a t ie n ts  w ith  normal blood group 
a n tig e n s , and 67% o f  193 p a t ie n ts  w ith  a n tig e n  d e le t io n  developed  
in v a s iv e  le s io n s . The fa ls e -n e g a t iv e  r a t e  was 5 (3 ,7 )% . The
r e s u lt in g  s l id e s  cannot be k e p t, however, and, u n t i l  th e  d eve lo p -
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ment o f the r e la t iv e ly  weak an ti-H  antibodies, patien ts  w ith  
blood-group 0 could not be tested . More modern irrmunoperoxidase 
studies ( ta b le  8 , fp36) had a higher fa lse-n egative  ra te , 14
(5 ,2 4 )*  o f 59 p a tie n ts , than the in i t ia l  reports , and would 
requ ire  fu rth e r prospective study before they were used to  
minimise the in te n s ity  o f fo llow -up . The Thomsen-Friedenreich or 
T- antigen is  s lig h t ly  more complex, in th a t i t  is normally 
masked, and is  abnormal i f  i t  is  unmasked, or deleted, but small 
studies w ith  a three-year fo llow -up reported progression in 69 
patien ts  w ith  o f 7 (1 ,1 3 )*  o f 69 patien ts  (Coon, Weinstein & 
Summers, 1982; Sumners, Coon, Ward e t a l . ,  1983). A s im ila r
p o ten tia l use been suggested fo r irrmunohistochemical s ta in ing  of 
cytokeratins (Abel, C o rn e ll, Buamah e t a l . ,  1987; F e itz  Beck,
Smeets e t a l . ,  1985), and o f the receptor fo r epidermal growth 
fa c to r , EGFR1 (N eal, Marsh, Bennett e t a l . ,  1985).
The presence o f marker chromosomes on karyotyping has been 
reported to  have a very low fa lse -n egative  ra te  (Sandberg, 1977; 
Sumners e t a l . ,  1983), and in time th is  may be a useful
in ves tig a tio n , but the figures so fa r  re la te  to  patien ts  in whom 
the study could be carried  ou t, and the te s t is both d i f f i c u l t  
and time-consuming to  perform. Ploidy a t the time o f diagnosis is  
te c h n ica lly  eas ier to  measure, but has not yet been convincingly  
shown to  p red ic t progression (Sumners e t a l . ,  1983). Various
authors have examined in v i t r o  te s ts  on tumour biopsies, in a 
manner akin to  a n t ib io t ic  chemosensitivity te s tin g , w ith the
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in ten tio n  o f p red ic tin g , a t  an e a rly  stage in treatm ent, the drug 
most e f fe c tiv e  fo r the ind iv idual (Hamburger & Salmon 1977; 
Lathan, Von Hoff & C lark , 1984; Hanuske e t a l . 1989). The time 
required fo r  c e llu la r  growth, the nurtoer o f patients fo r  whom 
tumour cu ltu re  is unsuccessful (Salmon 1984; Sarsody e t a l . ,  
1982), the proportion o f fa ls e -p o s itiv e  and fa lse -n egative  tes ts  
(Tannock, 1978), and the possibly heterogeneous response o f 
primary versus m etastatic  tunours (Von Hoff & Clark 1984), have 
lim ited  the benefits  hoped fo r to  the p re c lin ic a l assessment o f  
new drugs. The te s t  bears seme re la t io n  to  tumour behaviour in  
vivo (Lathan e t a l . ,  1984). A te s t  carried  out a t  the s ta r t  o f
treatm ent would address only inherent resistance, not resistance  
induced by suboptima 1 treatm ent, but i f  the mechanics o f the te s t  
were simple enough, th is  would not be an overwhelming d i f f ic u l t y .  
At present, however, th is  te s t  is  not a re lia b le  or e f f ic ie n t  way 
of assessing the f e a s ib i l i ty  o f treatm ent by in traves ica l chemo­
therapy .
Of the methods o f pa tien t se lection  and surve illance proposed as 
an a lte rn a tiv e  or adjunct to  rod-lens cystoscopy w ith  
e lec tro resec tio n , f ib re o p tic  cystoscopy has had the greatest 
impact on the q u a lity  o f l i f e  in  p a tien ts  w ith bladder cancer. 
The transform ation to  a la rg e ly  o u t-p a tien t su rve illance  
increases the importance o f any p o s s ib ility  o f postponing or 
abolishing recurrence or progression by treatments th a t can be 
applied in o u t-p a tien ts .
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I mUNOTHERAPY
In tra v e s ic a l, intraderm al, and oral treatm ent w ith  agents th a t  
can provoke or mimic an immune response to  tumour have been used 
as prophylaxis against recurrence a f te r  resection , and in the  
therapy o f polychronotopic recurrences. In traves ica l in terferon  
alpha is  expensive, and early  c l in ic a l  studies are not 
encouraging (Kwok e t  a l . ,  1989).
B ac illu s  Calmette-Guerin was f i r s t  applied by both intradermal 
and in trav es ica l routes in bladder cancer (Morales, 1981). I t  has 
since been reported th a t there is  no d iffe ren ce  in  e ffe c t  on the  
treatm ent o f d iffu s e  carcinoma in s itu  i f  the intradermal 
treatm ent is  w ithe ld  (Lamm, De Haven, Shriver e t a l . ,  1991).
There is  seme evidence th a t, in add ition  to  reducing recurrence 
more than Adriamycin (M artinez-P ineiro , Jimenez-Leon, M artinez- 
P ineiro  e t a l . ,  1990; Lamm, Blimenstein, Crawford e t a l . ,  1987) 
or ThioTEPA (Rodriguez-Netto, Caserta & Lemos, 1981; Camacho, 
Pinsky, Kerr e t  a l . ,  1980; M artinez-P ineiro  e t a l . ,  1990), BCG
prophylaxis can delay progression (M artinez-P ineiro  e t a l . ,  1990; 
H err, 1991). The main drawback seems to  be th a t BCG prophylaxis  
subjects a mainly asymptomatic patien ts  to  a 90% r is k  of 
c y s t i t is ,  43% o f haematuria, 28% of feve r, 24% of malaise (Lamm 
e t a l . ,  1986), and a small but recorded r is k  o f death (Rawls e t
a l . ,  1988; Deresiewicz, Stone & Aster, 1990) or o f l i f e -  
threatening in fe c tio n  (Steg, Belos, Leleu e t a l , 1989).
39
INTRAVESICAL CHEMOTHERAPY
The frequency w ith which cystoscopy induces i ts  unwanted e ffe c ts  
may be as important as th e ir  s e v e rity . In travesical chemotherapy 
has been widely used to  t r e a t  tunour s th a t prove d i f f i c u l t  to  
manage endoscopically, and th is  has been said by seme to  be i ts  
main ro le  (England e t a l . ,  1981), ra th er than prophylaxis against 
the development o f recurrence or progression. G enerally , drugs 
produce complete response in one th ird  o f /  p a tien ts , p a r t ia l  
response in one th ird , and no response in one th ird  (Lun, 1983; 
T o rti & Lino, 1984). Duration, frequency, in te n s ity , and condi­
tions o f treatm ent remain to  be standardised and optimal condi­
tions to  be defined. O u t-patien t drug treatm ent fo r bladder 
cancer might contribute in two ways to  reducing the need fo r  
cystoscopy and fo r tumour resection , even i f  i t  does not cure the  
tunour o u trig h t.
F ir s t ,  i t  might space out recurrences. In travesical chemotherapy 
has been widely used to  t re a t  s u p e rfic ia l tumours with roughly 
30% complete response, and 30% p a r t ia l response (Lum, 1983; T o rti 
& Lum, 1984). At f i r s t  (Jones & Swinney, 1961) i t  was mainly 
appled to  those lesions not responding to  endoscopic treatm ent 
("therapeutic" in s t i l la t io n s ) ,  but i t  has also been used pro- 
p h y la c tic a lly , a f te r  resection o f a l l  v is ib le  tumours, both w ith  
and without maintenance treatm ent (Lum, 1983; T o rti & Lum, 1984).
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Prophylactic in s t il la t io n s  have been reported to  delay recur­
rence, both in terms o f the in te rv a l per lesion id e n tif ie d  
(Burnand, Boyd, Mayo e t a l . ,  1976) and o f recurrence ra te
(Schulman, Robinson, Denis e t  a l . ,  1982 ) and tim e to  f i r s t
recurrence (Prout, Koontz, Coombs e t a l . ,  1983), although th is
has not been found by a l l  investigators (NBOOGA, 1983; MRC 
Working Party , 1985). Patients who had responded to  therapeutic  
thioTEPA previously, and were then randomized, in a study of 
thioTEPA prophylaxis, to  surve illance and TUR only, had a s im ila r  
disease-free in te rv a l to  new patien ts  who received prophylactic  
thioTEPA (Prout e t  a l . ,  1983), so i t  may be th a t thioTEPA
treatm ent selects pa tien ts  w ith low diease a c t iv ity .
In travesical chemotherapy might o ffe r  the patien t a delay o f the  
progression o f s u p e rfic ia l tumour to  one th a t spreads through the  
bladder wall to  metastasise. While progression implies th a t the  
tumour has persisted or recurred, i t  is  an add itional phenomenon, 
and i t  is possible th a t only Ta tumours should be considered to  
have a low p o ten tia l fo r progression, as Ti lesions have, by 
d e fin it io n , the necessary mechanisms to  breach tissue layers. The 
low ra te  o f progression to  muscle invasion a t two to  three years, 
6% fo r T * , and 29% fo r  Ti ( ta b le  4 , fp24), is l ik e ly  to  be a
major obstacle to  id en tify in g  d ifferences in  progression as a 
re s u lt o f treatm ents. Progression to  muscle invasion has not been 
delayed in con tro lled  comparisons o f the e ffe c t  of in traves ica l 
agents (Schulman, Sy lvester, Robinson e t a l . ,  1981; Heney,
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Koontz, Barton e t a l . ,  1988; Rubben, Lutzeyer, Fischer e t a l . ,
1988), despite expectations (Green, Robinson, Glashan e t a l . ,  
1984).
The commonest drugs in use in the United Kingdom u n til the recent 
advent o f ep irub ic in  were doxorubicin (Adriam ycin), ethoglucid  
(Epodyl), Mitomycin-C, and tr ie th y le n e  thiophosphor amide 
(thioTEPA). The conditions and duration of ad n in is tra tio n  are 
highly variab le  between studies, and optimal use o f any one agent 
remains to  be defined. ThioTEPA has been in c lin ic a l use fo r the  
longest tim e, and is  re la t iv e ly  inexpensive. I t  has a molecular 
weight o f 189, and is absorbed system ically from the bladder, 
producing myel©suppression, i ts  main adverse e f fe c t ,  in  about 10% 
of patien ts  (Jones & Swinney, 1961; Koontz, Prout, Smith e t a l . ,  
1981; H o llis te r  and Coleman, 1980; Horn, Eidelman, Walach e t a l . ,  
1981). The others, o f greater molecular weight, are absorbed much 
less, and have th e ir  greatest to x ic ity  in the bladder, causing 
c y s t it is  and bladder contracture. The anatomical separation of 
thioTEPA e ffe c t and to x ic ity  makes i t  th e o re tic a lly  possible th a t  
one e ffe c t  might be enhanced w ithout increasing the o ther, and 
was a fac to r in choosing thioTEPA as the main subject in the  
chemotherapy studies. Nevertheless, factors investigated in re ­
spect o f thioTEPA may also be o f relevance in the use o f other 
agents.
INTRAVESICAL CHEMOTHERAPY: R es is tan ce
While in tensive in s t il la t io n s  over one month can c lea r the  
bladder o f m u ltip le  s u p erfic ia l tumours (Jones & Swinney, 1961), 
and s i ng1e i nst i 11a t i ons a f te r  resect i on have been found to  
increase the delay per recurrent lesion (Burnand e t a l . ,  1976),
prophylactic in s t il la t io n s  a t three-month cystoscopy/resection  
have not been found to  improve the recurrence ra te  over resection  
alone in a m ulticen tre  study (MRC Working Party , 1985). When
thioTEPA is used as a s ing le  dose a t the time o f resection  
(Burnand, e t  a l . ,  1976; Boyd and Burnand, 1974; Pan, Slocum, 
Rustun e t  a l . ,  1989) the mechanism of action may be d iffe re n t
from use in a course of in s t il la t io n s  (Jones & Swinney, 1961; 
Koontz e t a l . ,  1981). There is wide v a ria tio n  in schedules, from
single doses inrmediately a f te r  resection , to  weekly or monthly 
in s t il la t io n s  (Burnand e t a l . ,  1976; England, Blandy & P aris ,
1980; Schulman e t a l . ,  1982; Flanigan, E lliso n  & B utler e t a l . ,
1986; Zincke, Benson, H ilto n  e t a l . ,  1985; Koontz e t a l . ,  1985). 
Even among the studies o f prophylaxis w ith thioTEPA, there is  
wide v a ria tio n  in the schedules o f adm inistration , from a lte rn a te  
days fo r a week, then three-monthly (England, e t a l . ,  1980),
weekly fo r one month, then monthly (Schulman e t a l . ,  1982),
weekly fo r two months, then monthly (Flanigan, e t  a l . ,  1986),
biweekly fo r f iv e  cycles (Zincke e t a l . ,  1985), monthly (Koontz
e t a l . ,  1981), or three-monthly (MRC Working Party , 1985). The 
lack of e ffe c t  in the las t study may re f le c t  the d iffe re n t  dose-
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ra tes , or a tendency fo r resistance to  develop. A c le a r under­
standing o f the process is  essential i f  medical treatm ent is  to  
promote the w ell-being  o f patien ts  w ith bladder tumours.
C e llu la r  resistance to  drug e ffe c t  has been recognised since 
Pasteur's era (Kossiakoff, 1887), and is  a major obstacle to  
curative  cancer chemotherapy (De V ita , 1989). Resistance has been 
found to  develop in  v it r o  to  escalating concentrations o f various  
anticancer drugs in continuous exposure experiments (Bedford, 
Shellard , Walker e t a l . ,  1987; Me Govern, Kachel, V ijan  e t a l . ,
1988), and may be yet more o f a problem w ith in te rm itte n t  
exposures to  steady concentrations used in in traves ica l chemo­
therapy.
Drug resistance is  thought to  be of two main types, inherent and 
acquired, the former g iving a clone a survival advantage in the  
presence of the drug, and an a ll-o r-n o th in g , substantial 
resistance, whereas the la t te r  is progressive may be small in 
degree, and cannot be id e n tif ie d  in c e lls  th a t have not been 
exposed to  the drug. This d is tin c tio n  is  somewhat s im p lis t ic , 
however, and the two ch a ra c te ris tics  are not m utually exclusive.
The hypothesis o f Goldie and Colduan (1979), th a t spontaneous 
mutations induce resistance, re lie s  on an inherent property of 
the c e l l ,  and not on the presence o f the drug. S e lec tive  growth 
of these re s is ta n t subpopulations would be more l ik e ly  in the
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presence of the agent to  which they, but not th e ir  parent clone, 
had become re s is ta n t. This had been e a r l ie r  postulated by Luria  
and Delbruck (1943) in the behaviour o f the b ac te ria l species E. 
C o li. The ra te  o f spontaneous mutation to  drug resistance has 
been said to  be o f the order o f 10"3 to  10-6 mutations per c e ll 
div is ion (G o ld ie  & Coldnan, 1979) w ith the presence o f drug giving  
a fu rth e r se le c tiv e  advantage to  otherwise less vigorous mutant 
clones. I t  is  argued th a t seme slow-growing v iscera l tunours 
which shed c e lls  copiously (because o f the mechanical function of 
the organ o f o r ig in )  may appear to  be in tr in s ic a l ly  drug 
re s is tan t because, although o f small volume a t diagnosis, they 
have already undergone many doublings to  reach th a t small tumour 
mass. A large, stepwise change in s e n s it iv ity  could e a s ily  be 
understood to  re s u lt  from a change in  the conformation of the  
c e llu la r  mechanism targ etted  by the drug, but equally , m odifica­
tio n  o f ra te -c o n tro llin g  genes might modulate, but not abolish  
drug s e n s it iv ity . In the more extensive studies o f resistance in 
b ac teria , there  is  only one example o f resistance induced by 
means o f s tru c tu ra l a lte ra tio n s  o f a b ac te ria l ta rg e t produced by 
a plasmid conferring  resistance. The m ethylation of two adenine 
residues on 23S RNA molecules o f b ac te ria l ribosomes, prevents 
binding o f linccmycin or erythromycin (Davies & Smith, 1978).
There are many mechanisms which l im it  the e f fe c t  o f anticancer 
drugs on tumours (De V ita , 1989), including changes in  permea­
b i l i t y ,  re p a ir o f DNA damage and drug in a c tiv a tio n . The most
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widely-researched phenomenon in tumour drug resistance is th a t of 
p le io tro p ic  drug resistance, or m ultidrug resistance, which 
appears to  re s u lt from modulation o f an ex is tin g  process, rather  
than the creation  o f a new one. C e ll lines grown in escalating  
concentrations o f a drug may be found in time to  be re s is ta n t not 
only to  th a t drug, but to  a range o f others, mainly natural 
products (B ied ler & Riehm, 1970). This resistance has been shown 
to  be associated w ith reductions in in tra c e llu la r  drug concentra­
tio n s , and the presence of P-glycoprotein in the c e ll membrane 
(Juliano & Ling, 1976; Bech-Hanson, T i l l  & Ling, 1976; Ling &
Thompson, 1973; Kartner, Riordan & Ling, 1983). The amino acid
sequence of P-glycoprotein shows s tructu ra l homology w ith a 
bac te ria l membrane transport protein  (Gros, Croop & Housman, 
1986; Chen, Chin & Ueda, 1986; Gerlach, Endicott, Juranka e t a l . ,  
1986; Pastan & Gottesman, 1988), and, as P-glycoprotein RNA 
expression has been found in high levels  in  normal kidney tissue , 
and in moderate levels in l iv e r  and colon, i t  is  tempting to
surmise th a t P-glycoprotein is  a normal defence against environ­
mental poisons, purping them out o f the c e lls  in organs l ik e ly  to  
be exposed to  tox ins . Its  ro le  in the development o f drug 
resistance would not then be new or chance, but dependent on 
a lte ra tio n  of a re levan t, normal process, and lik e ly  to  be
modulated ra ther than a ll-o r-n o th in g . Verapamil, which is  used in 
the treatment o f cardiovascular diseases, binds to  P-glycoprotein  
in competition w ith such agents as v inb las tine  (Cornwell, Pastan 
& Gottesman, 1987), and has been found to  enhance the e ffe c t  of
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thioTEPA (Simpson, Tseng, Anderson e t a l . ,  1984). I f ,  as th is
suggests, P-glycoprotein contributes to  thioTEPA resistance, one 
mechanism of thioTEPA resistance may be subject to  gradual, and 
perhaps inducible, v a r ia tio n .
On the other hand, as spontaneous mutation is a cormnon event 
(Goldie & Coldnan, 1979; R ichter, Park & Ames, 1988) there is  
normally an array of DNA re p a ir mechanisms which might be used to  
re p a ir a lk y la tio n  damage produced by thioTEPA. Patients w ith the  
inherited  DNA-repair deficiency syndromes xeroderma pignentosim  
(Arrand, Bone & Johnson, 1989), a ta x ia -te la n g ie c ta s ia  (Henner & 
Blazka, 1986), and Bloom's syndrome (N icotera , Notaro, Notaro e t  
a l . ,  1989) have a cancer-prone tendency, and c e lls  are highly
sensitive  to  mutational agents, including drugs and ra d ia tio n . 
Indeed, as H arris  (1985) has pointed out, drug resistance is  
present in normal c e lls , and i t  is  s e n s it iv ity  th a t is unusual. 
Ames has likew ise been emphasising the natural a b i l i t y  o f c e lls  
to  re s is t mutagenic stim uli (Forman, 1991)
Graduated resistance can also be produced experim entally , as in 
bacteria  (Bainbridge, 1980). Cancer c e lls  can to le ra te  progress­
ive ly  increasing concentrations o f drugs (Bedford e t a l . ,  1987;
lie Govern e t  a l , 1988) by adaptation o f a number o f p re -ex is tin g
c e llu la r  processes (De V ita , 1989). Continuous exposure to  c is -  
platinum, fo r example, has been used to  induce resistance  
(Bedford e t a l . ,  1987), and differences in c is-p latinum  s e n s it i­
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v ity  are asssociated w ith d ifferences in rep a ir o f platinun-DNA 
adducts (Bedford e t a l . ,  1988). As both thioTEPA and cis-p la tinum  
are thought to  act mainly as a lk y la tin g  agents, s im ila r re ­
sistance to  thioTEPA might be possible also.
I t  also remains to  be explained how prophylactic in traves ica l 
chemotherapy acts, and whether exposing the urothelium to  drugs 
in the absence o f v is ib le  tumour contributes to  drug resistance. 
This might be analogous to  the development o f a n t ib io t ic  
resistance in e n te r it is  organisms as a re s u lt o f u n c rit ic a l use 
of a n tib io tic s  in the feed o f pigs and chickens (Swann Report, 
1969), leading to  a resistance fac to r th a t could be transm itted  
between c e lls  (Watanabe, 1963).
Agents given a t the time o f resection have been in terp reted  as 
preventing reim plantation o f f re e -f lo a t in g  but v ia b le  tumour 
c e lls  (Boyd & Burnand, 1974), but courses o f in s t il la t io n s  may 
act by other mechanisms. As the e ffe c t  o f s ingle in s t i l la t io n s  is  
not to  a lte r  episodes o f recurrence, but on time per recurrent 
lesion, i t  may be th a t the dose-rates used in th is  way are too 
low, and have a po ten tia l fo r the induction o f resistance.
I t  can be d i f f i c u l t  to  t e l l  whether resistance is  inherent or 
acquired. C e lls  present a f te r  a drug exposure may be o rig in a l 
tunour c e lls  th a t were already re s is ta n t before treatm ent, 
o r ig in a lly  sen sitive  c e lls  th a t have been modified to  become
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re s is ta n t (p red icating  a sublethal dose-rate in the exposure), or 
parvenus, not present a t  the time o f the exposure (p a r t ic u la r ly  
contaminants in laboratory s tud ies ). For example, Koontz' group 
(1981) ccrrmented on the favourable outcome o f patients  w ith  
m u ltip le  tumours which responded completely to  a therapeutic  
course o f thioTEPA, without fu rth e r prophylaxis, confirmed la te r  
(Prout e t a l . ,  1983). This might be seen as ind icating  se lection
between clones or tumours w ith inherently  d iffe re n t drug s e n s it i­
v it ie s  as England’ s group suggested (1981). Such post hoc 
evidence could s t i l l  be in terpreted as induction o f a resistance  
by mutation in one group (c f  Goldie & Coldnan, 1979), or as 
varia tio n s  in e ffe c tiv e  dose-rate resu ltin g  from therapy, timour 
mass, or from the degree o f modulation o f d e to x ific a tio n  of the  
drug. As w ith a n t ib io t ic  resistance in bac te ria , inherent and 
acquired resistance are not m utually exclusive.
The ch a ra c te ris tics  o f c e lls  established as continuous lines  in 
cu ltu re  have usually  been described in terms of the morphology of 
the c e lls  and colonies growing on p la s tic ;  o f the a b i l i t y  to  grow 
as xenotransp1 ants in irrmune-deficient animals; o f the h istology  
of the xenotransp1ants; o f the pattern  o f isoenzymes produced; o f 
the karyotype; or o f ce11u1ar growth ra te s . A r e 1a t i onsh i p 
between drug s e n s it iv ity  and changes in these ch arac te ris tics  has 
not been demonstrated, w ith the exception of small abnorm alities  
of karyotype, but, i f  a lte re d  in re s is ta n t sublines in v i t r o ,  
might be useful as a c lin ic a l marker o f resistance.
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In response to  the suggestion th a t a n t ib io t ic  prophylaxis  
might promote the development o f re s is ta n t bac te ria , i t  was said  
th a t "Dead bugs don’ t  get re s is ta n t" . The same may be tru e  of 
cancer c e lls ,  unless the dose-rate is  inadequate to  achieve cure. 
In the Ridgeway osteosarcoma model, Skipper and his colleagues 
(1986 & 1987) noted th a t even when treatm ent produced a complete 
response, there was a p o s s ib ility  o f improvement in the o vera ll 
cure ra te  by increasing the dose ra te  above the leas t th a t  
produced 1003* complete remission. The im plication was th a t , in 
complete response, undetectable tumour could p e rs is t, to  m u ltip ly  
and recur la te r .  More e f fe c tiv e  treatm ent is  needed. Complete 
response is  not enough.
INTRAVESICAL CHEMOTHERAPY: Optimum pH
The most e f fe c tiv e  pH fo r in traves ica l chemotherapy is  not known. 
The pH of human urine varies between 4 .5  and 9 .0  and is generally  
s lig h tly  ac id ic  in carnivores. At pH less than 6 .0 , thioTEPA 
decomposes, w hile s t i l l  re ta in in g  i ts  a lk y la tin g  a c t iv ity  (Cohen 
e t a l . ,  1984), but commercial thioTEPA is  supplied buffered w ith  
bicarbonate, so th a t when i t  is dissolved in water a t a 
concentration o f 1mg/ml, i t  has a pH o f 8 .2  (Groos, Walker & 
Masters, 1986) to  keep i t  chemically s tab le . Other agents, such 
as adriamycin, are more e ffe c tiv e  a t a lk a lin e  pH (Groos e t  a l . ,  
1986).
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There is evidence in rodent tumours in vivo and in v i t r o ,  th a t  
thioTEPA is  more e ffe c tiv e  a t low pH (P h ill ip s , Bibby & Double, 
1988), and p i lo t  studies ind icate th a t the same is  tru e  in one 
human u ro th e lia l cancer c e ll lin e  (Groos, e t a l , 1986). I f  th is
e ffe c t  is  general, not an idiosyncrasy o f the human c e ll lin e  
tested , pH may be an important tool w ith which to  maximise the  
desirab le e ffe c ts  o f in traves ica l treatm ents.
INTRAVESICAL CHEMOTHERAPY: Solvent Enhancement
There is a range o f possible mechanisms by which the tumour may 
be protected from the e ffe c t  o f cytotoxic  drugs (S ik ic , 1986). 
Reduction in drug e fflu x  is thought to  enhance the e ffe c t  of 
thioTEPA in  the presence o f verapamil (Simpson e t a l . ,  1984).
The e ffe c t o f thioTEPA has also been enhanced in v it ro  by the  
addition  o f a non-polar solvent, Tween 80, which was thought to  
act by increasing drug uptake in to  the tumour (P a rr is , Masters, 
Walker e t  a l . ,  1987). C lin ic a l studies o f combined use have found 
variab le  thioTEPA absorption and to x ic ity  (Masters, Me Dermott, 
Jenkins e t a l . ,  1990). L i t t l e  information is  a va ilab le  on other
poten tia l adjuvants to  thioTEPA. Dimethyl sulphoxide is  a non­
polar solvent which enhances the e ffe c t  of anticancer agents in
v itr o  and in vivo (Warren, Sacksteader, Jarosz e t a l . ,  1975;
T o filo n , Vines & M ilas , 1985), and has been used as an in tra v e s i­
cal treatm ent fo r in te r s t i t ia l  c y s t it is  in hunans (Stew art,
Branson, Hewitt e t a l . ,  1972). Its  e ffe c t  on in traves ica l
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chemotherapy is  not known, but p o s itiv e  find ings in v it r o  could 
re a d ily  be assessed in v ivo , without fu rth e r to x ic ity  studies.
AIMS OF THE PRESENT STUDY
A tissue cu ltu re  model o f a course o f ten exposures to  thioTEPA, 
based on week1y i nst i 11a t i ons between three-month1y surve i 11ance, 
was developed in three human u ro th e lia l c e ll  lin es . Sublines 
exposed to  thioTEPA, control sublines s im ila irly  grown, but in the  
absence o f thioTEPA, and stored parental sublines were tested in  
a paired fashion fo r s e n s it iv ity , using a s ing le  concentration of 
thioTEPA, to  see whether drug resistance had developed. Charac­
te r is t ic s  o f re s is tan t c e lls  were compared w ith  parental sub­
lin e s , to  exclude the p o s s ib ility  th a t th e ir  resistance could 
re s u lt from contamination w ithother lines  kept in the laboratory, 
and fo r po ten tia l markers o f thioTEPA resistance.
The influence o f pH on the e ffe c t  o f thioTEPA was tested in three  
human u ro th e lia l c e ll  lin e s , to  see whether the resu lts  
previously obtained in one o f the lines were an idiosyncrasy of 
th a t l in e , or pH might have a general influence on cytotoxic drug 
exposures in htman u ro th e lia l c e ll lin e s . As a possible adjunct 
to  treatment a t optimal pH w ith thioTEPA, the sodium/hydrogen ion 
exchange blocker am iloride was tested in v it r o .
The solvent, dimethyl sulphoxide, was added to  solutions of four
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ccnrmonly-used in traves ica l chemotherapeutic agents in v i t r o ,  to  
see whether i t  might enhance c y to to x ic ity .
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CHAPTER 2
A MODEL COURSE OF INTRAVESICAL CHEMOTHERAPY:
INDUCTION OF ThioTEPA RESISTANCE
INTRODUCTION
Resistance may develop by s e le c tiv e  survival o f a p re -ex is tin g  
re s is ta n t subclone; by new mutation; or by induction o f a c t iv ity  
in ex is tin g  enzymes. As the dose ra te  in c l in ic a l  chemotherapy is  
usually lim ited  by s id e -e ffe c ts , the development o f small degrees 
o f resistance is  l ik e ly ,  and might make a l l  the d iffe ren ce  
between useful treatm ent and in e fffe c t iv e  to x ic ity .
Chemotherapeutic agents may induce mutations, e ith e r  simple point 
mutations, or more complex translocations or compound changes, 
the consequences o f which w il l  depend on the gene or genes 
affec ted . The mutations cannot be predicted , and, as there are  
many loci th a t may be a fected , such a change is  l ik e ly  to  be 
absent in one fla s k  and present in another, s im ila r ly  trea ted . 
Survival advantage from such mutations is uncommon, but may 
occur. I f  the drug resistance developed as a re s u lt  of induction  
of ex is tin g  c e llu la r  mechanisms, the e ffe c t  in each trea ted  flas k  
would be comparable, and should be assessed as rep lic a te s  o f the  
same experiment.
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Cell Line
Cloning
Cloned Parent Subline Frozen Stock
T reatedControl
Medium only Medium + ThioTEPA Thawed
Ten Repeats
Control Subline Treated Subline Parent Sublinem in i
Comparison of the effect of exposure to 40mcg/ml ThioTEPA  
for 1 hour.
FIGURE 2
FLOW CHART OF MODEL COURSE OF INTRAVESICAL CHEMOTHERAPY
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MATERIALS AND METHODS
Cloned sublines o f three u ro th e lia l c e ll lines  were exposed ten  
times in s t r ic t  p a ra l le l,  to  a fixed  concentration o f thioTEPA. 
I f ,  a t  any po in t, a l l  c e lls  from one f la s k , eg Ca , on th a t  
exposure became contaminated w ith fungus, or died out fo r any 
other reason, a l l  other flasks  a t th a t exposure were also  
discarded, and the stocks from the previous exposure used, i f  a l l  
flasks  (C a - c and Ta - c )  were a v a ila b le . I f  not, stocks from 
e a r lie r  exposures s t i l l  were used, to  keep a l l  flasks  o f each 
c e ll sub lin e  a t a p a ra lle l stage in  the model course o f 
chemotherapy.
Following these exposures, the s e n s it iv ity  o f the thioTEPA- 
treated  c e lls  was compared w ith th a t o f p a ra lle l thioTEPA-free 
contro ls , and w ith th a t o f stored parent c e lls .  A flow  chart of 
the experiment is  given in fig u re  2 (fp 5 4 ), and the d e ta ils  of 
each section are i llu s tra te d  in figures 3-5 (fp p 55-57).
MATERIALS AND METHODS: ThioTEPA
The thioTEPA was supplied packed in dry ice as pure powder by 
Cyanamid, Pearl R iver, USA, and d ilu ted  in s te r i le  water fo r  
in je c tio n s , BP, a t a concentration o f 100 mg/ml fo r  storage in  
glass universal containers a t -20°C. Stock solutions o f 2 mg/ml 
were then a liq uo tted  in to  6 ml glass b ijou  b o ttle s  fo r experimen­
ta l  use. The concentration chosen had resu lted  in less than 20%
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survival in a one-hour exposure in previous dose-response experi­
ments w ith  corrmercial thioTEPA. This fig u re  was a rb itra ry , but 
attempted to  balance the rapid induction o f resistance w ith the 
most rap id  recovery o f stocks between exposures.
MATERIALS AND METHODS : Maintenance of Cell Lines
C e lls  were incubated a t 36 .5°C in 25cm? vented polystyrene flasks  
(Nunc, Gibco, Pais ley, UK) in the laboratory 's  standard median, 
Roswell Park Memorial In s titu tio n  Medium No. 1640 (RPMI 1640, or 
medium, supplied by Signa, Poole, UK) supplemented w ith  1% L- 
glutamine (Gibco, P a is ley , UK) and 5$ Fetal C a lf Serum (FCS, 
supplied by Flow, Irv in e , UK), in an atmosphere o f h un id ified  a ir  
containing 5$ OO2 . C e lls  were subcultured a f te r  detatchment with  
0.05$ tryps in  (D ifco , London, UK) and 0.016$ versene (disodium 
Edetate, BDH Chemicals, Poole, UK) a t a density between 1:10 and 
1:50. For freezer storage, c e lls  were separated by cen trifug ation  
a t 1000 rpm fo r 5 minutes, then resuspended in  median containing  
20$ FCS and 10$ dimethyl sulphoxide (DMSO, BDH Chemicals) and 
frozen a t 1°C/min before storage in liq u id  n itrogen. Thawed c e lls  
were seeded in Medium containing 20$ FCS fo r 24 hours, to  reduce 
the osmotic trauma.
MATERIALS AND METHODS: MGH-U1
MGH-U1, also known as EJ, and T24 (Masters, Bedford, Kearney e t 
a l . ,  1988), was derived from a p o o rly -d iffe re n tia te d  human
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bladder cancer (Bubenik, Baresova, V icki iky e t a l . ,  1973). I t  
shows a number o f karyotypic markers o f abnormality (Vi l ie n ,  
Christensen, Wolf e t a l . ,  1983). Its  isoenzyme p r o f i le  is
consistent w ith  T24 and EJ (Masters, Hepburn, Walker e t a l . ,
1986). I t  re a d ily  forms tumours in nude mice, the h istology of 
which is  comparable to  th a t o f the o rig in a l ttinour (V i lie n  e t  
a l . ,  1983; Masters e t a l . ,  1986). On p la s t ic , i t  forms irre g u la r  
but compact colonies.
MATERIALS AND METHODS: RT112
RT112 is a continuous c e ll lin e , established in the In s t itu te  of 
Urology, in 1973, from a m oderate ly-d ifferentated  hunan uro­
th e l ia l  carcinoma. On xenotransplantation, the c e lls  produced 
Grade 2 timours h is to lo g ic a lly  s im ila r to  the o rig in a l biopsy. 
The isoenzyme p r o f i le  is known (Masters e t a l . ,  1986). On
p la s t ic , i t  forms rounded, compact colonies.
MATERIALS AND METHODS: HU609
HU609 is a continuous c e ll lin e  derived from h is to lo g ic a lly  
normal urothelium . I t  has a modal chromosome number of 45-46, and 
has not been found tim ourigenic in nude mice (V ilie n  e t a l . ,  
1983). Its  isoenzyme p r o f i le  is  known (Masters e t a l . ,  1986) On
p la s t ic , i t  forms d iffu se  colonies u n til  confluence, when there  
can be m utilayered growth, forming nodules.
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FIGURE 3
DETAILED FLOW CHART OF CLONING
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MATERIALS AND METHODS : Cloning and Storage
At the beginning o f the experiment, c e lls  were cloned, by 
development o f sub lines from sing le c e lls ,  to  reduce the possi­
b i l i t y  th a t the experiment would se lec t out p re -ex is tin g  drug-
re s is ta n t s tra in s . In view of the length o f the model course of
treatm ent, th is  was l ik e ly  to  be a gesture. The method was based
on one described in Freshney (1987), and illu s tra te d  in fig u re  
3, fp57. C e ll suspensions, trypsin ised  as before, and passed
through a 23G needle three tim es, were d ilu te d  and plated in 6 cm 
p la s t ic  p e tr i dishes a t a concentration equivalent to  20 v iab le  
c e lls  per dish, and allowed to  adhere overnight. Single c e lls  
were id e n tif ie d  m icroscopically, and th e ir  position marked under 
the dish w ith ink. The medium was then asp irated , and the c e ll 
surrounded by a s te r i le  rin g  made o f a 4nm section o f a 1cm 
diameter polystyrene tube, sealed w ith s ilic o n e  microscope grease 
(Edwards, USA). Rings were placed so as to  include only one c e l l ,  
and only one ring  was placed per dish. Mediun was then in s t i l le d  
in to  the r in g , and the seal checked fo r  leakage before returning  
mediun to  the res t o f the dish. Dishes were then returned to  the 
incubator in hum idified a ir  containing 5% OO2 a t 36°C and allowed 
to  form colonies fo r about one week.
The Mediun was then aspirated separately from the rin g  and the  
surrounding area, and the contents of the ring  trypsin ised  as 
before, checking fo r  leakage of the trypsin/EDTA m ixture. Dishes 
were discarded i f  there was any sign o f leakage. The ce ll
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FIGURE 4
DETAILED FLOW CHART OF DRUG EXPOSURES
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suspension formed was inoculated in a 25cm? p la s t ic  flasks  w ith a 
vented cap, and returned to  the incubator fo r growth. Subcultures 
of the cloned c e lls  th a t grew were stored in liq u id  nitrogen in 1 
ml sealed p la s t ic  cryotubes (Nunc, Gibco, P a is ley , UK), as above. 
One cloned subline was successfully derived from each c e ll lin e .
MATERIALS AND METHODS: Induction o f Resistance
Cloned sublines o f the three c e ll lines used, HU609, MGH-U1, and 
RT112, were each seeded in s ix  25cm? p la s t ic  cu ltu re  flasks  
(Nunc, Gibco, P a is ley , UK), and divided a t random in to  three  
control flasks  (C a - c ) ,  and three fo r thioTEPA exposure (T a - c )  fo r  
each c e ll lin e .
Treatment flasks  were exposed to  Medium containing 40 mcg/ml 
thioTEPA, and the control flas ks , to  Mediun alone, fo r one hour. 
The Mediun and Trypsin/EDTA used was always from the same b o ttle  
fo r each c e ll lin e  a t each exposure, so Control and Treated 
flasks  were as comparable as possib le. At 1 hour, the solutions  
were aspirated and the c e lls  washed w ith 5ml Mediun three times 
before return ing them to  the incubator to  grow u n til  they 
approached confluence.
To compensate fo r the d iffe re n t  c e ll  losses between the trea ted  
and control sublines a t each exposure, treatm ent flasks  were 
passaged a t a r a t io  o f 1:5, and control fla s k s , o f 1:50. There 
were three Ca , th ree C&, and three Cc flasks  a t each exposure,
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( i . e .  3 Control bottles & 3 ThioTEPA bottles for MGHUl . )
FIGURE 5
PAIRING OF FLASKS IN SENSITIVITY TESTING
59
and likew ise fo r Ta - c , to  enable two flasks to  be kept in reserve  
against contamination of la te r  exposures. At subculture, one Ca 
f la s k  was seeded into  three fresh Ca flas ks , and so on fo r  the
other le tte re d  Control or Treated fla s k s , using the same
m ateria ls  fo r a l l  a t a given stage. Ten exposures were carried  
out, as i llu s tra te d  in  fig u re  4 (fp 5 8 ).
A fte r the p a ra lle l induction o f resistance, the c e lls  were tested  
fo r  resistance by clonogenic assay. Survival te s tin g  was carried  
out in p a ra lle l on parent, control and treated  c e lls ,  allowing  
the  use o f a paired t-T e s t fo r comparison o f most o f the data. 
The d iffe re n t  methods used to  keep the subline surv ivals  paired  
on each re p lic a te  are described in fig u re  5 (fp 5 9 ).
MATERIALS AND METHODS : Clonogenic Assay
Clonogenic assay measures the effectiveness o f a drug as the  
reduction in the proportion o f c e lls  re ta in in g  the a b i l i t y  to  
d iv ide  and form colonies, the mean percentage colony-forming  
a l b i l i t y  or mean percentage clonogenic c e ll su rv iva l. As th is  
f ig u re  can exceed 100$ in some cases, and the denominator is  the
nunber o f colonies formed in separate control dishes, i t  is  not
s t r ic t ly  a percentage but ra ther a proportion. Nevertheless, 
conventional nomenclature has been re ta ined .
The stock c e lls  were harvested from th e ir  flasks  using 
Trypsin/Versine m ixture (Appendix 4 ) .  A sample was then stained
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w ith 0 .1 *  Trypan Blue, counted, using a haemocytcmeter, and 
d ilu te d  to  provide 100-200 surviving colony-forming un its  per 
dish when 200 m ic ro litre s  of suspension were added, taking in to  
account the p la tin g  e ffic ie n c y  o f each c e ll lin e  (Freshney,
1987). C e lls  were plated in Medium in 60mm vented p la s tic  P e tri 
dishes. Dishes were then incubated a t 36.5°C in a hum idified  
atmosphere o f a ir  containing 5% OO2 , to  attach and to  recover 
from try p s in iza tio n  (Hepburn & Masters, 1983).
For dose-response experiments, stock thioTEPA was added to  Medium 
to  give a range o f concentrations from 1 mg/ml to  80 mg/ml. The 
Medium used in incubation was then asp irated , and replaced w ith  
Mediun containing thioTEPA or p la in  Medium. Dishes were incubated 
fo r 1 hour a t 36.5°C in hun id ified  a ir  containing 5% CQ2 , then 
aspirated of the so lution used in the exposure. The c e lls  were 
washed three times with Mediun, and returned, in fresh Medium, to  
incubate in the same conditions u n til countable colonies had 
grown. The mean number of colonies ( i . e .  o f c e lls  surviving  
exposure w ith clonogenic powers in ta c t)  a t each thioTEPA con­
centration  was expressed as a percentage of the mean nunber o f 
colonies growing in control dishes w ithout thioTEPA. No re s u lt  
was recorded fo r a given concentration unless two or more dishes 
were ava ilab le  fo r th a t re p lic a te  o f the experiment, and a t leas t  
two, and usually three rep lic a te s  were carried  out fo r each 
value.
There were s lig h t d ifferences between c e ll lines in the
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comparisons made to  te s t  fo r drug resistance, as i t  became 
obvious th a t the in i t ia l  method used fo r  MGH-U1 was very tim e- 
consuming, and th a t the numbers o f flasks o f RT112 th a t survived  
the  f in a l exposure were sm all. The same solutions were used to  
te s t  a l l  sublines on a s ing le  tra y  (Figure 5, fp59).
I n i t i a l l y ,  fo r  MGH-U1, three separate trays were used, one fo r  
each le tte re d  flask ,A -C . As a re s u lt , three batches o f Parent 
c e lls  from the same fla s k  were tested on separate trays on each 
day, which was avoided in other c e ll lin es . Each tra y  had eight 
dishes o f Parent c e lls , e igh t o f Control c e lls ,  and e igh t o f 
Treated c e lls .  A r b it ra r i ly ,  Ta was compared w ith Ca , and the  
Parental c e lls  tested  on th a t tra y  were designated Pa , and the Cb 
and Cb trays  s im ila r ly . A fte r asp ira tio n  of the p la tin g  Medium, 
h a lf  o f the dishes fo r each subline were r e f i l le d  w ith Medium 
containing 40 mcg/ml thioTEPA, and h a lf ,  w ith Medium alone, fo r a 
one-hour exposure. A fte r exposure, the Medium was asp irated , and 
the dishes washed w ith 3 ml Medium three tim es, before r e f i l l in g  
[/dth 5ml Medium and return  to  the incubator fo r 10-12 days to  
allow  countable colonies to  form.
The colonies were fixe d  in  70% methanol (BDH Chemicals, Poole) 
fo r 5 minutes, then stained w ith 1096 Giemsa (BDH), and counted 
using a d ig ita l  pen-marker/counter (S c ie n tif ic a  & Cook E lectron­
ics , UK) on a Nachet dissecting microscope a t x2 m agnification . 
The mean number o f colonies in dishes o f one c e ll type a f te r  
exposure to  thioTEPA was expressed as a percentage of the mean
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nunber o f colonies in dishes of th a t c e ll type not exposed to  
thioTEPA. The resu lts  were compared between c e ll types tested  on 
the same tra y , w ith the same chemicals.
For the comparison o f s e n s it iv ity  in HU609, each tra y  held c e lls  
of the Parenta l, one Control, and th ree  Treated sublines, which 
were d ea lt w ith in the same way as a tra y  in the MGH-U1 
comparison. For RT112, there were no Control sublines a v a ila b le , 
and only two Treated, but they were a l l  tested in a paired way.
MATERIALS AND METHODS: S ta t is t ic a l Analysis
Mean % clonogenic c e ll survival otherwise known as mean % colony- 
forming a b i l i t y  was the outcome measure. The estimates were made 
on pre-treatm ent c e lls  ( P a - c ) ,  control c e lls  ( C a - c )  and tre a te d  
c e lls  ( T a - c )  from each c e ll lin e . Paired s ta t is t ic a l  analysis was 
applied only to  data derived from c e lls  treated  on the same tra y
Assuming th a t any one o f the le tte re d  flasks might have undergone 
a mutation th a t was not present in the others, each le tte re d  
f las k  could be compared w ith the Parent or w ith the Control 
sub lin e  th a t was exposed to  the same Medium and to  the same 
d ilu tio n  o f thioTEPA in Medium. I f  the change in s e n s it iv ity  
occurred as a re s u lt o f a graduated phenomenon such as a ra te  
change in an ex is tin g  process, a l l  the le tte red  flasks would be 
expected to  show s im ila r changes in s e n s it iv ity .
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I f  the ind iv idual le tte re d  flasks o f Treated or Control c e lls ,  
kept consis ten tly  apart throughout the model course o f chemo­
therapy, are thought s u f f ic ie n t ly  d is t in c t  to  be considered 
d iffe re n t sample, but not to  be a separate attempt a t the  
induction o f resistance, because they derived from the same 
o rig in a l source, and were exposed to  the same solutions, then the  
value of n would be t r ip le d  fo r a paired t-T e s t. As th is  was 
l ik e ly  to  be a contentious assunption, the fo llow ing , less 
debatable in te rp re ta tio n  was adopted. I f  a l 1 the le tte re d  flasks  
represented was more o f the same c e lls ,  then the surv ivals  on 
each day should be averaged, to  give a s ing le  Control and a 
sing le  Treated value, w ith th e ir  respective confidence in te rv a ls .  
This assumption leads to  the paired comparison o f each o f the two 
types o f control w ith  Tm*«n.
C e lls  exposed to  Medium from another b o tt le , or on a d iffe re n t  
tra y , or to  thioTEPA from another d ilu tio n  would not give paired  
data. An unpaired t-T e s t would be less powerful, and would need 
more rep lic a te s  w ith  l i t t l e  day-to-day v a ria tio n  to  detect a 
given resistance, than would a paired experiment. Although an 
unpaired assay was not proposed as a f i r s t  step, fo r reasons o f 
economy, la te r  assessment suggested th a t the day-to-day v a ria tio n  
precluded th is  p o te n tia lly  more convincing approach.
MATER IALS AND METHODS: Dose-Response
The response o f uncloned RT112, HU609, and MGH-U1, and o f cloned
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8 /9
10/9
2/11
3/11
14/11
19.0
56.8
66.1
81.8
7.02
25.5
46.9
55.8
25.3
37.2
64.0  
40.6
57.0
24.7
46.8
71.9  
80.6  
79.3
26.3
38.9
98.2
75.8
60.9
i
25.4 !
i
41.0  !
i
78.0 !
i
65.7 !
i
65.7 !
p-value vs P 
o-value vs C 0.018
0.018 0.616
0.285
0.114
0.017
0.405
0.119
i
0.520 !
i
0.078 1
p-value vs P = p ro b a b ility  th a t d iffe ren ce  from Parent c e lls
occurred by chance, using t-T e s t  
p-value vs C = p ro b a b ility  th a t d iffe ren ce  from Control c e lls
occurred by chance, using t-T e s t  
P = Parent subline  
C = Control subline  
Ta= Treated sub line, flas k  "A"
Tb = Treated subline, flas k  "B"
Tc= Treated sub line, f la s k  "C"
Tm»«n= Treated sublines, mean o f a l l  flasks  on th a t re p lic a tio n
TABLE 9
THE MEAN % CLONOGENIC CELL SURVIVAL OF PARENT (P ), CONTROL (C ), 
AND TREATED ( T a - c ) CLONED SUBLINES OF HU609, AFTER A 1-HOUR 
EXPOSURE TO 40 mcg/ml OF ThioTEPA
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HU609 to  a range of concentrations o f thioTEPA was tested in a 
1-hour clonogenic assay, using ccmnercial thioTEPA (Lederle,UK), 
fre sh ly  d ilu te d  each day in s te r i le  water fo r in jec tio n s , BP 
(Beechams, UK). At least two, and usually three rep lic a te s  were 
carried  out.
RESULTS
RESULTS: HU609
Table 9 gives the mean 55 clonogenic c e ll su rv iva ls  o f parent (P ),  
Control (C) and Treated (T) sublines o f HU609 a fte r  a one-hour 
exposure to  40 mcg/ml thioTEPA. One le tte re d  fla s k  o f Control 
c e lls  was tes ted , but data were obtained fo r Treated flasks A-C. 
Tm«an is  the average o f flasks Ta - c on the day given. The mean 55 
survival o f uncloned HU609 c e lls  exposed to  40 mcg/ml thioTEPA 
fo r 1-hour in a dose-response experiment was 45$, w ith 95% 
confidence in te rva l (13,7755) (fig u re  6, page 66 ). The mean 55 
survival o f cloned HU609 c e lls  a t  40 mcg/ml thioTEPA was 
11(0,43)55 (f ig u re  6, page 67).
RESULTS: HU609 Parent vs. Control Flasks
These might be predicted to  have comparable re s u lts . In fa c t , in  
the th ree  paired experiments (ta b le  9, fp  64 ), the parent (P) 
c e lls  had a mean clonogenic survival o f 68(37,100)55, whereas the  
C c e lls  had 43(34,52)55. The control f la s k  was more sen s itive  to
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thioTEPA, w ith p=0.018, n=3.
RESULTS: HU609 Parent vs. Treated Flasks
There were four experiments comparing Parent and Treated c e lls . 
There is  no s ig n ific a n t d iffe ren ce  in survival between P, 
5 6 (1 3 ,9 8 )* ,  and Ta , 5 0 (2 9 ,7 0 )* ,  Tb , 7 0 (5 4 ,8 5 )* , and Tc,
6 8 (2 9 ,1 0 8 )*  in d iv id u a lly , or Tme«n, 6 3 (3 8 ,8 7 )* .
RESULTS: HU609 Control vs. Treated Flasks
There were four experiments which produced data fo r both Control 
and Treated c e lls . Replicates in which Control and Tb c e lls  were 
compared gave a mean fo r Control c e lls  o f 3 4 (0 .7 9 )* , and fo r Tb , 
64 (23 ,106 )*, w ith p=0.017. Comparison o f C with Tm#»n gave Tm««n 
survival o f 5 9 (2 2 ,9 4 )* , w ith p=0.08. Comparison w ith Ta gave 
p=0.29, and w ith Tc, p=0.12.
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RESULTS: RT112
The mean % clonogenic c e ll survival o f RT112 parent and trea ted  
c e lls  is  shown in tab le  10, fp 69. Because of fungal in fec tion  
during the growth o f the la s t exposure, no control c e lls  survived  
to  be assessed, as well as only two flasks o f trea ted  c e lls .  The 
survivals  of parent (P ), T b and Tc sublines were assayed using 
the same solution o f ThioTEPA fo r each, on each day. The dose- 
response curve o f uncloned RT112 exposed fo r 1 hour to  commercial 
thioTEPA is shown in fig u re  8 (page 69 ). At 40 mcg/ml, the mean % 
survival o f uncloned RT112 c e lls  was 4.3%, w ith a 95% confidence 
in te rv a l, (0 .5 ,8 .0 )% .
Application o f a paired t-T e s t w ith n=3 to  the mean % survival of 
P, 28(1,55)% , and o f Tb , 65(51,77)%, Tc, 70(24,116)%, and Tm. an , 
67(44,91)%, a l l  reach s ign ificance. The p values are 0 .04 , 0 .02 , 
and <0.001 respective ly .
fp69
RN P Tb Tc Tm»«n i
17/11 40.5 61.7 95.5
i
78.6 J
i
15/11 13.3 60.2 49.4 54.8  !
i
16/11 29.6 71.7 65.6 68.7 !
RN = re p lic a te  number
P = Parent subline
Tb = Treated subline, f la s k  "B"
Tc = Treated subline, f la s k  "C"
Tm«an = Treated sublines, mean o f both flasks  on th a t re p lic a tio n
TABLE f  \k>
MEAN % CLONOGENIC CELL SURVIVAL OF PARENT (P) AND TREATED ( T b - c )  
SUBLINES OF RT112 AFTER A 1-HOUR EXPOSURE TO 40 mcg/ml ThioTEPA
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DOSE-RESPONSE OF UNCLONED RT112 TO ThioTEPA
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RN ! ! P* Ca Ta I 1 Pb 0b T b ! P ^ l Cb ! Tc i
15/9
1
' ,19.8 20.6
i
3 1 . 9 !
i
122.1 16.7 3 5 . 0
i j
122.7 !
i i
! ! 
1 5 . 1 1 3 0 .5 !
j
6/10 i 3 2 . 0
i
2 4 .0 5 5 . 4 j
i
S 8 3 .0 ! 4 4 . 9 |
i i
4 9 . 0 1 6 4 . 8 !  
j j
12/10 116.9
i
16 .9 40.21
i
! 23 • 4 4 0 .7 6 5 . 5 119.1!
j i
3 0 . 0 j 4 5 . 4 j
i j
13 /10 jO .42
j
0 . 6 5 7 . 2 j
i
! 2 . 4 3 . 3 8 . 7 1 6 . 5 !  
! 1
6 . 2 1 1 8 . 8 !
j j
14/10 M Q .4 L . 6 r 7 | 3 ? t 5 i ! ? r 2 10 t 4 2 5 , 4 1 2 f 4 ! 2 » ? m , r Q ! .
RN = re p lic a te  nunber
Pa = Parent sub line, tested  w ith "A" flasks  o f Control and 
Treated sub lines  
P b , c = As P a , but fo r "B" and "C" flas ks , respective ly  
NB As Cb and Tb data were not obtained fo r  R ep lication  Nimber 
6 /10 , no paired comparison can be made, and the Parent data were 
not included in the mean o f the Parent data fo r  the "B" flas ks .
TABLE 11
THE MEAN % CLONOGENIC CELL SURVIVAL OF SUBLINES OF MGH-UV CELLS 
EXPOSED TO 40 mcg/ml ThioTEPA FOR 1 HOUR
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RESULTS: MGH-U1
The p a irin g  of data in the assays o f MGH-U1 parent (Pa - c )  control 
(C a - c )  and treated  (T a - c )  was made closer by the te s tin g  of 
separate a liquots o f P c e lls  on each tra y  o f C* and Ta , Cb and 
Tb, Cb and Tc, and by the use o f one b o ttle  o f each solu tion  for  
each tra y . Thus d iffe re n t sublines were trea ted  s im ila r ly , in 
equal numbers. The decision to  compare Ca w ith Ta ra ther than 
other Treated flasks  was a rb itra ry , but there was more day-to-day  
v a ria tio n  than between Ta , Tb, and Tc. The mean % clonogenic c e ll 
survivals  o f each group are given in ta b le  11, fp70. A dose-
response curve fo r uncloned MGH-U1 c e lls  exposed fo r 1 hour to  
ccmnercial thioTEPA is  given in fig u re  9, page 71. At a 
concentration of 40 mcg/ml, the survival was 33.8(0,76)56.
The paired data were compared by a t -T e s t , and fo r the "A", "B", 
and "C" sublines, the means, confidence in te rv a ls , and p- 
s ta t is t ic s  are given in tab les 11 & 12, fp  70-71. A ll comparisons 
ind icate s ig n ific a n t d ifferences between Treated flasks and the 
two types o f co n tro l, except Pb v s  T b , where there were four 
rep lic a te s  and p=0.087. The data ind icate  a consistent change in 
ThioTEPA s e n s it iv ity  a t th is  concentration o f the order o f 1:2.
fp71
Flask
Mean Survival (95% C l)  
P j C T
P*
P vs C
-value
P/T
i
C/T \
"A"
i
15.9 | 13.8
i
34.2 0.27 0.008
1
0.015j
i
(2 ,4 0 ) 1 (2 ,26) 
1
(12 ,56 )
iiii
"B" 14.0 | 17.8
i
33.7 0.49 0.087 0.027j
i
♦ (0 ,3 0 ) ! (0 ,4 4 )  
1 (0 ,7 1 )
iiii
"C" 19.1 J 20.5
i
34.1 0.67 0.01 <10-3!
1
(0 .4 0 ) 1 (0 ,44) (7 .6 1 )
11.......... 1.
*  indicates 4 paired re p lic a te s , otherwise n=5 
Cl = 95% confidence in te rva l 
P = Parent subline  
C = Control subline  
T = ThioTEPA-Treated subline.
p-value P vs C = comparing Parent and Control sublines
P/1  = comparing Parent and Treated sublines
C/T = comparing Control and Treated sublines.
TABLE 12
SURVIVAL (95% CONFIDENCE INTERVAL) AND RESPECTIVE p-VALUES OF 
PARENT, CONTROL, AND TREATED PAIRED SUBLINES OF MGH-U1
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DISCUSSION 
DISCUSSION: HU609
The most apparent explanation o f the data is th a t no resistance
was induced in HU609 c e lls  by the model course o f chemotherapy,
but th is  would mean th a t both the Tme»n and T b data exh ib ited
Type I e rro r . The p ro b a b ility  o f the apparent resistance in T b 
and TM#«n occurring by chance is  less than 0 .08 , but is  not n i l .
However, the find ings in  the other c e ll lines would then be
inconsistent w ith  those in HU609. As HU609 is  derived from
h is to lo g ic a lly  normal u ro the liim , th is  is  not inconceivable, but 
less l ik e ly .
The model course o f chemotherapy may have induced a rea l but 
small resistance, compared w ith c e lls  o f the same passage, but 
too small fo r s ta t is t ic a l  s ign ificance to  be demonstrated in two 
o f the three sublines. In th a t case, the lack o f s e n s it iv ity  o f 
the Parent sub lin e  also has to  be explained. The proxim ity  
o f the surv ivals  o f the Ta and Tc sublines to  th a t o f the
re s is ta n t T b does not suggest a mutational event causing
resistance, as th is  would be more lik e ly  to  induce a large  
change. Development o f resistance would be consistent w ith the  
d iffe rence  in MGH-U1, and the probable resistance in RT112. 
Although there  appears to  be a d iffe rence  in surv ivals  a t 40 
mcg/ml between cloned and uncloned sublines, the cloned subline  
was tested w ith  pure, unbuffered thioTEPA powder, w hile the
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uncloned c e lls  were exposed to  commercial thioTEPA, buffered w ith  
bicarbonate. The dose-responses on the uncloned c e lls  were 
intended as p ilo ts , to  choose a rough concentration w ith which to  
induce resistance, rather than as touchstones o f the development 
of resistance, fo r which a c losely paired assay o f Parent, 
Control and Treated c e lls  was more accurate, and required fewer 
re p lic a te s .
The resistance o f Parent c e lls  compared w ith Control c e lls  might 
re s u lt from the d ifference in passage. Other investigators have 
not found th a t successive subculture produced a change in  
s e n s it iv ity  o f T24 sublines (Masters & Hepburn, 1986), ea rly  and 
permanent c e ll lines derived from melanoma xenografts (T v e it,  
Fodstad & P ih l, 1981), and HeLa c e ll lines (Shoemaker, Abbott, 
Macdonald e t a l . ,  1983).
The Parent c e lls  may be re s is ta n t as a re s u lt o f the Dimethyl 
sulphoxide (DMSO) used in freez in g , as the Parent subline was 
only two or three passages from thawing when tested . The Control 
c e l ls ’ s u rv iva l, tested without freezing  a f te r  the model course 
of placebo treatm ent, is  n tm erica lly  closer to  th a t o f uncloned 
HU609 c e lls . DMSO was found to  induce d iffe re n t ia t io n  in  tumour 
c e ll lines (Borenfreund, S teinglass, Korngold e t a l . ,  1975; Kim, 
Tsao, Siddiqui e t  a l . ,  1980; Mickey, Meadows, Vassiliades e t a l . ,
1983), and to  increase the e ffe c t  o f anticancer drugs in vivo  
(Warren, Sacksteader, Jarosz e t a l . ,  1975), so the decrease
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observed is contrary to  the previous find ings. The Control 
resu lts  are closer to  the find ings in the uncloned dose-response, 
although not d ire c t ly  comparable because o f the use o f commercial 
thioTEPA in the dose-response studies.
The data may be in terpreted as showing th a t there is  no real 
d iffe ren ce  as a re s u lt o f the model course o f chemotherapy. I f  
so, the re s u lt fo r the Control Cb sub lin e  is anomalous, and 
should be explained. Type 11 e rro r has a low estimated prob- 
a b i l i t y .  A technical e rro r, such as om itting  the thioTEPA, was 
made improbable, both by the re p lic a tio n  o f the re s u lts , and by 
the use o f a sing le container o f thioTEPA in Medium fo r a l l  c e ll 
sublines on each day.
A d iffe ren ce  based on the condition o f the Control subline when 
tested , such as non-logarithm ic growth, was made less lik e ly  by 
standard and p a ra lle l maintenance o f Control and Treated sub­
lin es . In a l l  complete rep lica tes  o f the experiment, the ranking 
o f the Control subline was consistent.
The s ing le  Control flas k  used, chosen a r b i t r a r i ly ,  might have 
become infected w ith mycoplasma or some other contaminant. In 
view of the p a ra lle l management of Control and Treated sublines, 
contamination from ingredients such as medium or tryp s in  would be 
l ik e ly  to  a ffe c t other sublines. The rank of the Ta subline is  
next to  the Control sub line, and consistently  lower than the  
Parent or Tb or Tc sub lin e s , and might be so a ffec ted . The
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Control subline survival is  comparable to  th a t o f uncloned HU609. 
Both comparison w ith the s e n s it iv ity  o f other Control sublines  
and mycoplasma sta in ing  would be usefu l.
The meticulous use o f clean p ipettes and equipment fo r each flask  
a t each stage made cross-contamination of the sub lines im­
probable, and th is  is  fu rth e r supported by the d iffe r in g  s e n s it i­
v i ty  resu lts  in the three c e ll lin e s . HeLa c e lls  have not been 
kept or iso lated  in the laboratory. Microscopic morphology, 
isoenzyme p ro f ile s , and nude mouse xenograft tum ourigenicity of 
a l l  sublines o f HU609, RT112, and MGH-U1 were examined and no
changes were found (see Chapter 3 ) . Growth ra te  estim ations, 
which would also have been of in te re s t, were not carried  out fo r  
lack o f tim e, but there was no marked d iffe ren ce , a fte r  the 1- 
hour exposure, between Control and Treated c e lls  in the s ize  of 
colonies (w ith  or without thioTEPA exposure), and i t  seemed 
u n lik e ly  th a t th is  alone would explain a halving of the propor­
tio n  o f p lated c e lls  th a t go on to  form colonies.
In any lim ited  exposure assay, requ iring  removal o f medium a t the  
end o f the exposure, i t  is  not easy to  d istingu ish  between the  
asp ira tio n  o f detached, but v iab le  c e lls  a t the end o f the  
exposure, and clonogenic death. I f  th is  applied to  the present 
data, the model course o f thioTEPA treatm ent would need to  
in h ib it  the detatchment o f washed c e lls .  To produce the d i f f e r ­
ence seen in the assay of survival a f te r  40 mcg/ml thioTEPA, such 
a hypothetical mechanical e ffe c t  would have to  apply more to  the
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Control c e lls  than to  the Treated c e lls ,  and to  a ffe c t  treatment 
dishes in the assay more than control dishes of the same group 
(Parent, Control, or Treatm ent), which is  improbable.
A s im ila r po ten tia l fo r c e ll loss occurs when f ix in g  colonies, 
but a d if fe re n t ia l  loss, reduced by thioTEPA Treatment must again 
be postulated. As dishes were inspected unfixed before f ix in g ,  
and no obvious discrepancy was noted, and as c e ll loss would 
probably not a ffe c t  whole colonies, th is  po ten tia l source of 
erro r seems u n lik e ly  to  be s ig n ific a n t.
Errors due to  colony counting would likew ise requ ire  a d iffe rence  
between Treated and Control groups. High colony densities  might 
lead to  underestimations, p a r t ic u la r ly  o f the denominator o f % 
s u rv iv a l, and low d en s ities , to  overestim ations, g reater in the 
numerator. The p la tin g  densities  used were the same fo r P, C, and 
T c e lls ,  so th is  is u n lik e ly  to  explain the d iffe rence  in the 
data. There was a noticeable day-to-day v a ria tio n  in the mean 
survivals  fo r each subline, suggestive o f a technical problem in 
the experiment. This might have been a m atter o f the the pH or 
osm olality o f the RPMI 1640, the glutamine or the FCS. These were 
taken from the same batch and supp lier. The thioTEPA stock was 
d ilu ted  in a batch, and stored a t -70°C, u n til use, but v a ria tio n  
in p ip e ttin g  during d ilu tio n  in Medium is  a possible explanation  
fo r the v a r ia tio n . The ranking of the mean % survival data does 
not appear to  vary, and because o f the design o f the experiment, 
with p a irin g  o f the data, the data are not inva lida ted , but are
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s im ila r to  a d e lib era te  comparison o f dose-response curves. In 
re trospect, v a ria tio n  as a re s u lt o f thioTEPA concentration would 
probably have been reduced i f  the concentration used to  te s t fo r  
the development in resistance had been higher, as the e rro r in  
the survival is sm aller , both absolu tely , and as a proportion of 
the mean. This applies to  RT112 and MGH-U1 also.
DISCUSSION: RT112
The absence o f Control data l im it  the in te rp re ta tio n  o f the c lear  
d iffe rence  between Parent and Treated sublines. There is a 
d iffe rence  of a fac to r o f 2, apparent in each fla s k . This may 
represent the e ffe c t  o f passage, or a rea l consequence of 
treatm ent. The argument against v a ria tio n  in drug s e n s it iv ity  
with passage is given under HU609 Discussion. I f  the s e n s it iv ity  
of RT112 a lte red  w ith passage , i t  would possibly resemble th a t  
seen in HU609, increasing the d iffe rence  between Control and 
Treated sublines. The survival o f the uncloned RT112 c e lls  a t  a 
thioTEPA concentration o f 40 mcg/ml was much less than e ith e r the  
Parent or Control RT112 sublines, and does not ass is t in the  
assessment o f the data. The consistency o f the d iffe rence  in 
both a va ilab le  Treatment flasks  does not provide evidence fo r a 
low-frequency mutation as cause of any rea l resistance present.
The day-to-day v a ria tio n  in survival was again notable, and again 
the design of the study compensated. These resu lts  are strongly  
suggestive th a t a graduated resistance had developed to  thioTEPA
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a fte r  a model course of in traves ica l chemotherapy in RT112 c e lls .  
DISCUSSION: MGH-U1
The d iffe ren ce  in s e n s it iv ity  fo llow ing the model course o f 
chemotherapy was c lear in th is  c e ll l in e . I t  was not present in  
c e lls  o f high passage th a t were not trea ted  w ith thioTEPA. The 
survival o f uncloned c e lls  exposed to  ccrrmercial thioTEPA is not 
consistent w ith e ith e r  the Parent or the Control sublines, but is  
again subject to  wide v a r ia tio n . Use o f a higher concentration o f  
thioTEPA to  te s t  s e n s it iv ity  might again have reduced the  
p oten tia l va ria tio n s  in survival re la tin g  to  p ip e ttin g  e rrro rs .
SUMMARY
Taking the three c e ll lines together, the trend is  consistent 
towards the doubling o f the survival a t one thioTEPA 
concentration, a f te r  a series o f exposures to  thioTEPA modelled 
on a course of in traves ica l chemotherapy. The lack o f a d iffe re n ­
t i a l  between the lines derived from h is to lo g ic a lly  normal uro- 
thelium  and the cancer c e ll lines suggests th a t the basic  
mechanisms fo r the development o f th is  resistance are inherent in  
u ro th e lia l c e lls . Development o f resistance was not shown to  
have any re la tio n  to  the type o f c e ll lin e .
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CHAPTER 3
CHARACTERIZATION OF RESISTANT SUBLINES
The sublines surviving a model course o f thioTEPA were character­
ised w ith two aims. F ir s t ly ,  i t  was necessary to  see whether the 
resistance id e n tif ie d  in Chapter 2 was a re s u lt o f contamination 
w ith another c e ll lin e . Secondly, markers o f thioTEPA resistance  
might be useful in c lin ic a l p rac tice , to  avoid f ru it le s s  t r e a t ­
ment, and might ind icate a mechanism of thioTEPA resistance.
The c e ll lines were examined fo r a range o f features used in the 
d e fin it io n  and description of new c e ll lin es . Xenograft tumouri- 
g e n ic ity , isoenzyme phenotype, DNA fin g e rp rin tin g , karyotype, and 
colony morphology were compared. The h is to lo g ica l appearance and 
grade o f the tumours was reported fo r comparison w ith the  
reported appearances of the o rig in a l tumour biopsy.
XENOGRAFT TUMOUR IGEN ICITY
When MGH-U1 or RT112 c e lls  are in jected in to  irrmunoccmprcmised 
mice, almost a l l  form tumours . With HU609, tumours do not form 
(Masters e t a l . ,  1986), as w ith most non-malignant c e lls .
TUMOURIGENICITY: C ell Lines
The c e ll lin es , previously described, were grown in 175 cm? 
flasks  (Nunc, Gibco, P a is le y ), and tryps in ised , counted in a
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Neubauer counting chamber, washed three times in RPMI Medium, and 
resuspended in RPMI containing no FCS or glutamine, fo r in jec ­
t io n .
XENOGRAFT TUMOUR IGEN ICITY: Mice.
Male Nu/Nu BalbC mice, aged 3-12 weeks, were bred and maintained 
by the s ta f f  o f the B io logical Services U n it, The United Medical 
and Dental Schools, St Thomas' Campus, UK. Mice were in jected  
subcutaneously w ith 1-2 x 106 c e lls  suspended in 0.1 ml mediim. 
In each subline in jected was kept in separate boxes, in a Vickers  
Medical p o s itive  pressure is o la to r, in a room devoted to  the  
keeping o f nude mice. S te r ilis e d  food, autoclaved bedding and 
water and m ateria ls  fo r in je c tio n  were introduced in to  the  
iso la to r through an a ir - lo c k  a fte r  d is in fe c tio n  w ith pentacetic  
acid. F ifte e n  mice were not in jected , and were kept fo r three  
months as a negative c o n tro l.
XENOGRAFT TUMOUR I GEN ICITY: Tumour Harvesting
Mice were kept u n til three months from in je c tio n , or u n t il  the 
Unit V eterinarian  was concerned about po ten tia l s u ffe rin g , or 
when a timour reached a diameter o f 0 .5  cm in diameter. Mice were 
sac rificed  by e th e riza tio n  in a i r ,  th e ir  abdominal and peritoneal 
c av itie s  examined, and a l l  tumours excised, fixed  in W% 
form alin , or methacarn, p a ra ffin  embedded, sectioned, dewaxed in 
sequential Xylene and ethanol, and stained w ith Haematoxylin and
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Eosin.
The s lides were examined by a consultant in  Urological H is to - 
pathology, who reported the h is to lo g ica l appearances and Grade, 
fo r  comparison w ith the untreated tumours, and w ith the published 
histology o f the o rig in a l biopsy.
XENOGRAFT TUMOUR IGEN ICITY: Results.
A ll but three flan k  inoculations o f Parent MGH-U1 c e lls  grew 
turours, and the three mice w ith only one flan k  timour also had 
peritoneal tumour, as did two others (ta b le  13, fp 8 2 ), pre­
sumably from m isdirected inoculations. Histology showed tra n ­
s itio n a l c e ll carcinoma Grade I I I  in a l l  cases.
A ll but four RT112 inoculations, both Parent and Treated, grew 
flan k  tumours. Two mice grew in trap eritonea l tumours, w ith no 
flan k  tumours. Histology showed tra n s itio n a l c e ll carcinoma Grade 
I I ,  except for one s o lid /c y s tic  tumour w ith squamoid features , 
Grade I , in a mouse inoculated w ith Treated c e lls .
HU609 did not grow as tumour xenografts, e ith e r before or a fte r  
the model course o f chemotherapy.
XENOGRAFT TUMOUR IGEN ICITY: Discussion
The tumours id e n tif ie d  were presumed to  be of human tra n s itio n a l  
c e ll o r ig in , ra ther than mouse sarcomas, and in tra les io n a l
fp82
C e ll Line
Number o f 
S ites  In jected
Number o f 
Flank Tumours
Mice w ith  j
ii
l-P  Tumours!
HU609
Parent 14 0 0 !
i
Control "C" 8 0
i
0 i
i
Treated "A” 8 0
i
0 !
i
"B" 10 0 o i
i
"C" 8 0
i
0 !
RT112
Parent 11 7
iiiii
2 !
i
Treated "B" 8 16 o I
i
"C" 8 16
i
0 !
MGH-U1
Parent 16 13
iiiiii
5 !i
Control ”B" 6 6
i
0 !i
Treated "A" 8 8
i
o I 1
"B" 8 8
1
o !i
Treated "C" 6 6
i
0 !
TABLE 13
XENOGRAFT TUMOUR GROWTH OF PARENT, CONTROL, AND TREATED SUBLINES
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heterogeneity was not considered here, as i t  had not been in  
previous studies (Masters e t a l . ,  1986). Control mice in jected
w ith hea t-in activa ted  c e lls ,  or w ith RPMI containing no c e lls  
would have helped im plicate the c e lls  in the genesis o f the  
tumours, and a veterinary  pathologist might, be asked to  d is t in ­
guish them from murine sarcomas, e ith e r by appearance, or by 
d if fe re n t ia l  s ta in ing  w ith anti-human or anti-mouse antibodies. 
F a ilin g  th is  d e ta i l ,  i t  is  s t i l l  possible to  note th a t the  
response to  the Parent, Control, and Treated sublines is the 
same. Resistance did not appear to  a ffe c t  xenograft tumourigeni- 
c ity .
MORPHOLOGY
The morphology o f sublines was examined by the author using a 
Natchet inverted microscope, without s ta in in g , and w ith the c e lls  
s t i l l  in th e ir  flasks .
The Parent MGH-U1 c e ll lin e  was composed o f polygonal, s te l la te ,  
and fusiform  c e lls ,  in irre g u la r colonies in which c e lls  are  
mostly contiguous. The Treated subline had s im ila r appearances.
Colonies of RT112 are defined and rounded, and composed of 
rounded or polygonal c e lls , in both Parent and Treated sublines.
HU609 c e lls  were s te l la te  or fusiform , and colonies were d iffu s e . 
No d ifferences were seen between Parent and Treated sublines.
fp83
Subline ESD G6PD GLO PGMi PGMa PGP',
1 1 b 2 1 ba
ii
1 ! i
3 1 b 2 1 ba
i
1 !i
5 1 b 2 1 ba
•
1 ! i
8 1 b 2-1 0 ba
i
1 ! i
9 1 b 2-1 0 ba
i
1 ! i
10 1 b 2-1 0 ba
i
1 ! i
11 1 b 1 1 a
i
1 ! i
12 1 b 1 1 a
i
1 ! i
13 1 b 1 1 a
i
1 !
TABLE 14
ISOENZYME PHENOTYPES OF PARENT, CONTROL, AND TREATED SUBLINES.
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ISOENZYME PHENOTYPE
C ell lines have been distinguished by the pattern  o f isoenzymes 
they contain, as distinguished by e lectrophoretic  m o b ility  (Povey 
e t a l . ,  1976). In a case o f suspected cross-contamination of 4
u ro th e lia l c e ll lin e s , the isoenzyme evidence has been confirmed 
by DNA fin g e rp rin tin g  (Masters e t a l . ,  1988). He La c e l ls ,  which
can be a vigorous cross-contaminant i f  kept in the same labora­
to ry , have a d is t in c t iv e  Type A isoenzyme o f Glucose-6-phosphate 
dehydrogenase from th a t reported fo r MGH-U1, or RT112 (Povey e t 
a l . ,  1976). The sublines were examined fo r  isoenzyme phenotypes
and DNA fin g e rp rin ts  in the Galton Laboratory of U n ivers ity  
College London.
ISOENZYME PHENOTYPE: M ateria ls  and Methods
C ell sublines were grown in 175 an? fla s k s , tryp s in ised , and 
suspended in Medium in p la s tic  universal containers, as for  
xenografting. The suspensions were centrifuged a t 1000 rpm fo r 5 
minutes, the Medium asp irated , and the c e lls  resuspended in 20 ml 
PBSA (Appendix 4 ) .  The washing in PBSA was repeated, w ith  
cen trifug ation  as before. A fte r the las t wash, the c e lls  were 
resuspended in 1-3 ml PBSA, depending on the s ize  of the p e lle t ,  
and a liq uo tted  in to  1ml cryotubes w ith a conical base (Nunc, 
Gibco, P a is le y ), and centrifuged a t 1500 rpm fo r 10 minutes. The 
supernatant was then asp irated , and the cryotubes inverted on 
tissue to  dry . The dried p e lle ts  were then stored in liq u id
Lane 1 (q '7' 8 1^-
Key: Lane 1 RT112 P aren t
Lane 2 MGH-U1 T re a te d
Lane 3 RT112 T re a te d
Lane 4 HU609 P aren t
Lane 5 MGH-U1 C o n tro l
Lane 6 HU609 C o n tro 1
Lane 7 HU609 T re a te d
Lane 8 RT112 T re a te d
Lane 9 MGH-U1 P aren t
FIGURE 10
PHOTOGRAPH OF GLYOXYLASE ISOENZYME ELECTROPHORESIS GEL 
FLOW CHART OF MODEL OOURSE OF INTRAVESICAL CHEMOTHERAPY
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nitrogen u n til te s t in g  fo r isoenzymes and DNA. The methods o f 
isoenzyme analys is  were the in tern ationa l standard methods, as 
described in H a rris  and Hopkins, 1976. The p e lle ts  were tested  
fo r  phosphoglycolate phosphatase, glyoxylase, esterase D, and 
phosphogluccmutase, and glucose-6-phosphate dehydrogenase.
ISOENZYME PHENOTYPE: Results
The enzyme electrophoresis resu lts  are given in ta b le  14, fp 83, 
and samples of P o laro id  photographs o f two of the ge ls , fo r g ly ­
oxylase, and fo r phosphogluccmutase, are given in figu res  10 & 
11, fpp84 & 85 There was no d iffe ren ce  in isoenzyme pheotype 
between Parent, Control or Treated sublines examined.
ISOENZYME PHENOTYPE: Discussion
There is no evidence o f cross-contamination of c e ll lin e s , or o f 
mutations in the enzymes studied. This does not exclude p leo- 
morphism in other c h a ra c te ris tics  o f the c e ll lin e s , which might 
be polyclonal, but derived from the same in d iv id u a l, o r , a t  a 
much lower p ro b a b ility , th a t contamination with a c e ll l in e  w ith  
an iden tica l phenotype in these respects, but d if fe re n t  in  
others. The la t te r  p o s s ib ility  was examined more c losely by DNA 
fin g e rp rin tin g .
Lane
Key: Lane 1 
Lane 2 
Lane 3 
Lane 4 
Lane 5 
Lane 6 
Lane 7 
Lane 8 
Lane 9
RT112
MGH-U1
RT112
HU609
MGH-U1
HU609
HU609
RT112
MGH-U1
P aren t 
T rea ted  C 
T re a te d  C 
P aren t 
C o n tro 1 B 
C o n tro l C 
T re a te d  C 
T rea ted  B 
P arent
FIGURE 11
PHOTOGRAPH OF PHOSPHOGLUCOMUTASE ISOENZYME ELECTROPHORESIS GEL
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DNA "FINGERPRINTING"
The p rin c ip le  o f th is  method is  th a t a certa in  base-pair sequence 
occurs a t d iffe re n t points in the genome of d iffe re n t people. 
Cutting the chromosomes wherever th a t sequence appeared, using 
a re s tr ic t io n  enzyme, would re s u lt in fragments o f DNA w ith a 
given pattern  of length and ion iza tion  fo r  each in d iv id u a l. The 
commoner the sequence, the greater the number o f fragnents, and, 
in general, the higher the nunber o f points o f d if fe re n t ia t io n  
between ind iv iduals . The pattern  o f the fragnents is  
distinguished by th e ir  e lectrophoretic  m o b ility . The author 
caried out these studies in the Galton Laboratory o f U n ivers ity  
College, London.
DNA "FINGERPRINTING": M ateria ls  and Methods
Abbreviations of chemicals and th e ir  suppliers are d e ta ile d  in 
Appendix 4.
C ell p e lle ts , prepared and stored in liq u id  nitrogen as described 
under Isoenzyme Phenotype, were suspended in 6ml STE (Appendix 
4 ) ,  and the to ta l nuc le ic  acid was extracted in phenol chloroform  
in an ABI Nucleic Acid Extractor (Model 340A, Applied Biosystems 
In c ., USA).
The DNA p re c ip ita te  was dissolved in TE, and the concentration of 
DNA estimated by absorption spectrophotometry a t 260 nm, assuming
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th a t h a lf the absorption was due to  DNA. Five microgranmes of DNA 
were digested by the re s tr ic t io n  enzyme HinF I , in  the presence 
of spermidine, and the re s tr ic t io n  fragnents separated by e lec­
trophoresis on a 0.8% agarose gel in a b u ffer containing 40mM
Tris/20rrM sodium acetate/lrrti EDTA/0.5 mcg/ml eth id iun  bromide
(Appendix 4 ) ,  using a current o f 40-50 mA, a t  20 V overnight.
The DNA fragnents were b lo tted  on a nylon f i l t e r  (QeneScreen 
Plus, Du Pont, USA), by the method o f Southern. The f i l t e r  was 
prehybridised in a so lution  containing 4 x SSC, 0.5% SDS, and 1M 
Sodium Chloride a t 65°C fo r  1 hour. The probe, p-lambda-G3, was 
rad io lab e lle d  w ith 32P dCTP using the random prime reaction . The
f i l t e r  was hybridised in a s im ila r so lution to  th a t used in the
\
p re -h yb rid isa tio n , but containing the labe lled  probe, and 5 
mcg/ml salmon sperm DNA a t 65°C overnight. The f i l t e r  was then 
washed down a t high stringency (0 .1  x SSC and 0.1% SDS), to  
remove DNA probe fragments o f low a f f in i t y  to  the b lo tted  DNA.
The f i l t e r  was then exposed to  Kodak X-OMAT f ilm  a t -70°C
overn ight, and the resu ltan t autoradiograph developed the next 
day using the appropriate Kodak process.
DNA "FINGERPRINTING” : Results
There was no d is tin c tio n  between Parent, C ontro l, and Treated  
sublines. The three types o f subline showed no evidence o f  
in te r  cont ami nation , or o f contamination from other lines kept in  
the laboratory, w ith a high degree o f c e rta in ty . The autoradio-
fp87
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FIGURE 12
TYPICAL KARYOTYPE OF PARENT SUBLINE OF MGH-U1
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graph was not preserved.
DNA "FINGERPRINTING": Discussion
The s im ila r ity  between the Parent, C o n tro l, and Treated sublines  
is  h igh, and fo r  p ra c tic a l purposes, they are  derived from the  
same in d iv id u a l. The th ree  lin es  have not been intercontam inated. 
Some other explanation must be found fo r  the d iffe ren ces  betwen 
Parent/Control sub lines, and the Treated sublines.
KARYOTYPE
Chromosomal ana lys is  o f bladder tumours by banding has been 
reported to  be a h igh ly  s e n s itiv e  p red ic to r o f the  behaviour o f  
bladder tin o u rs  (F a lo r & Ward, 1978; Sunrmers e t  a l . ,  1981). No 
s ing le  common abnorm ality has been confirmed as re la te d  to  
progression or recurrence, but the presence o f marker chromosomes 
is  gen era lly  seen as s ig n if ic a n t ,  and th ere  has been in te re s t in  
the  ro le  o f chromosome 1 (Sandberg, 1984). There is  l i t t l e  
inform ation on gross chromosome defects and c l in ic a l  drug sensi­
t i v i t y .
The karyotypes o f Parent and Resistant (T reated ) sublines o f MGH- 
U1, the most c le a r ly  re s is ta n t, were compared to  see i f  any 
d iffe re n c e  could be detected. This was c a rrie d  out in  the  
Imperial Cancer Research Fund Laboratories, L in co ln 's  Inn F ie ld s , 
by P Gorman and S W illiam s.
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TYPICAL KARYOTYPE OF TREATED SUBLINE OF MGH-U1
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KARYOTYPE: M a te ria ls  and Methods
Parental and Treated sublines o f MGH-U1 were exposed to  0 .05  
mcg/ml colcemid in  Medium fo r  0 .5  to  3 hours to  induce metaphase 
a r re s t , before detachment from the  f la s k  w ith  tryp s in /versen e  
(Appendix 4 ) .  C e lls  were harvested in  0.075M KCl and f ix a t io n  in  
3:1 methanol:g la c ia l a c e tic  ac id . Metaphases were spread by 
dropping on a c lean , wet s l id e ,  and a i r  d rie d . S lides  were banded 
by irrmersion in  2 x SSC a t  60°C fo r  10 to  30 m inutes, and stained  
w ith  W rig h t's  s ta in , d ilu te d  in  50% Sorensen’ s b u ffe r . The method 
is  based on th a t  described by Bern and P e rle  (1986 ).
KARYOTYPE: Results
Nine metaphase spreads o f MGH-U1 Parent c e l ls  were examined. The 
chromosome nunribers were 71, 77, 83, 83, 83, 84, 85, and 91. The
mode was th e re fo re  83, and the  karyotype h yp o te trap lo id . The 
m a jo rity  o f  chromosomes appeared normal, but th e re  were several 
consis ten t markers, including i (1 p ) ,  t (7 q ;1 4 q ), 10p+, and i(1 9 p ).  
Figure 12, fp87, shows a ty p ic a l karyotype.
E ight metaphase spreads o f MGH-U1 Treated c e l ls  were examined. 
Chromosome nunrtoers were 75, 78, 81, 81, 82, 83, 127, 132, and the  
mode was 81. The karyotype was as the  Parent su b lin e , although  
the  chromosome numbers appeared to  be more v a r ia b le . F igure 13, 
fp88, g ives an example o f th e  karyotype o f a Treated c e l l .
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KARYOTYPE: Discussion
Although the  numbers o f spreads examined were sm all, and th ere  
was no attem pt to  examine fo r  double m inutes, th e  karyotype was 
not so grossly changed as to  be o f p o te n tia l value in  the  ro u tin e  
examination o f bladder tumours fo r  drug s e n s it iv ity .
EPIDERMAL GROWTH FACTOR RECEPTOR
Epidermal growth fa c to r  receptor is  a transmembrane glycoprotein  
o f low m olecular w eight, p o s itiv e  s ta in in g  fo r  which has been 
found to  be more cannon in  frozen section  specimens o f poorly  
d iffe re n t ia te d  bladder tumours than o f  w e ll-d if fe r e n t ia te d  (Neal 
e t a l . ,  1985). I ts  in tr a c e llu la r  p a rt is  a p ro te in  kinase th a t  
has s im ila r  a c t iv i ty  to  seme oncogene products (Soderquist & 
Carpenter, 1983), and has considerable sequence homology w ith  the  
transform ing p ro te in  v -erb  B (U l lr ic h ,  Coussens, H a y flic k  e t  a l . ,
1984). The antibody used by N eal’ s group, EGFR1, binds to  the  
externa l domain o f Epidermal Growth Factor (EGF) Receptor 
(G u llic k , Marsden, W h itt le  e t a l . ,  1986), which is  d ire c t ly  
accessible in  c e ll  suspensions. This approach was hoped might 
lead to  te s ts  o f u ro th e lia l c e lls  e x fo lia te d  in to  bladder 
washings, as an o u tp a tie n t d iagnostic  or prognostic examination. 
The EGFR1 s ta in in g  used A431 c e lls  as a p o s itiv e  c o n tro l, as they  
are known to  express high leve ls  o f EGF surface receptor  
(Stoscheck and Carpehter, 1983; L in  e t  a l . ,  1984).
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EPIDERMAL GROWTH FACTOR RECEPTOR: Method
Subconfluent 175 cm? flasks o f c e lls  were incubated fo r the  
shortest necessary time (3 -5  minutes) w ith Trypsin/Versene 
m ixture (Appendix 4 ) .  The c e lls  were suspended in RPMI 1640 
medium, containing 5% Foetal C a lf Serum and 1& L-glutamine 
(Medium, Appendix 4 ) .  C e lls  were stained by Trypan Blue (Appendix 
4) exclusion, and counted using a haemocytcmeter. The stock c e ll 
suspension was then spun a t 1000 rpm fo r 5 minutes, the  
supernatant asp irated , and the c e lls  resuspended in Medium, to  
give 106 c e lls  per 200 m ic ro litre s . To three conical-bottomed 
cryotubes (Nunc, Gibco, P a is ley , Scotland), 200 m ic ro litre s  of 
c e ll suspension were added, then the tubes were kept a t 4°C fo r  
30 minutes, before addition o f 5 m ic ro litre s  o f the f i r s t ,  mouse- 
derived antibody, EGFR1 (Dako, Amersham, UK), and 30 minutes' 
incubation a t room temperature. A fte r 5 minutes' cen trifu g atio n  
a t 1000 rpm, the supernatant was asp irated , the c e lls  resuspended 
in 2ml Medium, recen trifug ed , and the supernatant asp irated. A 
m ixture o f the second, rabbit-anti-m ouse antibody (F(ab ) 2  fra g ­
ments), labe lled  w ith the fluorescent agent FITC was made by 
adding 60 m ic ro litre s  of antibody (F 313, Dako Ltd, High Wycombe, 
UK) to  3 ml o f medium. To prevent loss o f fluorescence, the  
m ixture was protected against lig h t . To each c e ll p e l le t ,  0 .5  ml 
o f second-antibody m ixture was added and mixed before incubation  
in the dark a t room temperature fo r 30 minutes. When the p e lle ts  
had been centrifuged again fo r 5 minutes a t 1000 rpm, and the  
supernatant asp irated , the c e lls  were washed in 2 ml medium,
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centrifuged, and the supernatant replaced w ith 1 ml 70% ethanol 
fo r overnight f ix a tio n  in the dark.
The fluorescence in te n s ity  o f a minimum of 10,000 c e lls  was 
measured on a Becton-Dickinson FACS c y to f1uorim eter, and the  
number o f c e lls  a t each (a rb itra ry )  fluorescence in te n s ity  was 
charted. In i t ia l  studies o f A431 c e lls  were compared w ith A431 
c e lls  from which the primary antibody had been om itted. P ilo t  
te s ts  o f Parent and Treated c e lls  from Chapter 2 were carried  out 
two years la te r ,  w ith antibody th a t had passed i ts  expiry date.
EPIDERMAL GROWTH FACTOR RECEPTOR: Results
The in i t ia l  fluorescence-separation o f stained and unstained A431 
c e lls  was approximately two logs of in te n s ity . Fluorescence of 
A431 c e lls  stained la te r , in the absence o f EGFRI-free A431 
contro ls , was apparently less marked, but the absence o f con­
t r o ls ,  and developments in the software used made comparisons 
d i f f i c u l t  to  in te rp re t re lia b ly . No d ifference in fluorescence 
was detected between Parent, Control, and Treated sublines o f the  
other c e ll lin e s , but the data were pre lim inary . Time and money 
were unavailab le to  explore th is  fascinating  lin e  of enquiry in 
more d e ta i1.
EPIDERMAL GROWTH FACTOR RECEPTOR: Discussion
The in i t ia l  findings were hopeful. The separation o f the
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fluorescence peaks in the in i t ia l  A431 c e lls  suggested th a t the  
antibody was l ik e ly ,  even w ith a r e la t iv e ly  simple machine, to  
distingu ish  the surface domain o f Epidermal Growth Factor w ith  
some s e n s it iv ity .  Regrettably, the time taken to  complete the  
induction and tes tin g  o f resistance was considerable, and the  
r e l ia b i l i t y  o f the s ta in  was in doubt when the u ro th e lia l c e ll  
lines were tes ted , so i t  is not c lear whether the c e ll lines  did 
not express the receptor, whether the antibody did not adhere, or 
the fluorescent marker had dimmed or become deconjugated from the  
antibody.
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CHAPTER 4
INFLUENCE OF THE SOLVENT DIMETHYL SULPHOXIDE ON THE EFFECT OF 
INTRAVESICAL CHEMOTHERAPEUTIC AGENTS
In travesical chemtherapeutic agents can delay tumour recur­
rence (Lun, 1983) and progression (Green e t a l . ,  1984) o f super­
f ic ia l  bladder cancer. Approximately one th ird  o f patien ts  do not 
respond to  in traves ica l chemotherapy (T o rti and Lum, 1984), and 
w ith in  s ix  months o f stopping curative  treatm ent, recurrences can 
occur (Esquivel, Mackenzie & Whitmore, 1965; O ravisto , 1965). 
Greater effectiveness might improve these outcomes, and achieve 
them w ith less to x ic ity .  More e ffe c tiv e  treatm ent is  needed.
Dimethyl sulfoxide (DMSO) is  a d ipo lar solvent used c l in ic a l ly  as 
a bladder in s t i l la t io n  fo r in te r s t i t ia l  c y s t it is  (Stewart e t a l . ,  
1972). In combination w ith  chemotherapeutic drugs, i t  increases 
antitumour a c t iv ity  in vivo in ra ts  (Warren e t a l . ,  1975) and in 
v it r o  against mouse hepatocarcincma c e lls  (T o filo n  e t a l . ,  1985). 
DMSO enhances the uptake o f acyclovir in to  the skin (Spruance, e t 
a l . ,  1983) and o f s a lic y la te s , and c is p la t in  through the bladder
(B orzelleca, H arris  & Bernstein, 1968; Schoenfeld, B e l lv i l le ,  
Jacob e t a l . ,  1983). DMSO was therefore  combined w ith the four
most commonly used in traves ica l chemotherapeutic agents, and the 
e ffe c t  on clonogenic c e ll survival measured in v i t r o ,  using a 
continuous c e ll l in e  derived from a human tra n s itio n a l ce ll 
cancer.
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MATERIALS AND METHODS 
MATERIALS AND METHODS: Drugs
Stock solutions o f commercial preparations o f four common 1 y-used 
in traves ica l chemotherapeutic agents were prepared and stored a t 
-20°C, Adriamycin (doxorubicin hydrochloride, F a rm ita lia  Carlo  
Erba, St Albans, England), Epodyl (ethoglucid , Imperial Chemical 
Industries, M acclesfie ld , England), Mitcmycin-C (Kyowa Hakko 
Kogyo Co Ltd, Tokyo, Japan), and ThioTEPA (tr ie th y le n e  th io -  
phosphoramide, Lederle Laboratories, Gosport, England) were d is ­
solved in s te r i le  water fo r in je c tio n , BP,(Beecham, Brentford, 
England) as stock so lu tions, and stored a t -20°C in glass 
containers, u n til use. The drugs were added to  tissue cu ltu re  
medium in concentrations th a t reduced colony-forming a b i l i t y  by 
approximately 50% a f te r  an hour's exposure: 400 ng/ml adriamycin, 
50 mcg/ml epodyl, 400 ng/ml mitcmycin-C, and 15 mcg/ml thioTEPA. 
Dimethyl su lfoxide was supplied by Signa Chemical Co, Poole, 
England).
MATERIALS AND METHODS: Cell Line
RT112, a continuous c e ll l in e , established in the In s t itu te  of 
Urology, in 1970, from a m oderate ly-d ifferentated  human uro­
th e l ia l  carcinoma (Hastings & Franks, 1981), is described in 
chapter 2.
fp95
DMSO Concentration 95 Survival 9595 Confidence In te rva l !
195 92
i
76, 107 !
i
2% 89 34, 143 |
i
395 96 71, 121 !
i
4% 96
COo*CO00
595 91
00OiCO00
695 81 77, 85 !
i
895 72 55, 89 !
i
1095 60 53, 67 !
i
2095 41
o00
Legend: The mean 95 colony-forming a b i l i t y  is  over 9095 fo r RT112
c e lls  exposed fo r  1 hour to  DMSO concentrations less than 595.
TABLE 15
MEAN PERCENTAGE CLONOGENIC CELL SURVIVAL AS A FUNCTION OF DMSO
CONCENTRATION (95 BY VOLUME)
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MATERIALS AND METHODS: C ell Culture
RT112 c e lls  were maintained as monolayer cultures in 25 cm2 
f las ks , as described in chapter 2. To minimise any changes 
resu ltin g  from long-term c u ltu re , assays were carried  out on a 
re s tr ic te d  range of ten passages.
MATERIALS AND METHODS : Clonogenic Assay
The essentia ls  o f the clonogenic assay were as in chapter 2. A 
suspension o f 500 colony-forming un its  o f RT112, w ith a p la tin g  
e ffic ie n c y  o f approximately 4096 were p lated  in 60 rrm vented 
p la s tic  p e tr i dishes (Nunc, Gibco, P a is ley , Scotland) and 
incubated fo r 48 hours a t 36 .5°C in a hum idified atmosphere o f 596 
CO2 in a i r ,  to  allow  attachment and recovery from try p s in is a tio n . 
To assess the dose-response to  DMSO, the Mediun in the dishes was 
then aspirated and replaced w ith Medinn containing a range of 
concentrations o f DMSO, or w ith Medium alone fo r con tro ls , and 
returned to  the incubator fo r an hour. A fte r exposure, the  f lu id  
in the dishes was asp irated , the c e lls  washed three times w ith 5 
ml medium, and replaced w ith 5m1 fresh Medium, before re tu rn  to  
the incubator fo r 10-14 days to  allow  colony formation.
To assay the e ffe c t  o f DMSO on the four agents, the cu ltu re  f lu id  
in dishes o f c e lls  th a t had been plated  and incubated was 
replaced w ith fresh Medium alone, or containing e ith e r 496 DMSO 
alone, drug alone, or drug in combination w ith 496 DMSO, in
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FIGURE 14
DOSE-RESPONSE OF UNCLONED RT112 CELLS TO A 1-HOUR EXPOSURE TO
DIMETHYL SULPHOXIDE (DMSO)
96
t r ip l ic a te .  A fte r incubation fo r an hour, the c e lls  were washed, 
allowed to  form colonies fo r 10-14 days, f ix e d , stained, and 
counted as in chapter 2. The mean colony-forming a b i l i t y  was 
expressed as a percentage o f the Medium-only contro ls . The data 
are derived from a minimum of, three separate experiments fo r each 
drug.
To control fo r an influence o f pH on clonogenic c e ll su rv iva l,
the pH o f Medium alone, or w ith 4% DMSO were compared a fte r
incubation fo r 24 hours in h im id ified  a ir  containing 5% OO2 a t  
36.5°C. Measurements were made a t 36 .5°C w ith a Dow Corning pH 
meter and a KCl/ AgCl electrode (Dow Corning, Halstead, England).
MATERIALS AND METHODS: S ta t is t ic a l Methods
The mean percentage clonogenic c e ll survival o f each re p lic a te  
experiment was compared using an unpaired, tw o -ta ile d  t-T e s t  
(Swinscow, 1976). Because rep lic a te s  fo r drug-only and drug+DMSO 
assays were not always carried  out on the same day, or w ith the
same container o f drug in Medium, a paired comparison was not
appropr i a te .
RESULTS
In ta b le  15, fp  95, and fig u re  14, fp  96, the dose-response of 
RT112 c e lls  exposed fo r 1 hour to  a range of concentrations of 
DMSO is  shown. At concentrations o f less than 5%, DMSO had a 
minimal e ffe c t  on colony-forming a c t iv ity .  The add ition  o f 4%
fp97
Drua Mean 35 Survival 9535 Confidence In te rv a l!
DMSO 92
i
83, 101 i
i
Adriamycin 40
oCDoCM
Adr i amy c i n+DMSO 42 18, 61 !
i
Mitcmycin-C 44 38, 49 J
i
M i tomy c i n-C+DMSO 58 41, 76 I
i
Epodyl 75 60, 90 J
i
Epodyl+DMSO 68 56, 80 I
i
ThioTEPA 50
CDCO
Th i oTEPA+DMSO 51 17. 84 !
Legend: 435 DMSO without other drugs produced a mean 35 colony-
forming a c t iv ity  (Mean 35 S u rv iva l) o f 9235. No reduction in  Mean 35 
Survival was found when DMSO was added to  thioTEPA, mitcmycin-C, 
or adriamycin.
TABLE 16
ADDITION OF DIMETHYL SULPHOXIDE TO ADRIAMYCIN, MITOMYCIN-C, 
EPODYL AND THIOTEPA : MEAN % CLONOGENIC CELL SURVIVALS
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DMSO to  Medium increased the mean pH value by 0.16 un its  a t a 
temperature of 36 .5°C.
The mean percentage clonogenic c e ll survival o f RT112 c e lls  
exposed fo r 1 hour to  DMSO alone, drugs alone, and in combination 
is  given in ta b le  16, fp 97 and fig u re  15, fp 98. The large  
confidence in te rv a ls  were produced by day-to day v a r ia tio n ,  
possibly as a re s u lt  of p ip e ttin g  errors  in drug concentration  
(Wilson, 1985). No enhancement o f tumour c e ll k i l l  was observed 
fo llow ing the add ition  of DMSO.
DISCUSSION
The basic method used to  te s t th is  hypothesis has been widely
used (Freshney, 1987). The clonogenic assay o f human bladder and
te s t ic u la r  cancer c e lls  in monolayer cu ltu re  p lated  as sing le  
colony-forming un its  provided resu lts  consistent w ith the c l in i ­
cal response of these tumours to  ra d ia tio n  and drug treatm ent in  
patien ts  (P a rr is , A r le t t ,  Lehman e t a l . ,  1988; Walker, P arris  & 
Masters, 1987), Testing the s e n s it iv ity  in s itu  a f te r  p la tin g  
avoids the va riab le  of try p s in is a tio n  a f te r  treatm ent inherent in  
tra n s fe r assays (Freshney, 1987; Hepburn & Masters, 1986), and of 
growth ra te s , and drug absorption in assays th a t measure c e ll 
numbers by v i ta l  s ta in in g , such as the MTT assay (Mosmann, 1983; 
A lle y , Scudiero, Monks e t a l . ,  1988). P a rt ic u la r ly  w ith a lk y la ­
t in g  agents, the cytotoxic e ffe c ts  may not be obvious fo r  two
c e ll cycles a f te r  exposure (Tidd & Paterson, 1974; F a irc h ild ,
fp98
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SURVIVAL OF RT112 CELLS EXPOSED TO FOUR DRUGS WITH AND WITHOUT
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Maybaum & Kennedy, 1986; Larramandy & Lopez-Larraza, 1989), so 
clonogenic assays are more sen s itive  than in d ire c t but quick 
measurements of metabolic a c t iv ity ,  such as ATP-bioluminescence 
(Jauhiainen, 1985). The pH a lte ra tio n  induced by DMSO is  sm all, 
and would be expected to  a ffe c t  d iffe re n t drugs d if fe re n t ly  
(Groos e t a l . ,  1986). The r is e  in pH found would tend to  reduce
the e ffe c t  o f Mitcmycin-C and thioTEPA, but to  increase the 
e ffe c t  o f adriamycin, and leave ethoglucid unchanged. With DMSO, 
the e ffe c t  o f mitomycin-C was less, but the r is e  in pH measured 
was small to  account fo r the s ig n ific a n t e ffe c t  on clonogenic 
c e ll su rv iva l. ThioTEPA, which, 1 ike mitoycin-C is less a c tiv e  in 
a lk a lin e  conditions, was not s im ila r ly  affected  by the add ition  
of DMSO. A small e ffe c t could have been masked by the experimen­
ta l  e rro r in the four rep lic a te s  tested . Adriamycin, which should 
be more e ffe c tiv e  a t higher pH, did not show a consistent change. 
This also could be a Type I I e rro r, but there were s ix  re p lic a te s  
in th is  case.
This study found no evidence th a t the add ition  of DMSO to  
in s t il la t io n s  o f the four drugs cannonly used to  t re a t  super­
f ic ia l  b1adder cancer w il l  i ncrease the i r  cytotox i c e f f e e t . 11
may reduce the e ffe c t  o f Mitomycin-C, but i f  so, th is  may re s u lt  
from a lte red  pH.
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CHAPTER 5
DOES pH INFLUENCE THE EFFECT OF ThioTEPA ON BLADDER CELLS?
Intravesical chemotherapy is  an o u t-p a tien t method o f prophylaxis  
which can be applied d ire c t ly  and co n tro llab ly  to  bladder 
tumours, w ith a view to  delaying recurrence or progression. The 
optimal conditions fo r in s t illa to n s  remain to  be defined.
In 1985, a group including the author reported th a t the  
clonogenic c e ll survival o f a human u ro th e lia l c e ll lin e , RT112, 
a fte r  thioTEPA exposure was lower i f  the in s t i l la t e  was acid  
(Groos e t a l . ,  1986). A s im ila r phenomenon has been reported in
murine colonic cancers (P h ill ip s  e t a l . ,  1988) and in vivo as a 
re s u lt o f acidosis induced by hyperglycaemia (Osinsky 
Bubnovskaja, Segienko e t a l . ,  1987). In Walker carcinosarcoma 
c e lls ,  however, ATP bioluminescence was not reduced a f te r  ex­
posures to  thioTEPA a t lower pH. Ccmrercial thioTEPA powder, 
dissolved in water a t a concentration o f 1 mg/ml as recorrmended 
by the manufacturer, has a pH o f 8 .2  (Groos e t a l . ,  1986). Since 
th is  is  l ik e ly  to  be the pH o f the in s t iH a te s  used in  most 
c lin ic a l studies, a c id ify in g  in traves ica l in s t il la t io n s  may 
increase the c lin ic a l b e n e fit. In v i t r o ,  a thioTEPA concentration  
th a t produced 91% survival a t  pH 8 .2  produced 1.4% survival a t pH 
5 .2 .
To confirm th a t th is  e ffe c t  was not an idiosyncrasy o f RT112, 
three human u ro th e lia l c e ll lines were tested fo r th e ir
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clonogenic c e ll survival a f te r  thioTEPA exposure in medium a t a 
range o f pH.
MATERIALS AND METHODS
MATERIALS AND METHODS: C ell Lines
The c e ll lines used were HU609, RT112, and MGH-U1 as described in 
chapter 2.
MATERIALS AND METHODS: Drugs and Chemicals
A l i s t  o f chemical names and th e ir  abbreviations and suppliers is  
given in  Appendix 4.
For prelim inary dose-response curves, commercial ThioTEPA 
(Lederle , Gosport, UK) was d ilu ted  fresh d a ily  w ith s te r i le  water 
fo r  in je c tio n s , to  give a stock so lu tion  o f 1 mg/ml before  
d ilu tio n  in Medium to  give a range o f thioTEPA concentrations. 
ThioTEPA (tr ie th y le n e  thiophosphoramide) was supplied in pure 
powder form, at-4°C  by Lederle In c ., Pearl R iver, USA, without 
the bicarbonate bu ffer added to  commercial preparations, and d is ­
solved in s t e r i le  water fo r in je c tio n s , BP (Beechams, UK) to  give  
a concentration o f 100 mg/ml fo r storage a t -20°C in glass 
universals . Stock solutions o f 2mg/ml were a liq uo tted  into  6m1 
glass b ijou  b o ttles  fo r experimental use, and stored a t -20°C. 
The stock solutions were then added to  Medium, Buffered or p la in ,
to  g ive  a thioTEPA concentration  o f 20 mcg/ml, which had produced 
s u rv iv a ls  about 50% in  the  dose-response experim ents.
B io lo g ic a l b u ffe rs  w ith  a low osmotic e f fe c t  fo r  th e ir  b u ffe r in g  
power were chosen to  m ain ta in  pH a t 9 values between 5 .0  and 9 .5 .  
B io lo g ica l b u ffe rs  were obtained in powder form, and d ilu te d  in  
S te r i le  Water fo r  In je c tio n s , to  g ive a concentration  o f 0.5M, 
and, in the  case o f MES, o f 1 M a lso  (MES2). In th is  way, 
in c lu s io n  o f 0 .4  ml stock b u ffe r  in  20 ml a liq u o ts  o f b u ffe re d  
medium gave a concentration  o f 10 m m o l / l i t r e ,  except fo r  MES2 a t  
20 m m o l / l i t r e .  So lutions were f i I t e r - s t e r i  1 ised, w ith  d isposable  
(F lo w f i l te r -D ,  Flow, Irv in e )  20 micron f i l t e r s .  Stock so lu tio n s  
were then stored a t  -2 0 °C between uses in 20 ml glass u n iversa l s. 
To o b ta in  a pH o f 5 .0 , or 5 .5 ,  a concentration  o f 1M MES was 
made; o f 6 .0 , or 6 .5 , 0.5M MES; 7 .0 , 0.5M MOPPS; 7 .5 , or 8 .0 ,
HEPES; 8 .5 ,  EPPS; and 9 .0 , CHES. Adjustments to  pH were made w ith  
Molar hydroch loric  acid  or Molar sodium hydroxide.
The la b o ra to ry ’ s standard medium, Roswell Park Memorial In s t i tu ­
t io n  No 1640 (RPMI 1640) was made up w ith  b u ffe rs  and acid  or 
a lk a l i ,  e q u ilib ra te d  overn igh t in a ir  a t  36°C, and the  pH 
adjusted w ith  1N hydroch lo ric  acid  or 1N sodium hydroxide, 
re q u ir in g  less than 5 ml in  80 ml preparations o f b u ffered  
medium. Th is  gave medium a t  a range o f pH values from 5 to  9, 
th a t were s ta b le  over several days in  a i r .  In 175cm2 vented  
p la s t ic  fla s k s  (Nunc, Gibco, P a is le y , UK) 4 ml stock b u ffe r  was 
added to  Medium to  g ive  a to ta l  volume o f 200 m l. The pH was
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Nominal pH N Mean D i f f . (Cl )______ p -V a lue
5 .0 5 0 .14 (0 .0 5 ,0 .2 3 ) 0.01
5 .5 5 0 .10 ( -0 .0 1 ,0 .2 1 ) 0 .07
6 .0 7 0 .04 (0 .0 2 ,0 .0 6 ) 0.01
6 .5 4 0 .0 3 ✓—
V I o ** o o ->
i 0 .06
7 .0 7 0 .07 ( -0 .0 8 ,  0 .2 3 ) 0 .3 0
7 .5 6 0 .0 3 (-0 .0 0 4 , 0 .0 7 ) 0 .08
8 .0 6 -0 .0 2 ( -0 .1 0 ,0 .0 6 ) 0 .49
8 .5 6 0 .02 ( -0 .0 2 ,0 .0 6 ) 0 .6 3
9 .0 8 0 .0 2 ( -0 .0 3 ,0 .0 7 ) 0.61
"C ontro l" 9 0 .07 i o to o o -J 0 .5 3
Mean D i f f .=  Mean D iffe re n c e  in  pH (A f te r -B e fo re ) .
N= number o f re p lic a te s  w ith  comparable data a t the  Nominal pH. 
( C l )= 95% Confidence In te rv a l
Legend: During each drug exposure, th e re  is  a small d iffe re n c e
(maximum 0 .2 3  pH u n its )  in the  pH measured before  and a f te r  the  
drug exposure, but only a t  pH 5 .0  and 6 .0  does the  95% confidence  
in te rv a l not include zero change.
TABLE 17
THE DIFFERENCES IN pH (AFTER-BEFORE) DURING EXPERIMENTS ON
HU609 CELLS
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adjusted roughly by th e  a d d itio n  o f 1N HCl to  a l l  o f th e  fla s k s  
except the  pH 9 f la s k s , to  which 1N NaOH was added. "C ontro l"  
Medium, fo r  c e l ls  to  be exposed in th e  lab orato ry  standard  
incubator, w ith  5% CO2 , w ithout b u ffe rs , was a lso  measured in to  a 
f la s k . Flasks were then e q u ilib ra te d  o vern igh t a t  3 6 .5 °C in  a 
hum id ified  atmosphere o f a i r .  Flasks fo r  Control Medium contained  
Mediim from the  same batch as th e  B uffered Medium, but no 
b u ffe rs , ac id  or a lk a l i  were added. The overn ight e q u ilib ra t io n  
o f ,  and la te r  c e l l  exposures in , Contro l Medium were c a rr ie d  out 
in  a hum id ified  incubator a t  3 6 .5 °C in  an atmosphere co n ta in in g  
5% CO2 . E q u ilib ra te d  Medium (B u ffe red  and C o n tro l) was then
sampled and samples kept in  double-stoppered s t e r i le  p la s t ic  te s t  
tubes (Flow , Irv in e , UK) in  a w ater-b ath  a t  36°C to  measure the  
pH. F ine adjustments o f pH in  the  f la s k s  was made w ith  ac id  or 
a lk a l i ,  and checked immediately and on th e  day o f the  experim ent 
(th e  Before pH). The fig u re s  given were a l l  measured on th e  day 
o f the  experim ent.
MATERIALS AND METHODS: A d ju s tin g  pH
The pH o f samples kept a t  36°C in a w ater-b ath  was measured w ith
a KCl/AgCl e le c tro d e  and a Dow-Corning 120 pH meter (Corning
Medical and S c ie n t i f ic ,  Halstead,UK) and pH -reference b u ffe rs  a t  
pH o f 4 , 7 , and 10 (Convol, BDH Chem icals, Poole, UK). Reference
b u ffe r  so lu tio n s  were made up to  500ml w ith  deionised w ater, and 
kept in p la s t ic  u n iversa Is  (Alpha L ab o ra to ries , E a s tle ig h , UK) a t  
-70°C  u n t i l  use. A new re fe ren ce  b u ffe r  sample was used d a ily .
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Nominal pH N_______Mean D i f f ♦ (C l )  p -V a lu e
5 .0 6 0.11 -0 .0 2 , 0 .2 5 ) 0 .09
5 .5 6 0 .02 -0 .0 1 ,  0 .0 6 ) 0 .16
6 .0 10 0.002 i o _t o o o 0 .96
6 .5 8 0 .07 I o o OJ * o 0 .12
7 .0 11 0 .0 8 0 , 0 .1 7 ) 0 .05
7 .5 11 0 .0 3 0 , 0 .0 5 ) 0 .03
8 .0 7 0 .003 i o b o '_
s 0 .95
8 .5 9 0 .0 2 1 o o o 0 .59
9 .0 7 0.01 1 o o o '—
' 0 .82
"C entro1" 11 0 .08 -0 .2 7 .  0 .1 2 ) 0 .39
Mean D i f f .=  Mean D iffe re n c e  in pH (A fte i—B efo re ).
N= number o f re p lic a te s  w ith  comparable data a t the Nominal pH. 
(C l)=  95% Confidence In te rv a l.
Legend: The mean d iffe re n c e s  in  pH include zero in  th e  95%
confidence in te rv a l in  a l l  cases, but a t  pH values o f 5 .0 ,  7 .0
and 7 .5 ,  th e  pa ired  t -T e s t  shows a high leve l o f s ig n if ic a n c e , 
w ith  a maximum d iffe re n c e  o f 0 .25  pH u n its  in the  95% confidence  
in te rv a ls . T h is , and the comparable po in ts  fo r  MGH-U1 a re  the  
only  evidence th a t  a system atic  change in  pH occurred during the  
course o f these experim ents.
TABLE 18
THE DIFFERENCES IN pH (AFTER-BEFORE) DURING EXPERIMENTS ON RT112 
CELLS
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C a lib ra t io n  s e ttin g s  o f + / -  0 .02  u n its  were accepted, and th e  
e le c tro d e  rinsed  w ith  deionised w ater and b lo tte d  w ith  tis s u e  
between each measurement.
Although th e  intended or ’’Nominal" pH should have been s ta b le  fo r  
a given re c ip e , the  actual value was checked a t th ree  stages in  
th e  experim ent to  assess the  p o s s ib i l i ty  o f v a r ia t io n  due to  c e l l  
in ju ry  and metabolism. Samples were taken from the  fla s k s  o f  
B uffered  and Control Media th a t were about to  be used to  make up 
th e  thioTEPA and contro l medium a t each pH, and the  "Before pH" 
measured. A fte r  exposure, B uffered Medium was asp ira ted  fo r  pH 
measurement from two contro l dishes a t each pH (th e  "A fte r  pH") 
and from dishes conta in ing  thioTEPA (th e  "Thio pH"). As the  
v a r ia t io n  between the  "A fte r  pH" and the  "Thio pH" was less than  
0 .05  on a l l  but one measurement, and as the handling o f samples 
co n ta in in g  c y to to x ic  drugs was more complex, the measurement o f 
th e  Thio pH was c a rr ie d  out once fo r  each c e ll  l in e .
MATERIALS AND METHODS: Experimental Method
The d e ta ils  o f clonogenic assay, and o f th e  dose-response curves 
o f uncloned HU609, MGH-U1, and RT112 are  given in chapter 2. A 
s im ila r  method was employed fo r  the eva lu a tio n  o f the in flu en ce  
o f pH. Four contro l dishes and four dishes fo r  thioTEPA trea tm ent 
a t  each pH were te s te d , and the  mean number o f colonies su rv iv in g  
in  the th io te p a  dishes expressed as a percentage o f the mean 
number o f co lon ies s u rv iv in g  in  the  dishes a t the  same pH th a t
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Nominal pH N Mean D i f f .  ( C l )  p - S t a t is t ic
5 .0 4 0 .0 9 ( -0 .0 5 ,  0 .2 2 ) 0 .13
5 .5 5 0 .0 3 ( -0 .0 1 ,  0 .0 7 ) 0 .13
6 .0 5 - 0 . 0 2 ( - 0 . 12, 0 .0 8 ) 0.61
6 .5 5 0 .0 7 ( - 0 .11, 0 .2 4 ) 0 .35
7 .0 6 0 .0 4 (0 .0 1 , 0 .0 8 ) 0 .02
7 .5 6 0 .0 2 (0 , 0 .0 3 ) 0 .0 3
8 .0 5 0 .0 2 ( - 0 .12, 0 .1 6 ) 0 .74
8 .5 5 0 .0 4 ( - 0 .11, 0 .1 9 ) 0 .49
9 .0 2 0 .0 7 ( - 1 .3 3 , 1 .47 ) 0 .64
"C ontro l" 3 - 0 . 1 3 ( -2 .9 1 . 2 .8 8 ) 0 .99
Mean D i f f .=  Mean D iffe re n c e  in  pH (After—B efo re ).
N= number o f re p lic a te s  w ith  comparable data  a t the  Nominal pH.
Legend: S ig n if ic a n t  increases in  the  pH a t  7 .0 , or 7 .5  are sm all, 
0 .0 5 , and 0 .0 3 , and u n lik e ly  to  introduce a b ias in to  the  
s u rv iv a l d a ta . At pH 7 .5 , th e  95% confidence in te rv a l includes  
zero . The d i f f ic u l t e s  o f measuring th e  pH o f th e  "C ontro l" mediim  
in  a i r  a re  discussed in  the  te x t .
TABLE 19
THE DIFFERENCES IN pH (AFTER-BEFORE) DURING EXPERIMENTS ON
MGH-U1 CELLS
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did not contain thioTEPA.
A fte r p la tin g  in the dishes, c e lls  were allowed 2 days to  adhere, 
and to  resume exponential growth. On the day o f the experiment, 
the Medium was aspirated from the dishes, and each dish washed 
w ith 2 ml o f Buffered Mediim a t the appropriate pH, to  flush out 
any remaining Medium, and minimise varia tio n s  in the pH of 
exposure. The wash was then asp irated , and replaced e ith e r  w ith  
buffered p la in  Medium, or buffered thioTEPA Mediun. "Control" 
dishes used unbuffered Mediim, w ith and w ithout thioTEPA, and 
were incubated fo r the duration of the exposure in the  
laboratory 's  standard conditions, h im id ified  a i r ,  containing 5% 
CO2 . Dishes buffered to  adjust the pH were incubated without the  
addition  o f CO2 , and the exposure tim e fo r a l l  was one hour.
A fte r exposure, Buffered and Control Medium was aspirated from 
a l l  dishes, seme being saved fo r "A fter" and "Thio" pH te s tin g . 
The dishes were washed tw ice w ith 2 ml Mediim, then r e f i l le d  w ith  
5 ml Medium and incubated in the presence o f 5$ CO2 to  allow  the  
formation o f countable colonies. This incubation took 7-10 days 
fo r  MGH-U1, 10-12 days fo r HU609, and 12-14 days fo r RT112. 
Dishes were then rinsed, f ix e d , stained and counted as before.
MATERIALS AND METHODS: S ta t is t ic a l Methods
The mean percentage clonogenic c e ll surv iva ls  were treated  as 
continuous variab les , although they are derived from integer
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colony counts. To assess the s ign ificance o f pH varia tio n s  a t  
d iffe re n t times during the experiment, comparisons were made 
using a paired t -T e s t, only using re p lic a te s  where data were 
ava ilab le  fo r both tim e-points.
RESULTS
The dose-response studies, w ith a minimum o f two re p lic a te s  a t  
each po in t, show th a t a t a concentration o f 20 mcg/ml, the mean % 
clonogenic c e ll survival is  on the sloping p art o f the curve fo r  
RT112, and on the plateau, or probably a t the shoulder o f the  
slopes fo r HU609 and MGH-U1 (fig u res  6 -9 , fpp 6 7 ,6 8 ,7 0 ,7 2 ). For 
s im p lic ity , one concentration, 20 mcg/ml, was used fo r pH studies  
in a l l  three c e ll lin es .
RESULTS: Nominal and Measured pH
The "Before" and "A fter" pH values a t each nominal pH were 
compared using a paired t -T e s t, fo r  re p lic a te  experiments where 
both values were ava ilab le  on the same day. Where the A fte r value  
is lower, the d iffe rence  is  given a negative sign (tab les  17-19, 
fpp 102-104). The d ifferences are s ig n ific a n t a t  the 0.05 level 
fo r nominal pH values 7.0 and 7 .5  fo r MGH-U1, 7 .0  and 7 .5  fo r  RT 
112, and 5 .0  and 6 .0  fo r HU 609. A ll o f the d ifferences were less 
than o r, in one case, equal to , one Standard Deviation (S .D .) o f 
the re levan t mean pH. The v a ria tio n  in  pH during one experiment 
does not exceed the v a ria tio n  between experiments on d iffe re n t
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days,and th is  is  con cis ten t w ith  the an alys is  o f the  S urv iva l 
data below. The average d iffe re n c e  between A fte r  and th e  Thio  
values fo r  each pH, averaged among the  th ree  c e ll  l in e s , is  less  
than one S.D. o f the A fte r  pH o f each c e ll  l in e .  The d iffe re n c e  
fo r  each ce11 1ine is  1 ess than the app ro p ria te  S.D. o f the  
Before pH.
I t  m ight be thought th a t  experim ental re p lic a te s  should be 
excluded from consideration  i f  the measured pH devia ted  markedly  
from th e  mean measurement a t  th a t nominal pH, as th a t  would tend  
to  in d ic a te  a tech n ica l e r ro r . L im itin g  th e  % S u rv iva ls  graphed 
to  those re la t in g  to  a pH w ith in  0 .25  pH u n its  o f the  mean fo r  
each nominal pH p o in t produced no change in the  shape o f the  
graphs fo r  any o f the  c e ll  l in e s , and in  the  case o f HU609, only  
one p o in t o f one re p lic a te  would have been excluded. The outcome 
was l i t t l e  a ffe c te d  by these v a r ia tio n s  in  pH.
The Mean % Clonogenic C e ll S urviva l or Mean % Colony-Forming 
A b i l i t y  was re la te d  to  pH. I t  is  expressed as a fu n c tio n  o f the  
Before pH in fig u re s  1 7 ,1 8 ,2 1 ,2 2 ,2 5 , & 26, and as a fu n c tio n  o f
the  A fte r  pH in fig u re s  1 9 ,2 0 ,2 3 ,2 4 ,2 7 , & 28 (see pp 107-118).
Ir re s p e c tiv e  o f the pH measure used, and desp ite  th e  wide 
confidence in te rv a ls , the trend  in d ica tes  reductio n  in  s u rv iv a l , 
s ig n if ic a n t  a t the  5% le v e l, as the pH approaches 5. The e rro r  
bars represent the  95% confidence in te rv a ls .
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Nom. pH N Mean dH(95% C l) Mean % C.C.Surv. (95% C l)
5 .0 4 5.26 (5 .0 3 ,5 ,4 8 ) 0 (0)
5 .5 4 5.53 (4 .9 9 ,6 .0 6 ) 1.9 (0 ,4 .3 )
6 .0 6 6.06 (5 .9 9 ,6 .1 4 ) 8 .3 (0 ,1 9 )
6.5 3 6.51 (6 .5 1 ,6 .5 1 ) 46 (10,82)
7.0 5 7.07 (6 .9 8 ,7 .1 6 ) 63 (42 ,85)
7.5 4 7.65 (7 .5 9 ,7 .7 1 ) 77 (61 ,94)
8 .0 4 8.27 (8 .0 7 ,8 .4 7 ) 94 (86,102)
8 .5 4 8.58 (8 .3 2 ,8 .8 3 ) 87 (62,112)
9.0 6 9.11 (8 .9 0 ,9 .3 2 ) 80 (57,103)
Contro1 5 8.05 (7 .4 2 ,8 .6 7 ) 79 (65 ,93)
Mean % C.C Surv. = Mean % Clonogenic C ell Survival
= Mean % colony-forming a c t iv ity  
(95%CI) = (95% Confidence In te rv a l)
N = the number of rep lica tes  with data a t each nominal pH
Nom. pH = nominal pH
Legend: These data are presented g raph ica lly  in figures 16-17.
There is a c lear trend towards lower mean % colony-forming
a c t iv ity  a t lower pH. "Control" c e lls  re fe r  to  assays of thioTEPA 
e ffe c t  in the laboratory 's  usual OO2 incubator.
TABLE 20
SURVIVAL OF HU609 AS A FUNCTION OF "BEFORE pH"
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FIGURE 16
SCATTERGRAM OF SURVIVAL OF HU609 AS A FUNCTION OF "BEFORE pH"
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NB: at p H = 5 .26 , the Survival was 0 , and could not 
be p lo tte d  on log axes.
FIGURE 17
MEANS (95% CONFIDENCE BARS) OF SURVIVAL OF HU609 AS A FUNCTION OF 
"BEFORE pH"
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FIGURE 18
SCATTERGRAM OF SURVIVAL OF HU609 AS A FUNCTION OF "AFTER pH"
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NB: The survival at pH =5 .38  was 0  and could not  
be p lo tted  on log axes.
FIGURE 19
MEANS ( 95% CONFIDENCE BARS) OF SURVIVAL OF HU609 AS A FUNCTION OF
"AFTER pH"
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FIGURE 20
SCATTERGRAM OF SURVIVAL OF RT112 AS A FUNCTION OF "BEFORE pH"
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NB: a t  p H =5 .16 , the Survival was 0, and could not  
be p lo tted  on log axes.
FIGURE 21
MEANS (95% CONFIDENCE BARS) OF SURVIVAL OF RT112 AS A FUNCTION OF 
"BEFORE pH"
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FIGURE 22
SCATTERGRAM OF SURVIVAL OF RT112 AS A FUNCTION OF "AFTER pH"
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NB: at pH=5.23, the Survival was 0, which could not 
be plotted on log axes.
FIGURE 23
MEANS (95% CONFIDENCE BARS) OF SURVIVAL OF RT112 AS A FUNCTION OF 
"AFTER pH"
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FIGURE 24
SCATTERGRAM OF SURVIVAL OF MGH-U1 AS A FUNCTION OF "BEFORE pH"
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FIGURE 25
MEANS (95% CONFIDENCE BARS) OF SURVIVAL OF MGH-U1 AS A FUNCTION 
OF "BEFORE pH"
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FIGURE 26
SCATTERGRAM OF SURVIVAL OF MGH-U1 AS A FUNCTION OF "AFTER pH"
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FIGURE 27
MEANS ( 25% CONFIDENCE BARS) OF SURVIVAL OF MGH-U1 AS A FUNCTION
OF "AFTER pH"
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DISCUSSION
In v i t r o ,  acid in s t iH a te s  decreased the Mean % Clonogenic C ell 
Survival o f human u ro th e lia l c e lls  exposed to  20 mcg/ml ThioTEPA 
fo r  one hour, below the Survival o f c e lls  exposed in  a lk a lin e  
conditions.
The thioTEPA concentration used allowed some scope fo r  the  
demonstration o f an unexpectedly enhanced s u rv iva l, ie  a reduced 
drug e f fe c t ,  but l e f t  a wider range o f values fo r  increased c e ll  
k i l l  a t lower pH. Repeating the experiments w ith a lower 
concentration o f thioTEPA might reduce the e ffe c t  o f errors in  
p ip e ttin g  thioTEPA. On the other hand, th is  might extend the  
plateaux o f the Survivals to  the le f t ,  masking the e ffe c t  o f pH. 
I t  is  p a r t ic u la r ly  compelling evidence o f the importance o f pH 
in  th is  model th a t , despite a choice o f thioTEPA concentration  
th a t might have had no e ffe c t  in HU609 and MGH-U1, the influence  
of pH on Survival was marked. Although the osm olarity o f the  
buffered Mediun was not measured a fte r  preparation, the amounts 
o f acid or a lk a l i  added to  adjust the pH were r e la t iv e ly  sm all, 
and the main opportunities fo r varia tio n s  in the osm olarity would 
have arisen in the preparation o f the Medium. The osm olarity o f 
batches o f RPMI 1640 prepared and s te r il iz e d  by the preparation  
u n it a t the Imperial Cancer Research Fund's f a c i l i t i e s  a t  
Linco ln 's  Inn F ie ld s , London, was checked ro u tin e ly  before use. 
Higher osm olarity has been found to  decrease c y to to x ic ity  in  
RT112, using the assay used here (Groos e t  a l . ,  1986(b )).
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The log scale used fo r  the survival ( ie  colony-forming a b i l i t y )  
beter re f le c ts  the log ical d i f f ic u l t ie s  of assessing zero or 
negative s u rv iv a l, than would a lin e a r scale, but excludes some 
zero survival data given in tab les  20-25, fpp 107-117, and in the  
scattergrams, esp ecia lly  a t a pH o f 5 .0 . I f ,  as discussed above, 
a lower concentration o f thioTEPA had been used, th is  d i f f ic u lty
also would have been avoided. In the c lin ic a l s itu a tio n , i t  is
hoped th a t zero tumour suvival would be a corrmon event.
The v a ria tio n  in the pH values during the course o f an 
exposure was sm all, and u n lik e ly  to  bias the resu lts  (tab les  
17-19, fp  102-104). The day-to-day v a ria tio n  in actual pH a t each 
Nominal value was la rg er, perhaps because o f v a ria tio n  in the  
preparation o f the medium. As adjustments to  the pH of buffered  
Medium were avoided wherever possib le, the errors in  measured pH 
were perhaps larger than would have been id ea l. Measurements in 
pH were p a r t ic u la r ly  d i f f i c u l t  in the Control Medium, which was
unbuffered, and which, w hile incubated would contain dissolved
CO2 as carbonic acid . When samples, p a r t ic u la r ly  small samples, 
were taken fo r pH measurement, and kept fo r even h a lf  an hour 
before measurements were taken, OO2 was lo s t, even in a stoppered 
te s t  tube, in to  the a i r  space, causing the measured pH to  be 
higher than the r e a l i t y  during incubation. The influence o f the  
pH o f the in s t i l  la te  on the e ffe c t  o f thioTEPA in s t il la t io n s  has 
been observed in  two bladder cancer c e ll lin e s , and in a c e ll  
lin e  derived from h is to lo g ic a lly  normal urothelium from a patien t  
w ith a renal c lear c e ll carcinoma (HU609). This confirms the
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in i t ia l  study in RT112 ( Groos e t  a l . ,  1986), and demonstrates
th a t the e ffe c t  is  not a property o f one c e ll l in e  only. In th is  
and in the previous experiment, the colony-forming a b i l i t y  
reta ined  a t each pH is  not expressed as a percentage o f th a t o f 
c e lls  a t  standard pH, but o f c e lls  growing in control dishes a t  
the appropriate pH, e lim inating  the known e ffe c t  o f pH on c e ll  
growth and survival (Eagle, 1973; Ceccarini & Eagle, 1971; 
Taylor, 1962). Recent studies demonstrate th a t pH has an e f fe c t  
on the a c t iv ity  of anticancer drugs on murine colonic timours 
(P h ill ip s  e t a l . ,  1988) and on Walker 256 carcinosarcoma c e ll
lines (Jauhiainen, Kangas, Kapyla e t  a l . ,  1985) in v i t r o ,  
although the la t te r  method showed no increased e ffe c t  from 
thioTEPA exposures a t pH below 7 .0 . Control o f pH in the bladder 
in s t i l la t io n  seems to  have inrmediate c lin ic a l ap p lica tio n . Past 
studies o f c lin ic a l effectiveness and to x ic ity  may need to  be 
reassessed, taking th is  va riab le  in to  account.
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CHAPTER 6
PILOT STUDY OF THE EFFECT OF AM I LOR IDE ON ThioTEPA CYTOTOXICITY
AT LOW pH
Am iloride has been in c lin ic a l use as a d iu re tic  fo r  a nunber o f 
years. I t  a ffe c ts  the control o f in tra c e 1lu la r  pH by blocking  
Na+/H* exchange across the c e ll membrane (R otin , Wan, G rinste in
e t a l . ,  1987). As thioTEPA had been found to  be more e ffe c tiv e  in
6
acid Medium, studies were undertaken to  see whether blocking . i f  s A . 
in tra c e 1lu la r  pH-regulation by the add ition  o f th is  drug might 
enhance the e ffe c t  o f th io tepa a t low pH on the c e ll l in e  model 
o f su p erfic ia l bladder cancer.
MATERIALS AND METHODS
MATERIALS AND METHODS: C ell Lines
The lines used were uncloned HU609, MQH-U1, and RT112, in  
exponential growth, as in the previous pH experiments.
MATERIALS AND METHODS: Drugs
Pure am iloride powder (MSD, UK) was d ilu ted  in  water fo r  
in jec tions  ( Beecham, UK) to  a concentration o f 100 irti, and kept 
a t -70°C in glass b ijou  containers u n til  use. Pure ThioTEPA 
powder was supplied by Lederle, and d ilu te d  and stored as fo r the  
pH experiments. Drugs were d ilu ted  w ith  Medinn or buffered Medium 
irmnediately before each experiment. Actual pH was not measured, 
and the figures given are the nominal values fo r the formulations
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used in th e  pH experim ent, as the  d iffe re n c e s  between pH 5 and 
7 were l ik e ly  to  be obvious i f  p resent. The b u ffe rs  used were 
those in the  pH study (chapter 5 ) .
MATERIALS AND METHODS: Assay Method
From the  p rev ious ly  a v a ila b le  dose-response curves o f th e  c e l l  
lin e s  to  thioTEPA, a concentration  o f 8 mcg/ml thioTEPA was
chosen to  g ive  the sm allest ap p rec iab le  e f fe c t ,  in order to  g ive  
a large  range o f c e l l  s u rv iv a l w ith in  which synergy m ight be 
detected . C e ll s u rv iv a l was measured once fo r  am ilo rid e  concen­
tra t io n s  ranged above and below those found to  a f fe c t  re g u la tio n  
o f in tra c e 1lu la r  pH (Roos & Boron, 1981). A concentration  o f 0 .1  
mM am ilo rid e  was se lected  fo r  th e  p i lo t  s tu d ies .
C e lls  were p la ted  to  g ive approxim ately 200 co lon ies in contro l 
dishes not exposed to  am ilo rid e  o t to  thioTEPA. I n i t i a l l y ,  dose- 
response below and above the 0.1  mM A m iloride concentration  used 
by R otin ,D  e t  a l . (1987) was measured a t  standard pH (=
approxim ately 7 .4 )  in  a 1-hour exposure.
To assess the  combination o f a m ilo rid e , thioTEPA, and low pH, 
Medium was b u ffered  and e q u ilib ra te d  and used to  wash th e  
unbuffered Mediurn from the  dishes as in  chapter 4. Dishes 
conta in ing  b u ffered  Medium alone, and w ith  a m ilo rid e , w ith
thioTEPA, and w ith  both were incubated fo r  one hour a t  3 6 .5 °C in  
a i r  w ithout added CO2 , a s p ira te d , washed w ith  Medinn, and allowed  
to  grow as in Chapter 2. F ix a tio n , s ta in in g  and counting o f
fp124
Mean % Clonogenic S urviva l a t!
11
A m iloride  Concentration (rrM) 1
i
C e ll L in e / Passaqe RN 0.06 0.1 0 .4 1.0 !
HU 609/41 25/3 100 95 99
i
94 !
i
MGH-U1/116 26/3 114 113 139 154 Ji
RT 112/44 26/3 109 110 109 97 !i
RT 112/45 6 /4 90 77 ---- 59 !
i
RT 112 mean 100 94 109 78 !
TABLE 26
MEAN % CLONOGENIC CELL SURVIVAL AND AMILORIDE CONCENTRATION
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co lonies were as described p rev io u s ly .
RESULTS
The minimal reductio n  in  mean % co lony-form ing a b i l i t y  ( mean % 
clonogenic c e ll  s u rv iv a l)  fo llo w in g  exposure to  a range o f 
concentrations o f a m ilo rid e  are given in  ta b le  26, fp  124. Only 
one re p lic a te  o f the  experiment was c a rr ie d  ou t fo r  HU609, and 
MGH-U1, and two fo r  RT112.
The mean % colony-form ing a b i l i t y  a f te r  exposure to  am ilo rid e  and 
thioTEPA a t  pH 5 and pH 7 is  d e ta ile d  in ta b le  27, fp  125. 
A ddition  o f 0.1mM a m ilo rid e  produced no larg e  reduction  in  
s u rv iv a l.
DISCUSSI ON
The absence o f an e f fe c t  might have been re la te d  to  an inappro­
p r ia te  choice o f a m ilo rid e  co n cen tra tio n . Experiments using 
higher concentrations would be needed to  c la r i f y  th is .
As the  stock thioTEPA had a lready been used w ith  e f fe c t ,  loss o f 
drug potency in  storage or p rep ara tio n  was u n lik e ly  although i t  
could have a ffe c te d  the  am ilo rid e . The low concentration  o f 
thioTEPA used m ight have masked a r e a l ,  but small reduction  o f 
s u rv iv a l, perhaps up to  30%, but such a synergy would be o f 
lim ite d  p ra c t ic a l a p p lic a tio n .
fp125
C e ll L ine pH
Number o f  
R eo lica tes Ami lo r id e ThioTEPA
iiii
Ami 1 + Thio 1
RT112 5
7
1
0
81 ----
i
8 6 .6  ! 
1 1
1
MGH-U1 5 2 102 89 .7
1
106.6 !
i
7 1 89 .0 67 .2 6 6 .2  !
HU 609 5 2 98.1 82 .8
•
7 2 .6  !
t
7 3 102.7 106.3 94 .7  !
TABLE 27
MEAN % CLONOGENIC CELL SURVIVAL WITH AMILORIDE, THIOTEPA, AND THE 
COMBINATION OF BOTH (AMIL+TH10)
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There could p o te n tia lly  have been a lack o f s u s c e p tib ility  o f the  
c e ll lines  used to  the e ffe c ts  o f am iloride. The Na+/H+ exchange 
o f MGH-U1 is  known to  be a ffected  by am iloride (R otin , e t  a l . ,  
unpublished observations quoted in Rotin e t  a l . ,  1987), so th is
seems improbable. Although pH was not measured, the d ifferences  
in  thioTEPA e ffe c t  previously observed were large between pH 5 
and 7 (chapter 5 ) .  The colour indicators in the Medium showed no 
change in pH. I t  may be th a t the a c id ity  o f the e x tra c e llu la r  
environment, combined w ith am iloride was in s u ffic ie n t to  a ffe c t  
the in tra c e llu la r  environment in the time o f the exposure. The 
previous studies (R otin  e t a l . ,  1987) used a six-hour exposure,
which would not be a c lin ic a l option. They found a g reater e ffe c t  
when am iloride was combined w ith the bicarbonate exchange block­
ing agent DIDS ( 4 ,4 ’ -d iiso th io cyan o s ti1bene 2 ,2-disulphonic acid) 
and the ionophore n ig e r ic in , which allows the exchange of 
in tra c e llu la r  K* fo r  e x tra c e llu la r  H *. When am iloride is  used 
alone, in a 1-hour exposure, less e ffe c t  might be expected. 
Reduced in tra c e 1lu la r  pH, and hence a lte re d  response to  thioTEPA 
might have been found i f  the am iloride had been added a t low pH 
seme tim e before the thioTEPA. This would be more d i f f i c u l t  to  
achieve in vivo than add ition  o f am iloride to  in traves ica l 
in s t i l la t io n s . Further, there did not appear to  be any d iffe re n ­
t i a l  between tunour c e ll lines and HU609, which would be 
p a rtic u la r ly  b e n e fic ia l in in traves ica l chemotherapy. Measure­
ments o f in tra c e llu la r  pH would have been in te re s tin g .
As am iloride is  already in c lin ic a l use, i t  was considered
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appropriate to  assess i t ,  ra ther than the other agents, in a 
p ilo t  study. No data were obtained th a t encouraged fu rth e r  
investigation .
127
CHAPTER 7 
DISCUSSION OF METHODODLOGY
TISSUE CULTURE METHODS
The clonogenic assay employed is  a va rian t on a widely-used 
survival assay, which measures c y to to x ic ity  as the loss of 
reproductive a b i l i t y ,  which has a c lin ic a l relevance beyond mere 
m etabolic s u rv iva l. I t  is conceivable th a t local destruction of 
v ita l  structures or functions might occur in  the absence o f a 
reproductive capacity , but in p ractice  th is  is  ra re . Other tes ts  
used to  measure drug e f fe c t ,  such as the MTT assay (Mossman, 
1983), or ATP-bioluninescence (Jauhiainen e t a l . ,  1985), w ith the  
advantage o f ra p id ity  o f te s tin g , depend on the absorption and 
reactions o f other agents. This in d ire c t measure might th e o re t i­
c a lly  ind icate  p o s itiv e  a f te r  a recoverable m etabolic in s u lt, or 
negative in the presence o f a DNA lesion which would prove le th a l 
a fte r  a number o f c e ll cycles (Tidd & Paterson, 1974; F a irc h ild ,  
Maybaum & Kennedy, 1986; Larramandy & Lopez-Larraza, 1989).
Clonogenic assay methods remain to  be standardized, both as to  
the use o f feeder c e ll layers, and to  the point a t  which drug 
exposure and try p s in iz in g  fo r c e ll p la tin g  occur. In RT112 
exposures to  adriamycin and m ethotrexate, feeder c e lls  appear to  
make no d iffe ren ce  (Hepburn & Masters, 1986), but immediate 
try p s in iza tio n  reduced the e ffe c t  o f methotrexate a t higher 
concentrations, by comparison w ith p la tin g  a f te r  24 hours. Data
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on thioTEPA were not a v a ila b le , but the method used was the  
standard used in  the In s t itu te  o f Urology's laboratory. Using 
short drug exposures a t 48 hours' in te rva l a f te r  p la tin g  of 
exponentially-growing c e lls  avoids the drug d e te rio ra tio n  
possible in continuous exposures, and the va riab le  growth ra te  
and growth fra c tio n  o f c e lls  in  monolayers approaching 
confluence, more lik e ly  in tra n s fe r assays. The po ten tia l 
bias from in te ra c tio n  between try p s in iza tio n  and drug treatm ent 
(Hepburn & Masters, 1986) is also avoided. On the other hand, 
c e llu la r  co-operation, which may be important in v ivo , is  
minimised in the in -s itu  assay.
The te s t  o f drug s e n s it iv ity  a f te r  the model course of
in traves ica l thioTEPA can be c r it ic is e d  fo r  i ts  large day-to-day  
varia tio n s  in s u rv iv a l, and fo r i ts  use o f a s ing le  drug
concentration. The v a ria tio n  could have resulted  from inaccurate
p ip e ttin g  o f thioTEPA, e ith e r as a re s u lt  o f poor technique, o f 
arithm etica l errors in d ilu t io n , or o f m is id e n tific a tio n  o f stock 
concentratons; from degeneraton o f drug in storage; or from
v a ria tio n  in the growth status o f the c e lls  tested . As fa r  as 
possible, c e lls  were used before reaching confluence, w hile s t i l l  
in logarithm ic growth. There was no evidence o f a systematic 
decline in drug e f fe c t ,  and i t  was more l ik e ly  th a t random 
p ip e ttin g  errors led to  variatons in the actual concentrations 
used.
The choice o f a s ing le  value in the assessment o f resistance was
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based on expediency. Occasionally, there  appear to  be crossovers 
in  drug dose-response curves o f d iffe re n t  c e ll  lin e s , but they 
are sometimes less rea l than aparent, due to  the use o f standard 
e rro r bars instead o f 95% confidence in te rv a ls . Nonetheless, i t  
would have been more convincing i f  i t  had been possible to  carry  
out f u l l  dose-response curves fo r trea ted  c e lls  and controls o f 
both types, preferab ly  in a paired fashion, fo r  comparison o f the  
areas under the curves.
Because o f the paired technique used in  the assay o f s e n s it iv ity ,  
the power o fthe rep lic a te s  carried  out was considerably incresed, 
and the e ffe c ts  o f day-to-day varia tio n s  were reduced. For each 
comparison o f Parent, C ontrol, and Treated c e ll lin e s , a s ing le  
preparation o f Mediin was used both fo r  the drug-free control 
dishes, and to  d ilu te  the s ing le  container o f te s t  thioTEPA used 
fo r  dishes o f a l l  sublines compared on one tra y . Separate 
preparations were used fo r HU609, RT112 and MGH-U1 on each day,
to  avoid cross-contamination. Separate tra y s , eg o f MGH-U1, were 
not paired , as d iffe re n t  Medium and thioTEPA solutions were used, 
and were not s im ila r ly  compared, even although an unpaired te s t  
would have been app licab le , as i t  was obvious th a t the d a ily  
v a ria tio n  would swamp any drug e f fe c t .  Although comparisons o f 
d iffe re n t  le tte red  sublines o f Control and Treated c e lls  would 
have been equally v a lid , the method used compared lik e  le tte rs  
fo r s im p lic ity 's  sake, thus avoiding confusion o f flas ks .
In the model o f chemotherapy, drug exposures required higher c e ll
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densities  than control exposures, to  allow  fo r c e ll losses from
treatm ent. I t  was expected th a t the lower p la tin g  d en sities  o f
the control flasks  produced a s im ila r  rumber o f surviving c e lls  
a t the next subculture.
The resu lts  o f te s ts  o f resistance in HU609 are inconsistent, but 
the pattern  in the three c e ll lin e s , i f  they can be taken 
together, indicates a trend to  development o f resistance a f te r  a 
model course o f in traves ica l chemotherapy. I f  resistance was not 
induced in HU609, then the d iffe ren ce  found in Tb and Tme«n 
compared w ith  Control c e lls  might be random, w ith a p ro b a b ility  
less than 0 .08 . A lte rn a tiv e ly , the lack o f a d iffe rence  between 
Control c e lls  and Ta and Tc c e lls  has a p ro b a b ility  less than 
0 .3 . The Tb f la s k , compared w ith  the Parent c e lls ,  had a p-value
o f 0 .11 , whereas the other Treated flasks showed much higher
fig u res . This may ind icate a p e c u lia r ity  developed in  T b , such as 
a mutation or other low-frequency event inducing resistance. 
Studies w ith less v a r ia b i l i t y  would be o f considerable in te re s t.
In e ith e r event, the s ta t is t ic a l ly  s ig n ific a n t d iffe ren ce  between 
Parent and Oontrol flasks  remains to  be explained. I t  might 
r e f le c t  an increase in s e n s it iv ity  w ith passage, th a t was 
reversed by the model course o f thioTEPA, measurably in Tb , but 
below threshold in other flas ks . Such a change in s e n s it iv ity  
was not observed in MGH-U1, but th is  does not preclude i t  in 
HU609. The survival o f uncloned HU609 c e lls  a f te r  a 1-hour 
exposure to  40 mcg/ml commercial thioTEPA was 45%, 95% confidence
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in te rva l (13,779$), and cloned, 10.7(0,42.8)9$, a f te r  exposure to  
unbuffered thioTEPA. The te s ts  o f uncloned HU609 were not 
intended fo r comparison w ith the re s is ta n t sublines, but to  
ind icate  a su itab le  concentration fo r  the induction o f re ­
sistance. A comparison o f uncloned HU609 w ith Cx, C& and Cc o f 
HU609 would be very in te re s tin g .
The DMSO used in freezing  is a known d iffe re n t ia t in g  agent 
(Borenfreund e t a l . ,  1975; Kim e t a l . ,  1980; Mickey e t  a l . ,
1983), but i ts  influence on c e ll lines (chapter 6) when combined 
w ith thioTEPA a t the time o f exposure is  l ik e ly  to  be neutral or 
to  reduce s u rv iv a l. I t  m ight, however, be made greater by v ir tu e  
of the fa c t th a t the DMSO exposure preceded the thioTEPA exposure 
(chapter 6 ) .
As the Control and Treated sublines were maintained in p a r a l le l ,  
differences in confluence or growth phase o f Control subline  
c e lls  a t  the tim e o f tes tin g  seem u n lik e ly . The survival o f the  
Control subline, 43(34,52)9$, was comparable w ith th a t o f the  
uncloned c e lls  to  commercial thioTEPA, 41(28,54)9$, although the  
e ffe c ts  o f the commercial bu ffer and the cloning cannot be 
distinguished from the a va ilab le  data. The expected e ffe c t  o f the  
a lk a lin is a tio n  in commercial preparations would be increased 
survival over pure drug, so the data suggest th a t cloning may 
have reduced the survival o f Control and Parent cloned c e lls  
exposed to  thioTEPA. I f  so, the apparent increase in the survival 
of the Treated C e lls  is l ik e ly  to  be re a l.  Paired comparisons o f
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the dose-response o f uncloned, Parent, and Control c e lls  w ith one 
drug form ulation would be usefu l.
In any lim ited  exposure assay, whether p la tin g  o f colony-forming 
un its  occurs 2 days before exposure to  the drug, as here, or 
a fte r  exposure, as e 1sewhere ( Freshney, 1987), v ia b le c e l ls  may
be lost in the process of washing away the te s t  drug. Unless the  
drug is  postulated to  have a cel 1-suspending e ffe c t  in one 
subline p re fe re n t ia lly , eg by se lec tin g , during the model course 
o f chemotherapy, c e lls  th a t were l ik e ly  to  remain attached as 
well as v ia b le , such a process cannot be s ig n ific a n t in  these 
data. A s im ila r p o ten tia l fo r c e ll loss might be postulated a t  
the time dishes are washed and fixe d  fo r  counting. In th is  case, 
there would need to  be a d iffe ren ce  between control dishes and 
drug-exposed dishes o f the same subline, a d iffe ren ce  th a t caused 
the loss o f whole colonies ra ther than o f indiv idual c e lls  w ith in  
colonies. This might be a fac to r i f  the nunbers o f colonies per 
dish were s n a il, or i f  the colonies contained few c e lls  a t  the  
time o f f ix a t io n , but again th is  seems improbable, as no major 
discrepancies were noted between the inspection o f unfixed dishes 
and the colony counts.
The meticulous use o f clean equipment, esp ec ia lly  p ip e tte s , fo r  
each flas k  in the model course o f chemotherapy made cross­
contamination w ith in  and between c e ll lines  u n lik e ly . This is  
fu rth e r supported by the d iffe re n t  s e n it iv it ie s  of the three c e ll  
lin es . Most s ig n if ic a n t ly , isoenzyme te s tin g  and DNA
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fin g e rp rin tin g  show no evidence o f extraneous or contaminated 
sublines. He La c e lls  have not been kept or iso lated  in the  
laboratory. Growth ra te  estim ations, which would have been of 
p a rtic u la r  in te re s t in  the HU609 comparisons, were not carried  
out fo r  lack o f tim e, but there  was no marked d iffe rence  in 
colony s ize  as assessed by naked eye, between Control and Treated  
sublines, a f te r  the 1-hour exposure e ith e r  to  Medium alone or 
w ith thioTEPA. Behavioural changes seemed u n lik e ly  as an explana­
t io n  fo r the data.
The absence o f Control data l im it  the  in te rp re ta tio n  o f the  
d iffe ren ce  between Parent and Treated RT112 sublines. There is  a 
d iffe rence  o f a fac to r o f two, apparent in both Treated flas ks . 
While th is  might represent the e f fe c t  o f passage, the evidence 
from HU609, i f  in terp reted  as due to  passage, showed an increase 
in s e n s it iv ity  in  Control c e l ls ,  which would be expected to  
am plify the fa c to r o f resistance in  Treated c e lls  compared w ith  
Control c e lls  o f s im ila r passage. The survival o f uncloned RT112 
a t a thioTEPA concentration o f 40 mcg/ml was 4 .3  (0 .5 , 8)&, much
less than the cloned sub lin e s , and does not illu m in a te  the  
comparison o f s e n s it iv ity . Indeed, i t  emphasises the need fo r  
caution when comparing cloned and uncloned sublines in general. 
The consistency o f the s e n s it iv ity  in both trea ted  flasks  
provides no evidence o f a low-frequency event, such as mutation 
is  thought to  be.
The day-to-day v a ria tio n  in  survival was again notable, and again
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the design o f the study compensated. These re s u lts  are strongly  
suggestive th a t a graduated resistance had developed to  thioTEPA 
a fte r  a model course o f in traves ica l chemotherapy in RT112 c e lls .
The d iffe ren ce  in s e n s it iv ity  fo llow ing the model course of 
chemotherapy was c lear in MGH-U1. I t  was not present in c e lls  o f 
high passage th a t were not trea ted  w ith thioTEPA. This is  
consistent w ith the lack o f e ffe c t  o f passage on drug s e n s it iv ity  
o f MGH-U1 previously reported (Masters and Hepburn, 1986) despite  
evidence th a t MGH-U1 is  polyclonal (Hastings and Franks, 1983). 
The survival o f uncloned c e lls  exposed to  commercial thioTEPA in  
prelim inary dose-response experiments is  higher than e ith e r  
Parent or Control sublines, but has a wide confidence in te rv a l, 
which would probably mean th a t the apparent d ifferences could 
have occured by chance. Use o f a higher concentration o f thioTEPA 
to  compare Parent, Control and Treated sublines might have 
reduced day-to-day varia tio n s  due to  minor p ip e ttin g  
inaccuracies.
RESISTANCE: C haracterisation
Although i t  has been reported th a t one clone a t  least o f MGH-U1 
does not form xenograft tumours (Hastings and Franks, 1983), 
tum ourigenicity was not reduced in the sublines th a t were c le a r ly  
re s is ta n t, or in the Treated RT112 or induced in HU609. The 
tumours induced were assumed to  be o f human o r ig in , on the basis 
of previous find ings (Masters e t a l . ,  1986). Uninjected control
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mice did not grow tumours, but fu rth e r controls in jected  w ith  
medium containing h ea t-in ac tiva ted  or no c e lls  would have helped 
im p licate  the c e lls  in the genesis o f the tumours. A veterinary  
patho log ist might also have examined the lesions to  characterize  
the species o f o r ig in . D if fe re n tia l s ta in in g  w ith anti-human and 
anti-mouse antibodies would have been in te re s tin g . With these 
q u a lif ic a tio n s , i t  appears th a t there is no evidence o f a change 
in xenograft tum ourigenicity.
Morphological examination o f the c e ll lines was ra ther  
s u p e r fic ia l,  and carried  out by the present author, who has 
lim ited  experience o f histopathology. I t  was carried  out ra ther  
to  id e n tify  cross-contamination among the three c e ll lin e s , which 
have obvious d ifferences in morphology, than to  make a r e a l is t ic  
comparison w ith the reported morphology o f the c e ll lines  
(Masters e t a l . ,  1986). There were no changes during the couse of 
the experiment.
The isoenzyme analysis has been used to  characterize  c e ll lines  
and to  d istingu ish  them from vigorous contaminants such as HeLa 
c e lls  (Povey e t a l . ,  1976). Isozyme id e n tif ic a t io n  o f the cross­
contamination o f a number o f apparently d iffe re n t c e ll lines has 
been confirmed by DNA fin g e rp rin tin g  (Masters e t a l . ,  1988). The 
d is t in c tiv e  type A glucose-6-phosphate dehydrogenase o f HeLa 
c e lls  was absent from a l 1 sublines, as has previously been 
reported fo r RT112 and MGH-U1 (Povey e t a l . ,  1976). Comparability  
between untreated and Treated sublines in respect o f a l l  o f the
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isoenzymes tested precludes ne ither the p o s s ib ility  th a t con­
tam ination had taken place w ith  c e lls  from an ind iv idual w ith  a 
s im ila r isoenzyme ccmbination, nor th a t there might be changes in 
other enzymes or surface antigens during the model course of 
thioTEPA. Knowledge o f the isoenzyme pattern  o f a l 1 lines used in  
the laboratory would have been o f some help in  excluding cross­
contamination, but the DNA fin g e rp rin tin g  data id e n tify  the  
sublines w ith  a high degree o f c e rta in ty . For p rac tica l purposes, 
the Parent, Treated and Control sublines o f each c e ll lin e  were 
derived from the same person.
The karyology was not carried  out to  great depth, fo r lack of 
tim e, but i t  was a useful p i lo t  study. Nimbers o f metaphase 
spreads examined were sm all, and no examination was made fo r  
double-minute abnorm alities, or SERs, which have been associated  
with drug resistance. The lack o f a d is tin c tio n  in karyotype was 
therefore  hardly surpris ing .
The in i t ia l  find ings in A431 c e lls  va lidated  the technique as a 
po ten tia l method o f q u a n tifica tio n  o f c e llu la r  surface antigen  
expression, even w ith a re la t iv e ly  simple instrument and 
software. The lack o f s ta in ing  may have resu lted  from the age o f 
the primary antibody, or frcm a lack o f antigen in the c e ll lines  
studied. Unfortunately, the prelimunary h is to lo g ica l s ta in ing  o f 
A431 c e ll p e lle ts  was not carried  out in any o f the u ro th e lia l 
c e ll lin es .
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DISCUSSION: pH
In th is  study, the colony-forming a b i l i t y  o f c e lls  exposed to  
thioTEPA fo r an hour a t  each pH was expressed as a proportion o f 
the colony-forming a b i l i t y  o f c e lls  exposed to  the same pH fo r  an 
hour in the absence o f thioTEPA. The "Control" exposure, made in 
laboratory standard conditions, and w ithout b u ffers , expressed 
survival o f dishes containing thioTEPA as a proportion o f dishes 
containing Mediun alone, incubated in  an atmosphere containing 5 *  
OO2 . "Oontrol" data were obtained as a measure o f the accuracy of 
thioTEPA p ip e ttin g , the influence o f the osmotic e ffe c t  o f the  
buffers  and o f the consistency o f the condition o f c e lls  tested , 
not as a denominator fo r the survival o f other pH values.
The t i t r a t io n  o f the Medium w ith acid or a lk a l i  a f te r  the  
add ition  o f b u ffer was a po ten tia l source o f osmotic v a r ia b i l i t y ,  
and might b e tte r have been avoided. On the other hand, despite a 
to lerance o f pH 0.15 pH un its  before t i t r a t io n  was used, the  
errors in measured pH were minimal fo r each Nominal pH, and the  
v a ria tio n  during the course o f the experiment was sm all, and 
u n lik e ly  to  bias the resu lts  (tab les  17-19).
The concentration o f thioTEPA chosen was ra th er low fo r HU609 and 
MGH-U1, i f  one looks a t the in i t ia l  dose-response curves to  
buffered thioTEPA, but in the pH studies themselves, the mean 
survivals  a t  pH 7 .0  are between 60 and 80%, and o ffe r  a small 
range in  which i t  was possible to  observe a loss of drug
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s e n s it iv ity ,  w ith more scope fo r observing the reduced survival 
th a t was expected a t low pH (Groos e t a l . ,  1986). In fa c t ,  there
might have been seme advantage in repeating the experiment w ith  
higher concentrations o f thioTEPA and higher colony numbers, to  
reduce the e ffe c ts  o f p ip e ttin g  errors on the confidence in te rva l 
o f the su rv iva ls . Higher colony numbers p lated  in  larger dishes 
would also have given more accurate measurement o f surv iva ls  
between 10° and 10- 2 . The use o f lower thioTEPA concentrations, 
w hile adding to  the p ip e ttin g  e rro rs , might have increased the  
contrast between pH 5 and pH 7, and avoided the zero su rv iva ls  a t  
pH 5. Although the e ffe c t o f a c id ity  on the e ffe c t  o f thioTEPA 
might have been b e tte r elucidated by te s tin g  more points in  the  
acid range, the e ffe c t  seems c le a r.
In two bladder cancer c e ll lin e s , and in a c e ll lin e  derived from 
h is to lo g ic a lly  normal urothelium from a p a tien t w ith a renal 
c lea r c e ll carcinoma (HU609), the pH o f the mediun during a 1- 
hour exposure to  thioTEPA influenced the mean colony-forming  
a b i l i t y .  This confirmed the o rig in a l study in  RT112 (Groos e t 
a l . ,  1986), and demonstrated th a t the phenomenon was not an 
idiosyncrasy o f th a t lin e .
AMILORIDE
The p i lo t  assays o f am iloride were not conclusive in any way, 
because o f shortage o f data, p a r t ic u la r ly  control data.
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I t  would have been more help fu l to  have concentrated on a s ing le  
l in e . In view o f the increased e ffe c t  o f thioTEPA a t low pH, and 
o f the day-to-day varia tio n s  above, a low concentration of 
thioTEPA was used, possibly too low to  produce any e f f fe c t  even 
a t acid pH. Although the concentration o f am iloride was 
comparable to  one found to  be e ffe c tiv e  in MQH-U1 by others  
(R otin  e t  a l . ,  1987), i t  might not have been adequate in the  
other lines used, or even in  MGH-U1 in the assay system employed 
here. The six-hour exposure used by the e a r l ie r  authors would not 
have been p rac tica l in  p a tien ts , and might have led to  
d e te rio ra tio n  in the e ffe c t  o f the thioTEPA.
DIMETHYL SULPHOXIDE
Solvents may increase the e ffe c t  o f anticancer drugs. As a 
po ten tia l adjuvant to  in traves ica l treatm ent, DMSO had the  
advantage th a t a 50% so lution was already in c lin ic a l  
in traves ica l use fo r the treatment o f in te r s t i t ia l  c y s t i t is ,  so 
any p o s itiv e  in te rac tio n  could d ire c t ly  be tested in  v ivo. 
Previous find ings in  animals (Thuning e t a l . ,  1983; Warren e t  
a l . ,  1975) and in  some mouse tumour c e ll lines (T o filo n  e t a l . ,  
1985) prompted the hypothesis th a t the add ition  of DMSO to  
bladder in s t i l la t io n s  might increase the e f fe c t  o f anticancer 
drugs on human c e ll  lin e s . In v it r o  observations on the enhance­
ment o f drug e f fe c t  by combination w ith another solvent, Tween 80 
(P a rr is  e t  a l . ,  1987) are supported by c lin ic a l data showing 
enhancement o f the e ffe c t  o f adriamycin combined w ith  Tween 80 in
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in trav es ica l treatm ent o f bladder tumours (Eksborg, Edsmyr & 
Nasiand, 1982).
The enhanced c y to to x ic ity  observed w ith DMSO in animal models and 
the mouse hepatocarcincma c e l ls  in v it r o  may represent a 
d if fe re n t  phenomenon from the p o ten tia tio n  o f antitunour e ffe c t  
seen w ith  the add ition  o f Tween 80, which is thought to  act by 
increasing membrane perm eability  to  drugs (Eksborg e t a l . ,198 2 ;  
P a rris  e t  a l . ,  1987). Tween 80 was most e ffe c tiv e  w ith la rg er,
r e la t iv e ly  impermeable, ionised drugs, such as adriamycin. 
Although i t  was tenable th a t a d ipo lar solvent such as DMSO might 
have a s im ila r e f fe c t ,  the present data do not support th is  
hypothesis.
An a lte rn a tiv e  hypothesis concerns non-solvent properties of 
DMSO. In tumour ce l l  lin e s , DMSO has been found to  induce 
d iffe re n t ia t io n  (Borenfreund Steinglass, Korngold e t a l . ,  1975;
Kim, Tsao, Siddiqui e t a l . ,  1980; Mickey, Meadows, Vassiliades e t  
a l . ,  1983). Enhancement o f cytotoxic  drug e ffe c t  was seen in 
murine hepatocarcincma ce l ls  (T o filo n  e t a l . ,  1985) when c e l ls
had been exposed to  DMSO fo r  48 hours before treatm ent w ith  
anticancer agents, and was not seen a f te r  exposures beginning 
simultaneously. The animals in which DMSO enhanced the e f fe c t  o f 
chemotherapeutic drugs had been given DMSO fo r 6 days previously  
(Thuning e t a l . ,  1983). I t  is  possible th a t pre-treatm ent of 
patien ts  w ith DMSO might increase the e ffe c t  o f chemotherapeutic 
agents. The c h a ra c te ris tic  smell o f even small amounts o f DMSO
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would probably make adequate length o f pre-treatm ent unacceptable 
to  p a tien ts . This hypothesis was not, th ere fo re , pursued.
The present author found no evidence th a t the add ition  o f DMSO to  
in s t il la t io n s  o f four drugs comnonly used to  t re a t  s u p e rfic ia l 
bladder cancer increased th e ir  cytotoxic  e f fe c t .  I t  may reduce 
the e f fe c t  o f mitcmycin-C. Drug enhancement in  other models may 
re s u lt from DMSO-induced d if fe re n t ia t io n  before drug exposure.
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CHAPTER 8
CLINICAL I IMPLICATIONS AND CONCLUSIONS
Transurethral resection o f tumours (TUR) is  the f i r s t  lin e  o f 
treatm ent fo r s u p e rfic ia l bladder cancer. Some authors have 
suggested th a t i t  may cause dissemination o f the tunour w ith in  
the bladder (Boyd & Burnand, 1974; Soloway & M asters,1980). 
Sunnarising a number o f studies, TUR is followed by recurrence in 
40% of 599 patients w ith in  1 year (ta b le  1, fp  21); 45% o f 349
patien ts  w ith in  two years (ta b le  2, fp  22); and 69% o f 261 
p atien ts  w ith in  f i v e  years (ta b le  3, fp  23 ). An estim ate o f 4% 
has been made fo r progression o f tumour stage in the f i r s t  year 
in  T« (Heney, e t  a l . ,  1982), 6% in 3 years (ta b le  4 , fp  24) ,  and 
26% o f 168 patients  in 5 years (ta b le  5, fp 25).  The d e fin it io n  
o f progression and the duration o f follow -up have been less 
consistent than fo r studies o f recurrence. In patien ts  w ith Ti 
tumours, one year data are few, but progression occurs in 29% of 
221 patien ts  in 3 years (ta b le  4 );  and in 31% of 203 patients  
followed fo r  5 Years (ta b le  5 ) . Mackenzie e t  a l . , ( 1 9 8 1 )  have 
reported th a t the ra te  of new progression was constant a t  around 
10% per year. The survival o f patien ts  w ith s u p e rfic ia l lesions 
has been reported to  be s im ila r to  th a t o f a s im ila r age-group 
w ithout bladder cancer (N icho lls  & M arshall, 1956), although 
improvements in the general standard o f operative management 
since the data were co llected  are l i k e ly  to  have a ffected  th is  
ccmaparison s t i l l  more favourably. There is seme doubt as to  
whether conventional treatm ent a lte rs  the course o f the disease
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favourably and c lear room fo r improvement in the re su lts  o f 
therapy.
INTRAVESICAL CHEMOTHERAPY: Rationale.
In traves ica l chemotherapy w ith thioTEPA can c lear the bladder o f 
m u ltip le  s u p e rfic ia l tumours (Jones & Swinney 1961; Veenema e t  
a l . ,1962 ;  Koontz e t a l . ,  1981) w ith complete response in 23-56%
o f cases, and p a r t ia l response in a fu rth e r 32-41% (Prout, 1984). 
There are also indications th a t in traves ica l chemotherapy may 
prevent invasive bladder cancer (Q^een e t a l . ,  1984).
The intrusiveness o f fo llow -up fo r s u p e rfic ia l bladder cancer 
might be reduced by drug prophylaxis or treatm ent, and the  
present studies were intended to  develop th a t con tribu tion . By 
delaying recurrences, and preventing or delaying invasion, the  
in te rv a ls  between cystoscopies might be lengthened, and the need 
fo r resection under anaesthesia reduced. Eventually, in traves ica l 
in s t il la t io n s  might be tested in the treatm ent o f small or s ing le  
recurrences being re fe rred  fo r resection , e ith e r  as a therapeu tic  
option, or w ith  a view to  prophylaxis against recurrence or la te r  
progression. There may also be symptomatic advantages. Episodes 
o f severe haematuria fo llow ing thioTEPA (T re ib le  e t a l . ,  1987)
are less common than a f te r  resection o f bladder tumours. As 
Skipper has pointed out (Skipper, Schabel & Lloyd, 1978), even 
w ith in  the group o f complete responders, there  is  scope fo r  
improvement in the cure ra te . Combined w ith a v iab le  o u t-p a tie n t
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cystoscopy technique su itab le  fo r use in most p a tien ts , in tra ­
vesical treatm ent might reduce the demands o f fo llow -up.
Other less invasive methods o f management e x is t , w ith d iffe re n t  
advantages and lim ita tio n s . Laser coagulation, which coagulates 
1-arm diameter on each ap p lica tio n , and seals the surrounding 
lymphatics, which may prevent m etastasis, requires expensive 
equipment, and special eye pro tection  fo r s t a f f .  Use o f haemato- 
porphyrins re s u lts  in  some generalised p h o to sen s itiv ity , fu rth e r  
reducing the q u a lity  o f p a tien ts ' l ives.  O ut-patien t in traves ica l 
therapy o ffe rs  a less invasive, and possibly less expensive 
method o f treatm ent.
In travesical B ac illu s  Calmette-Querin can postpone recurrence 
(Rodriguez-Netto e t  a l ,  1981) and c lear carcinoma in s itu  
(Harlsnd, Charig, Parkinson e t a l . ,  1991), but produces profound 
symptoms o f local i r r i t a t io n  and systemic i l lness ,  which would be 
hard to  ju s t ify  in prophylaxis against recurrence unless there  
was also a las tin g  b e n e fit , or a reduction in progression.
INTRAVESICAL CHEMOTHERAPY: pH
In ra ts  which have been rendered ac id o tic  by induced hypergly- 
caemia (Osinsky e t a l . , 1 9 8 8 ) ,  Guerin tumours show an increased 
s e n s it iv ity  to  thioTEPA, as do murine colon timours in v it r o  
( P h i l l ip s  e t  a l . ,  1988). There is  a report o f c o n flic tin g  
find ings in v i t r o  (Jauhiainen e t a l . ,  1985) probably because o f
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the use o f ATP bioluminescence, a marker o f m etabolic a c t iv i ty ,  
as an ind icator o f c y o to x ic ity . Drugs th a t act on DNA may not 
have th e ir  maximum e ffe c t  u n til  the second ce l l  cycle a f te r  
exposure (Tidd and Paterson, 1974; F a irc h ild , e t a l . ,  1986; 
Larramandy e t a l . ,  1989). The present study o f the pH o f the  
in s t i l  la te  confirms the in i t ia l  study o f one human u ro th e lia l 
cancer c e l l  lin e  (Groos e t a l . ,  1986), which observed th a t acid
in s t iH a te s  reduce clonogenic ce l l  surv iva l a f te r  exposure to  
thioTEPA, amongst other agents. The phenomenon was observed in  
c e l ls  derived from h is to lo g ic a lly  normal urothelium  and in  
u ro th e lia l cancer c e l l  lines derived from moderately d if fe r e n t ia ­
ted tumours.
The urine o f pa tien ts  rece iv ing  in traves ica l chemotherapy may 
have a pH greater than 6.0  in  a th ird  o f in s t i l la t io n s  and tends 
to  become more a lka l in e  during the period o f the in s t i l la t io n  
(Groos e t  a l . ,  1986). As the pH of ccrm ercial thioTEPA dissolved
in s t e r i l e  water a t  1mg/ml is  8 .2  (Groos e t  a l . ,  1986), i t  is  
l i k e ly  th a t previous c l in ic a l  resu lts  r e f le c t  the use o f thioTEPA 
a t other than i ts  most e f fe c tiv e  pH. The reported comparative 
studies o f thioTEPA w ith other in traves ica l agents, including BOG 
(Schulman e t  a l . ,  1982; Rodriguez-Netto e t  a l . ,  1981) may be
inval id  because the pH o f thioTEPA in s t i l la t io n s  was not optim al. 
The 26$ complete response ra te  fo r therapeu tic  use in  m u ltip le  
and recurren t s u p e rfic ia l tumours (Heney e t  a l . ,  1988) might be
improved.
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The degree o f d iffe rence  a t pH 5 .5  in the e ffe c t  o f 20 mcg/ml 
thioTEPA was around two logs o f c e ll  s u rv iv a l, w ith  no evidence 
o f a p lateau, so the c lin ic a l b en e fit might be o f p rac tica l 
s ign ificance . Although there are considerable d ifferences in
behaviour between himan so lid  tumour growth/regression and th a t  
o f the murine leukaemia L1210 (Yankee, De V ita , Perry e t  a l . ,  
1968; Young and De V ita , 1970; C larkson,et a l . ,  1967; Whang-Peng 
e t  a l . ,  1971; Tannock, 1978; Perry, Moxley, Weiss e t  a l . ,  1966; 
De V ita , Denham, Perry e t  a l . ,  1969; Simpson-Herren, Sanford,
Holmquist e t  a l . ,  1974; Mendelsohn, 1960), the log-growth model 
Skipper proposed (Skipper, Schabel & Wilcox, 1964; Skipper et 
a l . ,  1978; Skipper, Schabel, Mel le t  e t  a l . ,  1950) is  widely  
accepted as descrip tive  o f timour chemotherapy. Increases in log- 
k i l l  are important in moving from p a r t ia l to  complete response, 
and from complete response to  cure, and reducing the pH of
thioTEPA in s t il la t io n s  may contribute s ig n ific a n tly  to  th is  in
v ivo , as well as in  v it r o .
Enhancing the an ti-tim ou r e ffe c t  o f thioTEPA may also reduce its  
unwanted e ffe c ts . The dose-rate fo r  in traves ica l thioTEPA is
lim ited  by myelosuppression by absorbed drug (Soloway & Ford, 
1983). Myelosuppression in systemic chemotherapy has been c ircun- 
vented by autologous marrow harvesting and cryopreservation  
before treatm ent (Antman, Eder, E lias  e t a l .;  W olff , H erzig , Fay 
e t a l . ,1 9 9 0 ) ,  but th is  is  h ighly invasive compared w ith conven­
tio n a l management o f s u p erfic ia l bladder cancer. An a lte rn a tiv e  
th a t has been used w ith e ffe c t  in the combination chemotherapy of
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advanced bladder cancer is  marrow support using granulocyte  
colony-stim ulating factors  (Yagoda, A, 1988), but th is  is
untried  in thioTEPA monotherapy, and is  l ik e ly  to  be expensive 
fo r routine use. When administered a t pH 5, the weight o f drug 
given to  achieve the same cyto toxic  e f fe c t  lo c a lly  ought to  be 
less, in a given volume o f in s t i l  la te . I f  the bladder acts as a 
semipermeable membrane to  thioTEPA, lower in traves ica l concentra­
tions would lead to  less absorption, and so to  less myelo­
to x ic ity .  Absorbed thioTEPA would presumably be exposed to  the  
marrow a t a higher pH than in  the bladder, although the pH o f the  
marrow, even under res tin g  conditions, does not appear to  have 
been measured. Thus, less to x ic ity  might be expected in the  
marrow exp lo itin g  the currently-used or perhaps even higher 
concentrations o f thioTEPA, a t  acid pH, w ith one form o f marrow 
pro tection . R egrettab ly, planned studies o f absorption were not 
possible.
ThioTEPA decomposes a t acid pH, but w ithout loss o f i ts
a lk y la tin g  a c t iv ity .  The e f fe c t  on bladder cancer c e lls  is 
increased. The quantity  o f drug absorbed across the bladder a t  
acid pH, and its  consequent myelotoxic e ffe c t  remain unknown. The 
sm aller products o f decomposition could be expected to  d iffu s e , 
i f  anything, more e a s ily  than thioTEPA, increasing marrow damage, 
but th is  might be o ffs e t  by a lowering o f in traves ica l dose-rates  
needed to  achieve the same e f fe c t .  Perhaps the use o f granulocyte 
colony-stim ulating factors  to  support the marrow would be a
possible lin e  o f approach. This would be o f no b en e fit in the use
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o f mitomycin-C or adriamycin, where the lim itin g  to x ic ity  is  
bladder i r r i t a t io n  or contact d e rm atitis , although pH does 
influence the e ffe c t  o f these (Groos e t  a l . ,  1986).
To apply pH bu ffering  in v ivo  faces fu rth e r hurdles. To the  
d ilu tio n a l e ffe c t  o f urine production, might be added the  
v a r ia b i l i t y  o f absorption and breakdown o f thioTEPA a t d if fe re n t  
pH or temperature (Cohen e t a l . ,1984), and absorption or metabo­
lism o f the b u ffer used. In terference from substances excreted  
in the u rin e , such as methylxanthines (F in g e rt, Pu. Chen e t  
a 1.,1988) remains to  be tes ted . There e x is t b u ffe r systems th a t  
have been used in vivo to  a t ta in  the pH required , but would have 
a higher osm olality  which might o ffs e t  (Groos e t a l . ,  1986b) the  
p o ten tia l b en efits  o f pH optim isation . There is  the great 
advantage th a t both buffers and thioTEPA have been used in v ivo , 
and can be tested in hunans w ithout fu rth e r prelim inary te s ts .
Other approaches to  enhancing in traves ica l thioTEPA therapy were 
less premising. The am iloride p i lo t  in vestig a tio n , w hile qu ite  
possibly subject to  Type 11 e rro r, did not show a large  
enhancement, say o f one log. No useful conclusions were derived. 
Probably a combination o f am iloride and the s tilb e n e , DIDS, would 
be more e f fe c tiv e  (Rotin e t a l . ,  1987), but DIDS is  not in 
c lin ic a l use. DMSO may be a useful adjuvant anticancer therapy in  
seme studies, possibly by means o f inducing d if fe re n t ia t io n  p rio r  
to  g iving therapy, but no evidence was found to  suggest th a t  i t  
could simply be added to  the in traves ica l in s t i l  la te  in the way
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th a t Tween 80 has been (P a rris  e t  a l . ,  1987; Eksborg e t  a l . ,
1982).
INTRAVESICAL CHEMOTHERAPY: Resistance
I t  remains to  be explained how prophylactic in traves ica l chemo­
therapy acts , and whether i t  contributes to  drug resistance. 
Prophylactic use o f thioTEPA fo llow ing resection has reduced the  
number o f recurren t lesions per month o f fo llow -up (Burnand, 
Boyd, Mayo e t a l . ,  1976), recurrence ra te  (Schulman e t a l . ,  1982) 
and proportion o f patien ts  w ith  recurrence (Rodriguez-Netto and 
Caserta, 1981) and increased the d isease-free in te rva l (Koontz e t  
a l . ,  1981), although not consistently  (Schulman e t a l . ,  1982).
Seme have found i t  b en efic ia l mainly in Grade I lesions (Prout, 
Koontz, Coombs e t a l . ,  1983). Agents given a t the tim e of
resection have been in terpreted  as preventing im plantation of 
fre e -f lo a t in g  but v iab le  tumour c e lls  (Boyd & Burnand). As the  
e ffe c t  o f th is  form o f chemotherapy on recurrence is not on 
episodes o f recurrence (MRC Working P arty , 1985), but on tim e per 
recurrent lesion, i t  might be th a t these low dose-rates have a 
poten tia l fo r the induction o f resistance, but lim ited  b en efit to  
patien ts .
S ingle post-resection  in s t il la t io n s  may have a p a rt ly  mechanical 
e ffe c t . Im plantation o f disturbed tumour c e l ls ,  f i r s t  suggested 
by Albarran & Imbert (1903) in  renal tra n s itio n a l c e ll carcinoma, 
has been reported to  occur in the va u lt o f the bladder,
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possibly carried  up on bubbles o f gas produced by resection (Boyd 
& Burnand 1974). Delay in in s t i l la t io n  o f anticancer agents has 
been observed to  perm it more im plantation o f timour c e ll suspen­
sions a f te r  diathermy in a murine model (Pan e t  a l . ,  1989). This 
may indicate e ith e r  th a t the chemical e ffe c t  o f thioTEPA or 
Mitcmycin-C prevents im plantation, or causes detatchment or death 
o f newly-implanted tumour c e l ls ,  or th a t the mechani­
ca l/vo lum etric  e ffe c ts  o f the in s t i l la t io n  cause an ea rly  evacua­
t io n  o f unattached tumour c e l ls ,  or a combination. These factors  
may not apply in  treatm ent o f unresected tumours. I t  may be 
postulated th a t , as v iab le  timour c e lls  can be recovered from the  
urine more e a s ily  in  higher-grade (less  d iffe re n tia te d ) tumours 
than in low-grade tumours, timour c e ll adhesion is  stronger in 
more normal c e lls . This might then be surmised to  be a possible  
d if fe re n t ia l  on which anticancer drugs might be acting . This 
hypothesis might be tested by f i l t e r in g  or spinning the super­
natant a f te r  a thioTEPA exposure in v i t r o ,  washing the c e l ls ,  and 
then re -p la tin g  them to  see how many are v ia b le . The re s u lts  o f a 
study o f ir r ig a t io n  alone are awaited w ith  in te re s t.
The consequences o f treatm ent w ith suboptima 1 dose-rates of 
in traves ica l chemotherapy were also explored in v i t r o .  The 
simplest and most c red ib le  in te rp re ta tio n  o f the data is  th a t  
less than a twofold reduction in s e n s it iv ity  to  thioTEPA followed  
a model course o f in traves ica l chemotherapy. Marked resistance to  
other agents, such as adriamycin (Me Govern e t a l . ,  1988) and
cis-p latinum  (Bedford e t a l.,1 9 8 7 ) has been found to  fo llow
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continuous exposure to  fixed  or escalating concentrations o f
drugs. With the in te rm iten t regimen used fo r th is  study, which 
more closely approximates to  c lin ic a l treatm ent schedules, a 
lower level o f induced resistance is  not surpris ing . In the  
bladder, there  would be more social support fo r tumour c e lls  than 
in  v i t r o ,  and a g reater degree o f resistance is  l ik e ly  than in
v it r o .  On the other hand, because the dose-rate in vivo is
usually lim ited  by to x ic  e ffe c ts  on normal tissues , the r is k s  and 
ben efits  are usually  f in e ly  balanced, and the development o f a 
minor degree o f resistance might so m itig a te  the b en efits  o f 
treatm ent as to  make i t  worthless.
Pred icting  drug resistance from c e llu la r  ch a ra c te ris tics  is
d i f f i c u l t ,  as is  p red ic tin g  any other outcome (Abel, 1988). 
P oten tia l markers o f drug resistance, such as p-g lycoprotein , 
glutath ione transferase a c t iv ity  and metal lo th ionein  expression 
can only ind icate  a t  best a p art o f the possible mechanisms 
(S ik ic , 1986; Gerlach e t a l . ,  1986; Goldie & Coldnan, 1985; Weber 
e t a l ,  1989), and the c e llu la r  defences against thioTEPA e ffe c t  
are not yet c le a r. The studies carried  out here to  characterise  
the d rug-res is tan t sublines and contrast them w ith  the parent 
sublines found no d istingu ish ing  featu re  a t th is  low level o f 
drug resistance. Karyotype, isoenzymes, tum ourigenicity, EGFR1 
sta in ing  and DNA fin g e rp rin tin g  were not appreciably d iffe re n t  in  
the re s is ta n t sublines. This did have the advantage th a t i t  was 
c lear th a t the drug resistance was re la te d  to  the drug exposures, 
in  th a t i t  had not been produced by cross-contamination. I t  may
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be th a t the tes ts  used, p a r t ic u la r ly  the chromosomal analysis and 
EGFR1 s ta in in g , were not s u ff ic ie n t ly  sen s itive  to  recognise the  
rea l markers o f thioTEPA resistance. I t  seems more l ik e ly  th a t  
any changes induced by the model course o f chemotherapy would be 
id e n t if ia b le  in  the  regu lation  o f c e llu la r  processes, ra th er than 
in the appearance or disappearance o f functions or structures  
such as drug in ac tiv a tio n  or P-glycoprotein, and th a t the  
p o ten tia l markers examined were u n lik e ly  to  be f r u i t fu l  however 
great the resistance induced, or however sen s itive  the te s tin g . 
The examination o f other markers, such as double minutes, in 
resistance, or o f ,  e .g . ,  EGFR1 in recurrence or progression, is 
not invalidated  by the present find ings.
The opportunities fo r and consequences o f resistance in vivo are  
s ig n ific a n t. Malignant c e lls  not k i l le d  by treatm ent have 
an opportunity to  develop resistance, and i f  th is  were not 
recognised, and treatm ent changed, patien ts  would be exposed to  
the hazards o f treatment without prospect o f b e n e fit. Even 
where complete c lin ic a l response occurs, cure may not have been 
achieved (Skipper, 1987; De V ita , 1986). This f i t s  w ith  the 
c lin ic a l experience th a t recurrence can occur a f te r  complete 
clearance o f a l l  v is ib le  timour a f te r  resection or chemotherapy. 
Following the p rin c ip les  o f log—k i 11 k in e tics  (Skipper e t  a l . ,  
1964), and the mutational theory o f the development of resistance  
(Goldie & Coldnan, 1979), i t  would be log ical to  expect in tra ­
vesical chemotherapy to  be most e ffe c tiv e  where the tumour burden 
is  sm all, ie  a fte r  complete resection o f a s ing le  tumour, whereas
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its  ro le  had t ra d it io n a lly  been seen to  be in unresectable, or 
repeatedly recurrent disease (England e t  a l . ,  1981).
Cystoscopically normal uro theliun  is  also a lte re d  by in tra v e s i­
cal chemotherapy (D ro lle r  & Erzoan, 1985). The f ie ld  change and 
m u lt ih it  theories o f u ro th e lia l carcinogenesis imply th a t cysto­
scopical ly  normal uro theliun  contains c e lls  r ip e  fo r  carcinogene­
s is , which might be triggered  by the mitogenic and mutagenic 
stimulus o f therapy. Green e t  a l . (1984) found th a t the net
e ffe c t  o f chemotherapy on progression in vivo was b e n e fic ia l, but 
th is  may mask preventable d e te rio ra tio n  in  ind iv idual p a tien ts , 
as may occur in in  Tis (S ta n is ic  Donovan, Lebouton e t a l .  1987). 
The use o f the optimal m odality o f treatm ent and the optimal 
method o f de livery  is important, as "Dead bugs don 't get 
re s is ta n t" . Where d iscern ib le  improvement does not accrue to  the  
in d iv id u a l, the c lin ic ia n  should not h es ita te  to  in s t itu te  a new 
approach.
CONCLUSIONS
Granted th a t the diagnosis o f tumours by fibrescopes is  adequate, 
there remains a deficiency in therapy compared w ith  the rod-lens  
system. Opportunities do e x is t , however, fo r  b e tte r instruments 
and techniques to  be developed to  perform local surgery, w hile  
th is  remains the simplest and least invasive form o f treatm ent.
The app lication  o f in traves ica l treatm ent in optimal conditions
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might reduce the need fo r  surgery, even where surgery is  
e ffe c tiv e . Several possible options fo r  th is  approachJiave were 
studied, and one w ith p o ten tia l c l in ic a l app lication  has been 
found. Lowering the pH o f the in s t i l  la te  increases the anticancer 
e ffe c t  o f thioTEPA in v i t r o .  No evidence was found th a t th is  
could be enhanced by the add ition  o f am iloride. Phosphate b u ffe r, 
BP, could be used as a veh ic le  to  reduce the pH of in traves ica l 
thioTEPA in s t iH a te s , in order to  increase the e ffe c t  o f a given 
concentration o f thioTEPA. The experiment needs to  be t r ie d .
Another way o f enhancing in traves ica l chemotherapy might be by 
drug synergy, but he add ition  o f DMSO to  the in s t i l la t e  did not 
add to  thioTEPA e ffe c t  a t pH= 7 .4 . Previous studies th a t have 
showed enhanced tumour shrinkage may have been dependent on a 
period o f pre-treatm ent w ith DMSO, which might have a lte re d  the  
degree o f d iffe re n t ia t io n  o f the tumour. A simple solvent e ffe c t  
was not thought important. Short in s t il la t io n s  of 50% DMSO have 
been used in the treatm ent o f in te r s t i t ia l  c y s t i t is ,  and patients  
undergoing marrow transplants to le ra te  small volumes o f 50% DMSO 
systemical ly , in  the frozen marrow suspension, but the un­
pleasantness o f the DMSO ta s te  would requ ire  a large improvement 
in  prognosis to  balance th is  disadvantage in the management of 
s u p e rfic ia l bladder tumours.
Resistance to  thioTEPA developed in  c e lls  surviving a model 
course o f in traves ica l thioTEPA. Sublines derived from h is to lo g i­
c a lly  normal urothelium and from u ro th e lia l tumours showed
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evidence o f th is  e f fe c t ,  although there was a paradoxically high 
survival in parent c e lls . Resistant c e lls  were not d is t in ­
guishable from parent or control c e lls  in isoenzyme pattern  of 
four enzymes, DNA fin g e rp r in t, karyotype, or nude mouse tumouri-  
g e n ic ity . Chemotherapy therefore  requires to  be in tensive, and 
there may be considerable bonuses to  be obtained from the use of 
methods o f lim itin g  unwanted e ffe c ts , such as granulocyte colony- 
stim ulating  fac to r fo r bone marrow support, to  allow s t i l l  higher 
dose-rates to  be used w ith reduced to x ic ity .
The present studies, intended to  promote an o u t-p a tie n t approach 
to  the management o f s u p e rfic ia l bladder cancer, have taken 
modest steps in th a t d ire c tio n . In travesical thioTEPA in acid  
solutions is  worthy o f fu rth e r c lin ic a l studies, p a r t ic u la r ly  in 
those w ith low tumour burdens, ra ther than those w ith m u ltip le  
s u p e rfic ia l recurrent disease. Used conventionally, thioTEPA 
prophylaxis may induce resistance. While the need fo r a cure fo r  
s u p e rfic ia l bladder cancer remains, the management must be based 
on the p rin c ip le  "Primum non nocere".
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APPENDIX 1
ORGANIZATION AND ACCEPTABILITY OF A FLEXIBLE CYSTOSCOPY SERVICE 
INTRODUCTION
The f le x ib le  f ib re o p tic  cystoscope has been used under to p ica l 
analgesia in English Teaching Hospitals (Fowler, Badenoch and 
Thakar, 1984; Powell e t  a l . ,  1984) and in the USA (Soloway, 1985; 
dayman e t a l . ,  1984). Although, h is to r ic a lly ,  large instrunents  
have been passed without anaesthesia (W allace, 1978), current UK 
prac tice  uses general anaesthesia in most cases. In the USA, 
rod-lens cystoscopies are o ften  performed under to p ica l an­
a lg es ia . Because o f the high numbers o f check cystoscopies 
carried  out in f r a i l  p a tien ts , a large nunber o f bed-days are  
required fo r these p a tien ts , many o f whom have no ac tiv e  cancer. 
Even those selected p atien ts  having o u t-p a tie n t examinations need
a period o f recovery from general anaesthesia before they can
leave. I f  f le x ib le  cystoscopy under top ica l analgesia is
fe a s ib le  in d is t r ic t  hosp ita ls  in the UK, i t  w il l  make beds
av a ila b le  to  pa tien ts  on w a itin g -1 is ts  fo r more major procedures.
METHOD: the F a c il i t ie s  Used
In a mixed suburban/rural area, a f le x ib le  cystoscopy serv ice was 
set up, using an Olympus CHF-4B cho1edochof ibrescope which was 
already a v a ila b le . Patients who required cystoscopy fo r  the  
diagnosis of haematuria, frequency, recurrent u rinary  t ra c t
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in fe c tio n , or pain , or voiding d i f f ic u l t ie s  were o ffe red  f le x ib le  
cystoscopy as an a lte rn a tiv e  to  la te r  general anaesthetic  
appointments. Patients who had been undergoing check cystoscopy 
and who had been c lea r fo r two years, and patien ts  on fo llo w -  
up fo r  u re th ra l s tr ic tu re  were also o ffe red  th is  option.
New p atien ts  were given a cystoscopy appiontment on the next 
l i s t  a f te r  th e ir  c l in ic  appointment. Former patien ts  attended the  
o u t-p a tie n t c l in ic  one week before cystoscopy, to  review th e ir  
progress. Patients were asked to  re tu rn  one week a f te r  cystoscopy 
to  pass a mid-stream specimen o f u rine . Patients who fa ile d  to  
attend were sent a fu rth e r appointment. The reasons fo r fa i lu r e  
to  attend were obtained by enquiry where they were not 
volunteered.
Cystoscopies were carried  out by the author in two rooms in the  
Central Treatment S u ite , used a t other times fo r dressings and 
minor procedures. As only one cystoscope was a v a ila b le , i t  was 
c a rrie d , s t e r i le ,  between rooms, when the p a tien t was ready to  be 
examined. In preparation fo r each session, and between p a tien ts , 
the instrunent channel was brushed through and rinsed w ith  
aqueous chlorhexidine (H ibiscrub, IC I, M acclesfie ld , UK), then 
s te r il is e d  in 2% activated  glutaraldehyde (Cidex, Johnson and 
Johnson, High Wycombe, UK) fo r f iv e  minutes between patien ts  and 
ten minutes before and a f te r  each session. Before use, the  
gluteraldehyde was washed from the instrunent, and the channel 
flushed w ith s t e r i le  water fo r ir r ig a t io n .
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Whenever possib le, two nurses were used, one to  ass is t w ith the  
examination in  hand, and another to  help dress the previous 
p a tien t and to  prepare the next. Patients were shown in to  the  
room by a nurse and assisted to  undress from the w aist down and 
l ie  on a standard examination couch. The skin was cleansed w ith  
cetav lon / cetrim ide (S a v lo d il, 101, M acclesfie ld , UK), and 
f i f te e n  grams o f 2% lignocaine gel (Biorex Laboratories, London, 
UK) were in s t i l le d  in to  the u rethra , and given f iv e  minutes to  
take e f fe c t ,  w hile the previous p a tien t was examined, and the  
instrunent cleaned and s te r il is e d . While w a itin g , the p a tien t was 
covered w ith a s te r i le  towel.
The cystoscopist, the author, carried  out a surgical hand scrub, 
and wore s te r i le  gloves (Regent, London, UK), but surgical gowns 
and p a tien t towels were not used. The bladder and urethra were 
ir r ig a te d  through the instrument channel using Normal sa lin e  fo r  
intravenous use (Baxter,UK) given through a standard intravenous 
set (Travenol, UK), which was changed between p a tien ts . Each 
examination used between two and four hundred m i l l i l i t r e s  o f 
s a lin e . A fte r cystoscopy, the p a tien t was given a chance to  dry 
any gel or s a lin e , and assisted to  dress. In a n tic ip a tio n  o f 
re ten tio n  o f u rin e , p a tien ts  were asked to  w ait u n til they had 
voided. Where the appearances a t cystoscopy were doubtful, a rod- 
lens examination was carried  out, to  avoid missing important 
pathology.
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METHODS: Patients
Three p atien ts  opted to  be examined under general anaes­
th es ia . S ix ty -th re e  patien ts  were given appointments fo r f le x ib le  
cystoscopy, and s ix ty  attended, fourteen women and fo r ty -s ix  men, 
one man on two occasions. Thirty-seven patien ts  came fo r review  
cystoscopy fo r bladder cancer, s ix  o f whom required d ila ta t io n  of 
a known u rethra l s tr ic tu re  in add ition ; ten fo r investigation  of 
haematuria; th ree  fo r  assessment and d ila ta t io n  o f urethra l 
s tr ic tu re s ; fo u r, fo r investigation  o f frequency; one, recurrent 
urinary  in fections; one fo r  poor stream; and in four cases, the  
reason fo r  cystoscopy was not recorded. The average age was 62 
years 11 months.
RESULTS
F ifte e n  out o f s ix ty  patients  (25&) required fu rth e r management 
under general anaesthesia. Four had an inadequate view. Two 
patien ts  undergoing check cystoscopy were thought by the examiner 
to  be unable to  to le ra te  fu rth e r fib re o p tic  examinations. One had 
experienced d i f f ic u l t ie s  w ith dysuria a f te r  previous rod-lens  
cystoscopies, and another was anxious, cancer phobic, and had a 
recurren t bladder tim our. Two others expressed a s lig h t p re fe r­
ence fo r  general anaesthesia, not precluding fu rth e r fibreoscopy. 
In a l l ,  s ix  patien ts  had bladder timours; two, benign p ro s ta tic  
hyperplasia; one, carcinoma o f the prostate; one, a bladder neck 
s tr ic tu re ;  and one, a phimosis. In two patien ts  w ith urethra l
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s tr ic tu re s , the review fo r bladder tumour was inadequate because 
o f tu rb id  u rine . The s tr ic tu re s  were d ila te d  under local 
analgesia , and a t  three months, allowed unopposed passage o f the  
fibrescope. Of the th irty -seve n  patien ts  attending fo r check 
cystoscopy, seven (19%) required fu rth e r assessment or management 
under general anaesthesia.
F a ilu re  to  attend might ind icate  th a t the p a tien t was re lu c tan t  
to  undergo the new procedure, but was hes itan t to  say so. 
Eighteen patien ts  had m u ltip le  appointments, because o f fa i lu r e  
to  attend. Patients  who did not attend were sent another 
appointment in two weeks. Eight pa tien ts  were given incorrect 
appointments, and four did not attend because o f holidays or 
other social reasons. Two more men probably did not attend  
because o f work problems, one being abroad, and another was due 
to  s ta r t  a n ight s h if t  irrmediately a f te r  the examination. One of 
those g iving a social o b lig a tio n  as a reason fo r  non-attendance, 
and a t least two others were thought l ik e ly  to  have been 
re lu c ta n t to  undergo the new procedure, even although they had 
been given the option o f conventional examination. Those w ith  
appointments problems had an average age o f 58 years 3 months, as 
ocmpared w ith the general f ig u re  o f 62 years 11 months, but these 
are not d if fe re n t  a t the 5% level o f s ign ificance.
Preparation o f the p a tien t and in s t i l la t io n  o f lignocaine took 
about two minutes o f the appointment, the examination o f the  
p a tie n t, one or two minutes, and the cleaning and rin s in g  o f the
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instrument two minutes. The s te r i l iz a t io n  period was used to  
prepare another p a tie n t, and to  discuss th e ir  coming examination. 
As the procedure was new, appointments were scheduled every 
f i f te e n  minutes.
A fte r examination, patients  were asked inform ally by the nurses 
whether they had found the procedure acceptable enough to  have i t  
again i f  necessary. Of 51 who did not have u rethra l d ila ta t io n ,  
one rep ly  was not recorded, and three (6%) would have preferred  a 
general anaesthetic. One p a tien t was cancer phobic and found a l l  
procedures d i f f i c u l t ,  and two expressed a m ild preference fo r a 
general anaesthetic. Two others spontaneously expressed a p re fe r­
ence fo r f ib re o p tic  examination. Three of the ten patien ts  who 
had urethra l s tr ic tu re s  d ila te d  would not have found fu rth e r  
local anaesthetic procedures acceptable. Of those attending for  
check cystoscopy, seven had lesions requ iring  biopsy or assess­
ment under general anaesthesia, and 81% (959S Confidence In te r-  
val=68,949s) avoided a general anaesthetic.
DISCUSSION
The benefits  o ffered  by f le x ib le  cystoscopy re la te  to  avoidance 
of adnission, and to  the avoidance of general anaesthesia. 
I n i t ia l l y ,  bladder tumour review patients w ith a low r is k  of 
recurrence were examined, but th is  service has since been 
extended, to  reduce the number o f negative in -p a tie n t examina­
tio n s . This is expected to  increase the proportion o f patients
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th a t requ ire  re fe r ra l fo r general anaesthetic cystoscopy from the  
present 11/51=22(11,33)$, fo r a l l  pa tien ts  not known to  have had 
a u re th ra l s tr ic tu re , or from 13/47=28(15,41)$ o f p a tien ts  fo r  
tunour review or investigation  o f haematuria. A fig u re  fo r  the  
mmber o f general anaesthetic cystoscopies avoided per tumour 
diagnosis ( c . f .  lieuleman and Delaere, 1989) was not v a lid , as 
patien ts  w ith a recent recurrence were excluded from th is  study.
The avoidance of admission also has fin a n c ia l b en efits . Over the  
ten-year suggested replacement l i f e  o f the instrument, compara­
t iv e  costings favour the f le x ib le  instrument (Fowler e t  a l . ,  
1984; Powell e t a l . ,  1984), although more recent reports have
found replacement or re p a ir necessary a f te r  three to  f iv e  years 
(Fawcett e t  a l . ,  1991), and there may be increased costs to
comply w ith higher standards o f safety in instrument s t e r i l i z a ­
tio n  (Gibbs, 1990). The proposal in North-East Thames Region to  
remove glutaraldehyde from operating th eatres , and to  convert to  
cen tra lised  s te r i l iz a t io n  o f supplies would have much greater 
im plications fo r fib re o p tic  instruments than fo r the cheaper rod- 
lens cystoscopes.
Passage o f a rod-lens instrument o f s im ila r  s ize  requires fu rth e r  
sedation w ith benzodiazepines or op iates, and reversal w ith  
flun azen il before discharge, but does allow  a lim ited  range o f 
surgery to  be performed a t the same s it t in g  (M il le r ,  Parry, 
Creighton e t a l . ,  1989). In con trast, the a c c e p ta b ility  o f the
d is t r ic t  hospital local anaesthetic fib re o p tic  cystoscopy serv ice
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appears to  be adequate fo r general ap p lica tio n , w ithout the need 
fo r in jec tio n s  o f sedatives or reversing agents.
The symptomatic and social convenience to  the p a tien t o f a less 
stressfu l procedure, w ith l i t t l e  need fo r post-anaesthetic super­
v is ion  in or out o f hospital are more obvious to  the p a tien t than 
the  fin a n c ia l considerations. Anaesthetic hazards are p a rtic u ­
la r ly  important in the e ld e r ly  m ajo rity  o f these p a tien ts . 
P atien ts , who have previously to le ra te d  the passage o f a range of 
f le x ib le  and r ig id  instruments w ithout analgesia or anaesthesia 
(Abdel-Halim, 1990, W allace, 1978), were nevertheless l ik e ly  to  
welcome the advent o f a 15Ch, f le x ib le  instrument th a t could be 
passed w ith  re la t iv e  comfort under to p ica l analgesia in  out­
p a tien ts . The present author's unquantified experience and the  
data o f others (Flannigan e t a l . ,  1988; Figueroa, Thomas & Moon,
1987; Denholm e t a l . ,  1990) confirms p a tien t a c c e p ta b ility . In
view o f the long-term re la tio n s h ip  a p a tien t expects to  have w ith  
the follow -up team in a h o s p ita l, the responses to  the personal 
enquiries about a c c e p ta b ility  in the present study are l ik e ly  to  
produce an over-estim ate, as the resu lts  o f the second question­
n a ire  in the Edinburgh study suggest (Denholm e t a l . ,  1990). At 
the tim e o f the cystoscopy, 92% said th a t they would p re fe r to  
have th is  examination fo r  fu tu re  cystoscopies, but a week la te r ,  
a postal questionnaire e l ic ite d  such approval in  only 85%. The 
s p e c ific  questions about postoperative symptoms revealed dysuria  
(21%) frequency (14%) haematuria (6%) and malaise (8%) to  be 
s ig n ific a n tly  less than in the rod-lens group a t one week.
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The assessment o f a c c ep tab ility  in  the present report was subject 
to  b ias. The in i t ia l  selection  o f patien ts  who were o ffe red  the  
option was not monitored, but i t  is  not thought th a t c lin ic ia n s  
excluded many, i f  any, patients  as unsuitable fo r  e ith e r  examina­
t io n . Consideration o f the p a tie n t 's  psychological s u i ta b i l i ty  
fo r the examination w il l  avoid some broken appointments. Patients  
w ith a high level o f anxiety appeared less l ik e ly  to  fin d  the  
service s a tis fa c to ry , took longer to  examine, and are probably 
best not cajo led or persuaded to  undertake the examination. The 
patien ts  having urethra l d ila ta t io n  might also have been more 
comfortable and b e tte r managed by inp atien t urethrotcmy.The 
assessment o f missed appointments as an index o f p a tie n t re lu c ­
tance is  subject to  a number o f complicating fac to rs . The serv ice  
was in its  infancy, and adm in istrative  errors  occurred in 8/58  
appointments. Three patients a t  least were thought to  have been 
re lu c tan t to  undergo the procedure, but the numbers were too 
small fo r analysis o f the p a tien ts ' ages or the s e x -d is trib u tio n  
to  ind icate any d ifference in  those who did not attend . I t  
appeared th a t patients  were w il lin g  to  t r y  th is  quicker a lte rn a ­
t iv e .
Investigation  and surve illance o f bladder cancer was negative in  
a high proportion o f p a tien ts , who had been selected fo r  a low 
p ro b a b ility  o f recurrence. The "once-negative" c r ite r io n  o f 
Fawcett's study (1991) fo r changeover from rod-lens surve illance  
might be b e tte r suited to  the pressures o f c l in ic a l p ra c tic e , and
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reduce the need fo r admission.
The ro le  o f nurses and o f re c e p tio n /c le ric a l s ta f f  in the success 
of such a service should not be underestimated. Cutting the r a t io  
o f nurses to  cystoscopists from 2:1 to  1:1 would approximately 
double the appointment tim e, and less o f the cystoscopist’ s time 
would be spent a c tiv e ly . I f  a th ird  nurse was a v a ila b le , adding 
another instrument to  the service would make c e rta in  th a t there  
was no delay w hile awaiting instrument s te r i l iz a t io n .  In p r in ­
c ip le , i t  is  not essentia l th a t the examiner perform gen ita l 
antisepsis and the in s t i l la t io n  of lignocaine, but i t  is  an 
opportunity to  estab lish  a rapport w ith the p a tie n t, and consider 
the c l in ic a l  problem. H ypothetica lly , the examiner need only 
scrub, carry out the examination, and note the find ings , but in 
p rac tice , s ix  patients  per cystoscopist per hour is  l ik e ly  to  be 
the maximum achievable w ithout losing s t e r i l i t y ,  and the  
p a tie n t 's  confidence. To achieve such smooth serv ice , co-opera­
t iv e  s ta f f  fa m ilia r  w ith the technique are v i t a l .
In the s ix  months' service reported here, 40 patien ts  were 
diagnosed as c le a r , and not admitted fo r examination under 
general anaesthetic. Follow-up has given no reason to  doubt th is  
assessment o f th e ir  condition. Against th is , fourteen patien ts  
underwent f le x ib le  cystoscopy and went on to  have an in -p a tie n t  
procedure. In the fo rty  to  eighty p a tien t bed-days saved, 
approximately ten more patien ts  from the w aiting l i s t  fo r  
transurethra l prostatectomy could have been trea ted . The gain may
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be lim ited  by th eatre  or operator a v a ila b i l i t y ,  but could 
probably have been achieved. With a small s ta f f ,  a cho1edocho- 
scope th a t was in frequently  used in the b i l ia r y  tre e , and seme 
corrmon hospital s te r i le  supplies, a prompt, acceptable out­
p a tien t cystoscopy service was set up, instead o f an in -p a tie n t  
w a it in g - l is t .
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APPENDIX 2
DOES FIBREOPTIC CYSTOSCOPY INDUCE BACTERI UR I A?
Fever has been associated w ith  u rethra l instrumentation fo r  over 
one hundred years (C lark , 1883), and conventional th ea tre  s te r i le  
procedures have been successfully devised to  prevent in fe c tio n . 
Simpler aseptic precautions as used fo r  u reth ra l ca th e te risa tio n  
may be adequate in  o u t-p a tien ts  undergoing rod-lens cystoscopy 
(Fozard e t a l . ,  1983) and have been adopted fo r  f le x ib le  
cystoscopy (Fowler, 1984). I t  is  essential th a t they be e ffe c ­
t iv e .  The development o f b a c te r iu r ia  was monitored in the f i r s t  
patien ts  undergoing f ib re o p tic  cystoscopy w ith simpler asepsis in 
the Central Treatment Suite o f a d is t r ic t  general h o s p ita l. To 
compare the hospital prevalence o f postoperative b a c te r iu r ia  w ith  
reports from other centres, and w ith the study group, uncatheter- 
ised patien ts  having r ig id  transurethra l procedures in the 
operating th ea tre  over the same period.
PATIENTS AND METHODS
The patien ts  having f le x ib le  cystoscopy were as described in 
Appendix 1. Nine patients who had o u t-p a tien t u rethra l d i lta t io n  
were excluded from the study o f postoperative b a c te r iu r ia , and 
another twelve who had b a c te r iu r ia  a t presentation, required  
a n tib io t ic  prophylaxis, or had had a n tib io tic s  or instrumentation  
w ith in  the la s t four weeks. Four had incomplete specimens.
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T h ir ty - f iv e  e l ig ib le  patients  completed the f ib re o p tic  protocol, 
ten female, tw enty-six  male, average age 63 years 7 months, range 
25 years to  82 years. None was catheterised before or a fte r  
surgery. Twenty-three patients  attended fo r  check cystoscopy, 
eight fo r  investigation  of haematuria, three fo r  symptoms of 
frequency, one fo r poor stream, and in one case, the reason fo r  
re fe r ra l was not recorded.
METHODS: Asepsis and F ibreoptic  Technique
The Olympus CHF-4B choledochofibrescope used was s te r il is e d  by 
immersion o f the introduction tube, and ir r ig a t io n  o f the biopsy 
channel w ith 2% ac tivated  glutaraldehyde (Cidex, Johnson and 
Johnson, High Wycombe, UK) fo r  f iv e  minutes in a s te r i le  b a k e lite  
trough or th ea tre  washbowl. The cystoscopist (the  author) carried  
out a surgical hand scrub, and wore conventional s t e r i le  gloves. 
The Cidex was rinsed from the fibrescope and channel w ith water 
fo r ir r ig a t io n , before the cystoscopy. The p a tien t lay supine on 
an examination couch w ith a waterproof cover, women w ith  knees 
flexed  and abducted during the examination. The urethra l opening 
was washed w ith  aqueous Cetavlon (S a v lo d il, IC I , M acclesfie ld , 
UK), and draped w ith a s ing le  s te r i le  hand tow el. F ifte e n  grams 
o f 1$ lignocaine gel (Xylocaine, Biorex Laboratories, London) 
were in s t i l le d  in to  the urethra fo r  f iv e  minutes to  provide 
analgesia. The cystoscope was passed up the urethra under v is io n , 
ir r ig a t in g  w ith intravenous Normal sa lin e  through a standard 
intravenous set.
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PATIENTS AND METHODS: Rigid Cystoscopy
Of one hundred patien ts  undergoing r ig id  instrum entation, s ix ty -  
two were excluded, 43 because o f fa i lu r e  to  return  to  the  hospial 
to  provide a postoperative urine sample, nineteen because o f 
preoperative b a c te r iu r ia , c a th e te risa tio n , or a n t ib io t ic  
adm in istration . Twenty-three required postoperative ca th e te r- 
isa tio n , leaving a control group o f f i f te e n  p atien ts  undergoing 
r ig id  instrumentation of the urethra .
R igid instrumentation was carried  out under general anaesthesia, 
in an a ir-co nd itioned  th ea tre  s u ite , used by a number o f surgical 
s p e c ia ltie s . Patients were placed, supine, in to  lithotomy 
s tirru p s , and the  gen ita l area washed w ith  aqueous cetavlon  
(S a v lo d il, IC I , UK), before draping w ith  s te r i le  c lo th  leggings 
and s p l i t  towel. Surgeons wore th ea tre  gowns and gloves, but 
masks were usually removed to  prevent fogging lenses. Instruments 
were between 19 and 23 C harriere gauge.
METHODS: Microbiology
Mid-stream or clean-catch urine specimens were taken from a l l  
patien ts  in the 24 hours before examination, and again on the  
s ix th  postoperative day, on the hospital premises. Specimens were 
taken d ire c t ly  to  the laboratory fo r cu ltu re . The laboratory  
methods used were the standard fo r  the h o sp ita l, and were carried  
out by a fu ll - t im e  technician , Marian Clements.
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Standardised u rine  a liq u o ts  were p la ted  by the f i l te r -p a p e r  
method o f Leigh and W illiam s (1964 ), and the  concentration o f 
organisms ca lcu la ted  accordingly, from a c a lib ra tio n  curve. This  
was the  h o s p ita l's  p ra c tic e , in  preference to  counting b a c te ria . 
Mast B a c te r iu r ite s t  S tr ip s  12rm long were dipped in the mixed 
u rin e , and touched on to  c u ltu re  p la te s , fo r  id e n t if ic a t io n  by 
colony morphology. C y s tin e -la c to s e -e le c tro ly te -d e fic ie n t agar 
(CLED, CM301, Oxoid, Basingstoke) blood agar (CM331, Oxoid, 
Basingstoke, w ith  7$ horse blood, Tissue C u ltu re  Services, 
Slough) and MacConkey agar (CM76, Oxoid) were used fo r  overn ight 
c u ltu re . Gram s ta ins  were performed, and p o s itiv e  organisms were 
tes ted  fo r  cata lase  and coagulase, and negative, fo r  oxidase and 
urea production. A n tib io tic  s e n s it iv it ie s  were assessed on iso - 
sensotest agar (CM 471, Oxoid) using an tib io tic -im pregnated  disks  
(A m oxycillin , 25 meg, trim ethoprim , 1.25 meg, n itro fu ra n to in , 100 
meg, cephradine, 30 meg, n a l id ix ic  ac id , 30 meg, and sulpha- 
methoxazole, 100 meg, O xoid), and comparing w ith  standard organ­
isms, p la ted  d a ily .  Microscopy was c a rr ie d  out on 60 m ic ro litre s  
mixed u rin e , placed in a fla t-bo ttcm ed  m ic ro t itre  w ell and 
allowed to  s e t t le  fo r  10 minutes before examination w ith  an 
inverted  microscope. The number o f c e ll  seen per high-power f ie ld  
was reported as the nunber seen per m ic ro li t r e .  In p ra c tic e , no 
specimen w ith  a growth equ iva len t to  108 organisms / l i t r e  had a 
count less than 10 w hite blood c e lls  per high-power f ie ld .
S ig n ific a n t b a c te r iu r ia  was defined as a growth equ iva len t to  10®
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organisms/1I t r e  o f u rin e , w ith > 10 white ce lls /m l o f u rin e . 
METHODS: S ta t is t ic s
Numbers o f pa tien ts  w ith s ig n ific a n t b a c te riu ria  were compared 
using the chi-squared te s t  w ith Yates' correction fo r  small 
numbers (Swinscow, 1976). The upper and lower extent o f the 95% 
confidence in te rva l fo r  proportions were calcu lated  as described 
by Gardner and Altman (1989) using the Standard Error of 
prportions, m u ltip lie d  by 1.96, and are given in the form 
( low er,upper).
RESULTS
Of t h ir t y - f iv e  e l ig ib le  patien ts  undergoing f le x ib le  cystoscopy, 
excluding those who had cystoscopy fo r urethra l s t r ic tu re , none 
had s ig n ific a n t b a c te riu ria . Three more patien ts  who were o ther­
wise e l ig ib le ,  and had no r ig id  instrum entation, were being 
followed fo r u rethra l s tr ic tu re s . One had s ig n ific a n t b a c te r iu r ia  
w ith coagulase-negative Staphylococcus on the s ix th  postoperative  
day (2 .6 (0 ,7 )% ). The p a tien t had recurrent u rethra l s tr ic tu re s , 
one o f which had been d ila te d , in the presence o f a s im ila r  
Staphylococcus,seven weeks before the e l ig ib le  examination. F i f ­
teen e l ig ib le  in -p a tien ts  had r ig id  instrumentation w ithout 
postoperative ca th e te risa tio n . Two (13(0,31)% ) developed s ig n i f i ­
cant b a c te riu ria . One had a mixed growth o f predominantly 
Staphylococcus, and another, a pure cu ltu re  of coagulase-negative
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Staphylococcus. The p-value comparing the two groups was between 
0 .5  and 0 .1 .
DISCUSSION
This study addressed the p o s s ib ility  o f ascending in fec tio n  
introduced by the instrum entation, s im ila r to  catheter fever 
(C la rk , 1883). I t  did not measure the v ia b i l i t y  o f endoscopy in  
the p a tie n t w ith p re -ex is tin g  in fe c tio n , as both untreated or 
recen tly  trea ted  (1 month or less) in fec tio n  were a c r ite r io n  fo r  
exclusion. Circumstances so pressing th a t an endoscopy must be 
performed in the presence o f in fe c tio n , even w ith  a n tib io t ic  
cover are less lik e ly  to  a ris e  i f ,  as a re s u lt  o f b e tte r d irected  
resources, an ea rly  a lte rn a tiv e  appointment can be o ffe red . 
Equally, the transmission o f v ir a l  in fections was not tested , but 
there  is  only one documented example o f transmission o f h e p a titis  
B by an endoscope, the channel o f which had not been cleaned 
between p a tien ts .
The outcome measure compared, a growth equivalent to  105 
bacteria /m l in the presence of 10 or more leucocytes/ml is a 
cannon laboratory c r ite r io n  o f b a c te r iu r ia  th a t is  not due to  
contamination. I t  is  arguable th a t not a l l  patien ts  who meet th is  
c r ite r io n  have an in fec tio n  o f the u rinary t r a c t .  In the absence 
o f residual u rin e , b a c te riu ria  o ften  c lears spontaneously 
(Thomlinson, W illiam s & Cope, 1968; Wettergren, Hellstrcm , 
Stokland e t a l . ,  1990), and the presence o f bac teria  on th is  body
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surface does not necessarily imply disease. Symptomatology was 
not recorded, and would have had some value in assessing the  
pathological im plications o f the laboratory examinations. The 
c r i t e r ia  used were, however, those used ro u tin e ly  by the author 
and his laboratory co llaborators in  c lin ic a l p rac tice , are l ik e ly  
to  be commonly accepted by u ro lo g is ts , and were compared w ith  
lik e  tes ts  in patien ts  undergoing conventional management.
Patients having f le x ib le  cystoscopy in th is  study did not develop 
b a c te riu ria  more frequently than patien ts  having conventional 
examinations. The low incidence o f b a c te riu ria  , and i ts  tendency 
to  c lea r spontaneously ind icate  th a t i t  is  not l ik e ly  to  be a 
large c lin ic a l problem a fte r  f le x ib le  cystoscopy.
Although patien ts  w ith recent bladder timours were more lik e ly  to  
be included in the r ig id  group, and bladder tumours have been 
thought to  predispose to  the development o f b a c te r iu r ia  (Appel 1 
e t a l ,  1980), resection o f bladder timours was usually followed  
by c a th e te risa tio n , reducing the bias towards b a c te riu ria  in 
r ig id  instrum entation. The non-attenders fo r postoperative urine  
tes tin g  q u a lify  the v a l id ity  o f the control group.
The present author has previously reported a 29% incidence (9555 
confidence in te rva l 9, 4855) o f b a c te r iu r ia  in in -p a tien ts  f o l ­
lowing a range o f transurethra l procedures (Walker e t  a l . ,  1984), 
and a f ig u re  o f 2-855 has been reported fo r o u t-p a tien ts  (Lytton , 
1961; Hares, 1981; Richards and Bastable, 1977; Fozard e t a l . ,
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1983; B u tle r, 1985). To ensure th a t there  was no major d ifference  
in  b a c te r iu r ia  the lo c a lity  o f the hospital where the study was 
c arried  out, a control group o f in -p a tien ts  undergoing rod-lens  
examination was included. A larger control group would have been 
des irab le . The 43% o f entrants to  th is  arm who fa ile d  to  provide 
a post-operative specimen are a po ten tia l source o f bias to  th is  
measurement. The author was not always present when these 
patien ts  were discharged, and re lie d  on a nunber o f nurses and 
one medical colleague to  make appointments fo r  patien ts  to  re turn  
to  provide specimens on the s ix th  postoperative day. Given the  
d iffe re n t  p r io r it ie s  and duties o f the nurses, i t  is  l ik e ly  th a t  
th is  contributed large ly  to  the d iffe ren ce  in  the numbers of 
patien ts  completing the protocol. Patients who had no symptoms 
would be less motivated than those w ith  u rinary  d i f f ic u lt ie s  to  
re tu rn  fo r a te s t .  Problems severe enough to  requ ire  h o s p ita lisa ­
t io n  would mostly have resu lted  in readmission to  the hospital in 
which the study was being carried  out, so the bias introduced by 
non-returners is  l ik e ly  to  increase the apparent ra te  o f post­
operative  b a c te riu ria  in the control group. The post-entry  
exclusion from the control group of patien ts  requ irin g  ca th e te r- 
isa tio n  during th e ir  adnission might have tended to  exclude 
p atien ts  needing treatm ent fo r tumours or other problems th a t  
might predispose to  the development o f postoperative b a c te riu ria  
(Appel 1 e t  a l . ,  1980).
The find ings o f other authors (Fozard e t a l . ,  1983) suggest th a t
the p a tien t se lection  in the r ig id  cystoscopy group might have
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increased the ra te  o f b a c te riu ria  in the rod-lens group. The 
in fe c tio n  ra te  in  Fozard's patien ts  managed w ith conventional 
draping fo r  o u t-p a tien t cystoscopy was 4 (0 ,8 .5 )%  , and was
6(0.9 ,11)%  in the group in which an aseptic approach was used. 
These figures would compare equally w ell w ith the present study, 
but too few patien ts  were included in the conventional management 
group fo r i t  to  be possible to  id e n tify  any reduction in induced 
b a c te riu ria  (the  examination would have to  cure 0.4% of patients  
of p re -ex is tin g  b a c te r iu r ia ).
With these q u a lific a tio n s  in mind, the d iffe ren ce  between the new 
and the conventional approach in th is  comparison may have been a 
random event, as i t  does not reach the 95% level of s ta t is t ic a l  
sign ificance; but the incidence o f b a c te riu ria  in patients  
undergoing f le x ib le  cystoscopy was not greater than th a t in the  
control group, or than in other groups o f patien ts  undergoing 
transurethra l procedures studied by the present author.
This study indicates no reason to  doubt the e fficac y  of 
a n tib a c te ria l precautions used in th is  o u t-p a tie n t f ib re o p tic  
cystoscopy serv ice .
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APPENDIX 3
DOES FLEXIBLE CYSTOSCOPY MISS MORE TUMOURS THAN ROD-LENS
EXAMINATION?
INTRODUCTION
Data are scarce and incomplete on the like lihood  o f f a i l in g  to  
id e n tify  a tumour by fib re o p tic  cystoscopy under top ica l an­
a lg es ia . An examiner accustomed to  cystoscopy under general 
anaesthesia might r e s t r ic t  the extent o f the examination in the 
presence o f an aware p a tie n t, causing snail s o lita ry  tumours to  
be missed. The p a rtic u la te  nature o f the f ib re o p tic  p ic tu re  has 
also been c ite d  as g iving a less adequate view (Pope and Wickham, 
1991). A prospective, double-blind study was undertaken to  
compare the tunour episodes missed by f le x ib le  cystoscopy under 
top ica l analgesia, w ith th a t o f rod-lens cystoscopy under general 
anaesthesia.
Rod-lens cystoscopy has o ften  been used as a yardstick fo r the  
accuracy o f a lte rn a tiv e s  such as ultrasound and o f cytology in 
the diagnosis and follow -up o f s u p e rfic ia l bladder cancer. As a 
re s u lt ,  there are scant data on the accuracy o f rod-lens  
cystoscopy. P o s itive  findings on the ultrasound, th a t are not 
confirmed a t conventional cystoscopy are in terpreted as fa ls e -  
postive find ings (Abu-Youssef e t a l.,1 9 8 4 ; Boccon-Gibod e t a l . ,  
1985; Brun, Gammelgaard & C ris to ffe rsen , 1984; Dershaw & Scher, 
1987; Malone e t a l . ,  1986; Rosenki1de-Olsen, Jorgensen, Roed-
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Petersen e t  a l . ,  1985; Vallencien e t  a l . ,  1986). In most studies, 
the cystoscopist knew the ultrasound re s u lt ,  so i t  was not 
possible to  asssess the accuracy o f the cystoscopy. In the one 
c le a r ly  "b lind" study (Rosenki1de-Olsen e t a l . ,  1985), rod-lens  
cystoscopies were carried  out w ithout general anaesthesia. Of 64 
patien ts  w ith  p o s itiv e  ultrasound find ings , s ix  had no recurrence 
id e n tif ie d  a t cystoscopy, and were accounted fo r by "severe 
trab ecu la tio n , d iv e r t ic u la  o f the bladder, or impression o f a 
small atrophic uterus in to  the urinary bladder". I t  is  not 
recorded th a t the cystoscopy was repeated, so i t  is  possible th a t  
seme timours were genuinely missed by cystoscopy. Suture m ateria l 
(Boccon-Gibod e t a l . ,  1985) trabecu la tio n  and p ro s ta tic  hyper­
trophy (Brun e t a l . ,  1984) have been reported to  mimic timours on 
abdominal ultrasound, but th e ir  id e n tif ic a tio n  on cystoscopy 
should not be presimed to  exclude the presence o f tumour.
dayman, Reddy, and Lange (1984) report missing one o f two 
tumours in a p a tien t undergoing fib re o p tic  examination, and one 
p a tie n t w ith  a tunour was not diagnosed on rod-lens cystoscopy. 
The to ta l number o f timours was not given. The London Hospital 
group (Fowler e t a l . 1984), made both examinations under general
anaesthesia, and did not report whether the examiners were 
"b lind" to  the a lte rn a te  re s u lt .  False-negative ra tes  fo r  
f ib re o p tic  examination were not given. Powell and colleagues, 
from Newcastle-upon-Tyne (1984), likew ise compared both pro­
cedures under general anaesthesia. Webb, B utler and F itz p a tr ic k  
(1984) reported missing two lesions from an undisclosed to ta l
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number o f tunours in 25 p a tien ts , examined w ith the f le x ib le  
instrunent under to p ica l analgesia, then w ith rod-lens cystoscopy 
under general anaesthesia, apparently by the same examiners.
A prospective, randomised/'bl ind" comparison o f tumour-miss was 
th erefo re  carried  out, comparing the two options in 
p ractice  in  the United Kingdom, f le x ib le  cystoscopy under to p ica l 
anaesthesia w ith  r ig id  cystoscopy under general anaesthesia.
PATIENTS AND METHODS
For s ix  months, consecutive patien ts  admitted to  St Thomas’ 
Hospital fo r review cystoscopy fo r bladder ttrrour or fo r  
diagnosis o f haematuria were asked to  enter th is  study. F i f ty -s ix  
patien ts  gave informed consent. Three patien ts  did not complete 
the protocol. One tense p a tien t fa in ted  a f te r  a negative f le x ib le  
cystoscopy, one opted to  withdraw before examination, and a th ird  
did not have f le x ib le  cystoscopy because there  was not enough 
th eatre  time to  perform both examinations. T h ir ty -fo u r pa tien ts  
with bladder tunours completed the study.
A fte r premedication fo r general anaesthesia, p a tien ts  were 
examined w ith an Olympus CYF fib re o p tic  cystoscope, using ligno - 
caine g e l, and the technique decribed previously (appendix 1 ), in  
the anaesthetic room before induction o f general anaesthesia fo r  
rod-lens cystoscopy. Two surgeons were a llocated  to  e ith e r  
examination in paired days, on the basis o f a tossed coin.
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Tumours were tre a te d  under general anaesthesia, so i t  was not 
possible to  randomise the order o f the examinations. For e th ica l 
reasons, a f te r  recording h is  find ings, the rod-lens cystoscopist 
read the  re s u lts  o f the f ib re o p tic  examination, and re-checked 
the rod-lens examination i f  i t  appeared th a t he had missed a 
tumour id e n tif ie d  by the f le x ib le  cystoscopist. As the c r ite r io n  
was detection o f a lesion needing management under general anaes­
th e s ia , no d is tin c tio n  was made between s ing le  and m u ltip le  
tunours. Biopsies were not taken unless c l in ic a l ly  ind icated, as 
management o f small lesion was normally undertaken without 
biopsies.
The endoscopists, the Author and a colleague (TL ), were post- 
Fellowship re g is tra rs  o f more than two years' standing, and had 
performed several hundreds o f rod-lens cystoscopies, and a t least 
s ix ty  f ib re o p tic  examinations by the beginning of the study. Both 
were tra in ed  upper g a s tro -in te s tin a l f ib re o p tic  endoscopists.
RESULTS
Nineteen patien ts  were diagnosed as tum our-free by both 
examiners. Three (9%) o f the th ir ty - fo u r  tumours were missed by 
the f ib re o p tic  endoscopist. Three others were missed by the rod- 
lens examination. The author missed two diagnoses on f le x ib le  
cystoscopy, and one on rod-lens. A ll missed diagnoses were 
confirmed by both endoscopists a f te r  fu rth e r inspection under the
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same general anaesthetic, and trea ted  a t th a t s it t in g .
Tumour was missed in two o f the f i r s t  twelve f le x ib le  cystosco­
pies. One was on the edge o f a d iverticu lum . Another tunour was 
on the r ig h t  w all o f the bladder. As the cystoscopist always 
stood on the p a tie n t 's  r ig h t ,  the r ig h t wall was more d i f f i c u l t  
to  examine thoroughly. The th ird  was missed in  a bladder f i l l e d  
w ith tu rb id  u rin e . Tumours missed on rod-lens cystoscopy were on 
the la te ra l w alls  o f the bladder. A ll tunours missed were less 
than 5rrm in  diameter.
DISCUSSION
As the protocol chosen proposed th a t a l 1 patien ts  in whom tumour 
was diagnosed would be admitted fo r resectional treatm ent under 
general anaesthesia, the number of lesions present in  any one 
episode o f recurrence was o f less s ign ificance than the fa c t of 
recurrence. This would apply equally i f  treatm ent w ith  chemo­
therapy was intended, but not i f  local laser surgery or diathermy 
was planned. For th a t reason, the episodes o f recurrence were 
more appropriate measures o f outcome than number o f lesions. The 
to ta l number of examinations carried  out in  comparative studies  
largely  re f le c ts  the population examined, and is less important 
in determining the diagnostic accuracy o f bladder cancer s u rv e il­
lance than the number o f examinations a t which there was 
recurence to  be id e n tif ie d . I f  treatm ent w ith  f ib re o p tic  diagno­
sis  and in traves ica l therapy became ro u tin e , then the number of
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lesions seen would acquire importance, as a measure o f therapeu­
t i c  e f fe c t  on followup, and a fu rth e r assessment o f the a b i l i t y  
o f f le x ib le  cystoscopy to  detect every lesion would become 
re le v a n t. The accuracy o f diagnosis o f any abnormality present, 
the  fa ls e  p o s itiv e  ra te  (Fowler, 1984) is o f subsidiary impor­
tance i f  the cystoscopic assessment can be supported by h is to ­
log ical assessment o f biopsies.
The accuracy achieved, 9% o f 34 tumour diagnoses missed, 95% 
confidence in te rva l 0,18%, was ind istinguishable from th a t o f 
conventional examination, and compares well w ith th a t o f cytology 
and o f transabdominal ultrasound (see chapter 1). In view o f the  
u n fan i1ia r i t y  o f the researchers w ith  the fib re o p tic  cystoscope 
r e la t iv e  to  the rod-lens cystoscope, higher accuracy might be 
expected w ith  more experience. The element o f reassessment o f the  
bladder during the general anaesthetic, but a f te r  the te s t  
re s u lts  had been noted, gives a f i r s t  report o f the accuracy of 
rod-lens cystoscopy in tumour diagnosis, as previous studies have 
apparently assumed th a t p o s itiv e  find ings on a new te s t th a t were 
not confirmed by the rod-lens cystoscopist were the incorrect 
find ings . The present study found th a t conventional examinations 
were not p e rfe c tly  accurate.
In follow -up cystoscopy, where small lesions th a t are undetected 
a t one s it t in g  may be picked up three or s ix  months la te r ,  9% 
missed tumours could be acceptable, provided th a t the ra te  of 
progression was slow, or th a t the treatment th a t could be o ffered
182
did not prevent progression, but was p a l l ia t iv e .  For diagnostic  
examination, however, such a ra te  would give r is e  to  concern, as 
there  would not necessarily  be a second chance to  make the  
diagnosis. U nfortunately, there  is  no evidence th a t a s ing le  rod- 
lens examination would be any b e tte r . In the present study, the  
a b i l i t y  to  diagnose tumours f ib re o p tic a lly  was as good as the  
best cu rren tly  a v a ila b le .
The d if fe r in g  c h a ra c te ris tics  o f the f le x ib le  and r ig id  ins tru ­
ments s u it  them to  p a rtic u la r  circumstances. The presence of 
tu rb id  u rine  might be an ind ication  to  abandon f le x ib le  
cystoscopy, and to  use rod-lens cystoscopy fo r  th a t p a tie n t, as 
the bladder can conveniently and quickly be evacuated through the  
cystoscope sheath. A lte rn a tiv e ly , the bladder could be washed out 
through a ca th eter, and reviewed w ith  the f le x ib le  cystoscope. 
D iv e rtic u la  should be eas ier to  examine w ith  the f le x ib le  
cystoscope, p a r t ic u la r ly  larger d iv e r t ic u la  which can be entered  
w ith the instrument. Varied levels o f f i l l i n g  may be important to  
ensure tru e  negative examinations o f patien ts  w ith  d iv e rt ic u la .  
In view o f the prognostic importance o f missing a tumour in a 
diverticu lum , u ro log ists  who have had no tra in in g  in fib re o p tic  
endoscopy may p re fer to  exclude patien ts  w ith d iv e r t ic u la  from 
f ib re o p tic  fo llow -up u n til they have a broad experience o f the  
technique. ""See one, do one, teach one" w i l l  no longer do" 
(Walker, 1991). For gastroscopy, a fig u re  o f two hundred examina­
tions is  o ften  suggested as adequate tra in in g .
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This prospective double-blind study appears to  be the f i r s t  
substantial assessment o f the accuracy o f e ith e r  o f the p ra c tic a l 
options fo r  cystoscopy in B r it is h  p ractice . F le x ib le  cystoscopy 
was no more l ik e ly  than rod-lens examination to  miss tumours. 
With h indsight, a lower miss ra te  could have been achieved in 
f le x ib le  examinations by a s t r ic te r  d e fin it io n  o f an acceptable 
view, and using catheter lavage or rod-lens examination in those 
below standard. Voiding inrmediately before the examination 
(Fowler, 1984) would also ass is t the examiner by g iving a c lea re r  
view. The tumours missed on rod-lens cystoscopy were unaffected  
by these influences.
A f i r s t  comparison o f the tunour-miss ra te  o f f ib re o p tic  and rod- 
lens examinations as practised in the United Kingdom was made. 
F le x ib le  cystoscopy was no more l ik e ly  than rod-lens examination 
to  miss tumours. Although a 9& miss ra te  might be to le ra b le  fo r  
fo llow -up o f patien ts  w ith a low like lihood  o f progression before  
the next fo llow -up, i t  may not be acceptable in diagnostic  
cystoscopy. On the other hand, the current standard examination 
was as accurate in the present study.
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APPENDIX 4 
ABBREVIATIONS AND SUPPLIERS OF CHEMICALS
ABBREVIATION CHEMICAL NAME SUPPLIERS
Agarose Type T low E.E.O. Signa, Poole, UK
CHES ( 2 - ( N-Cyc1ohexy1 amino-) Signa, Poole, UK
ethane sulphonic acid
cannercial tr ie th y le n e  thiophos- Lederle, Gosport, Hants
thioTEPA phor amide UK
EDTA 0.016% Disodiun Edetate BDH, Poole, UK
EPPS (N- ( 2-Hydroxyethy1) P i - Sigina, Poole, UK
perazine)-N ' -3  Propane
Sulphonic acid
FCS Foetal C a lf Serum Flow, G ibco,Paisley, UK
Giemsa 10% aqueous Giemsa's Qurr, BDH, Poole, UK
sta in
Glutamine L-glutamine Gibco, P a is ley , UK
Hin F 1 R estric tio n  Enzyme BRL, Gibco, P a is ley , UK
Hin F I
HCl 1N Hydrochloric acid BDH, Poole, UK
(AVS Standard)
HEPES ( N-(2-Hydroxyethy1) P i­ Sigina,Poole, UK
p e ra z in e )^  ' -2-Ethane
Sulphonic acid
IMS 70% Industria l Methyla­ BDH, Poole, UK
ted s p i r i t
MES (2-(N-M orpholino) Ethane Signa, Poole, UK
Sulphonic Acid
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APPENDIX 4 (continued)
ABBREVIATION CHEMICAL NAME SUPPLIERS
MOPS (3-(N-M orpholino) Pro­
pane Sulphonic Acid
Signa, Poole, UK.
Na OH 1N Soditm Hydroxide 
(AVS Standard)
BDH, Poole, UK.
PBSA Phosphate buffered Supplied by Imperial
s a lin e  "A" Cancer Research Fund, 
London, UK.
32 p dTCP Radioactive deoxy C y ti- Amersham 1 n ternat iona 1
dine Triphosphate UK
pH 4 .0  b u ffe r C i t r ic  a c id / Sodiun 
C itra te  Reference Buffer
Convol, BDH, Poole, UK.
pH 7 .0  b u ffer Potassinn /Hydrogen D i­
hydrate Orthophosphate 
Reference Buffer
Oonvol, BDH, Poole, UK
pH 10.0 b u ffer Boric acid , K C l, and Na 
OH Reference Buffer
Convol, BDH, Poole, UK
p lambda Q3 m in is a te ll ite  probe Dr A. J e ffr ie s , IC I , Ul
RPMI 1640 Roswell Park Memorial 
In s t itu te  Mediim 1640
Flow, Irv in e , UK
Salmon sperm deoxyribonucleic acid Signa, Poole, UK
DNA from salmon sperm
SDS sodinn duodecy1 sulphate BDH, Poole, UK
Sorensen’ s 0.06M Na2HP04 + BDH, Poole, UK
buffer 0.06M KH2 PO4
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APPENDIX 4 (continued)
ABBREVIATION CHEMICAL NAME SUPPLIERS
SSC 0.15M sodiun chloride+  
0.015M tris o d iu n  c it r a te  
pH=7
BDH, Poole, UK
STE 150nrM sodiun chloride+  
lOmM TRIS + 10itM sodiun 
edetate, pH=8.1
BDH, Poole, UK
s te r i le  water S te r i le  Water fo r  In­ Beechams, Welwyn Garden
je c tio n s , BP C ity , UK
thioTEPA tr ie th y le n e  thiophos- Cyanamid, Pearl R iver,
phoramide New York, USA
Trypan Blue 0.1$  Trypan Blue S tain BDH, Poole, UK
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